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Abstract 
Tuberculosis (Tb) continues to be one of the world’s greatest challenges in the 
public health arena. The current treatment for Tb entails a long duration of therapy 
making adherence to the whole course difficult. This has given rise to drug 
resistant strains of Mycobacterium tuberculosis which are posing a significant 
threat to Tb control strategies. To counteract this problem, there is an urgent need 
to develop alternative anti-tuberculous drugs which target processes that are 
critical for the growth and/or survival of this microbe.  
 
 To identify such targets in M. tuberculosis, I used comparative genomics 
and mutagenesis data to identify conserved essential genes as viable targets for the 
development of broad-spectrum antibiotics. In addition, I validated the essentiality 
of three cell division genes in Mycobacterium smegmatis using conditional 
antisense RNA expression under different culture conditions. Furthermore, I 
performed high-throughput screens (HTS) using a differential susceptibility assay 
against one of the validated targets to identify its cognate inhibitor(s). Lastly, I 
developed a novel biochemical assay of the target to validate the specificity of the 
inhibitors identified in the HTS and evaluated the potency of the inhibitors against 
M. tuberculosis. 
 
This study identified 261 conserved putative essential genes as broad-
spectrum targets. I hypothesized that antisense RNA expression of such genes will 
lead to its down-regulation and thereby affect the viability of the cells if these 
genes are essential. I also hypothesized that an essential gene will be required 
under all culture conditions. One gene, parA, demonstrated that it was essential 
under various culture conditions. This gene encodes for a protein which contain 
the conserved Walker A motif thus I theorized that it may posses ATPase activity. 
The results illustrated that the M. tuberculosis ParA protein possesses ATPase 
activity. This biochemical activity was used to validate two specific inhibitors of 
ParA, phenoxybenzamine and octoclothepin, which were identified in the cell-
based HTS. Kinetic studies suggest that phenoxybenzamine is a mixed inhibitor 
while octoclothepin is a competitive inhibitor of ParA. This data is also supported 
 iv 
by in silico docking. Both these compounds show low minimum inhibitory 
concentrations in M. smegmatis under nitrogen starvation conditions.  
 
In summary, this thesis illustrates that ParA is a viable target for anti-
tubercular drugs. It demonstrates that ParA is an ATPase which has the potential 
to bind competitive and non-competitive inhibitors that can be exploited to target 
cell division in M. tuberculosis. Finally, this study presents phenoxybenzamine 
and octoclothepin as inhibitors of ParA. In conclusion, these compounds can 
either be developed to increase potency or be used as reference structures to 
screen for more potent inhibitors of the enzyme.  
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1.1  Preface 
 
Mycobacterium tuberculosis (M. tuberculosis) is the fundamental etiologic agent 
for human tuberculosis and is the biggest killer due to bacterial infection in the 
world today [1]. This thesis attempted to identify the genes required by this 
organism to survive and validates one of these genes as being essential. It also 
characterizes its function and presents some potential inhibitors against this target.  
 
 This chapter commences with introducing M. tuberculosis as a human 
pathogen followed by the current treatment regimens for the multiple strains and 
their mechanisms of action. This is followed by a section on some of the drugs 
currently in the Tb pipeline. It also provides an in-depth review of the drug 
discovery process from a genomics point of view which is the focus of this thesis. 
Specific introduction relevant to the separate results chapters are included at the 
beginning of the respective chapters.  
 
 
1.2  Global Burden of Tuberculosis 
 
Tuberculosis, a disease which has afflicted humanity since ancient times still 
remains a major public health concern with an estimated one third of the world’s 
population being infected with M. tuberculosis [2]. The earliest confirmation of 
the disease comes from skeletal evidence dating back to about 9,000 years from a 
Neolithic settlement in the Eastern Mediterranean [3]. Humans are the only 
known reservoir of this microbe [4]. According to the 2005 World Health 
Organisation (WHO) report, 8.8 million new cases and 1.75 million deaths 
occurred in 2003. These figures escalated to 9.24 million new cases and 1.7 
million deaths in 2006 and 9.27 million new cases and 2 million deaths in 2007. 
The WHO has predicted that a failure to stop this epidemic will lead to about one 
billion people being newly infected, 200 million people developing Tb and at least 
35 million deaths from the disease by 2020 [5-7].  
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 One of the major global burdens of Tb is due to human immunodeficiency 
virus (HIV). HIV can reactivate latent Tb infections (latency is discussed in 
section 1.4) and greatly hasten the progression of Tb infection into disease [8]. A 
person with a Tb infection has a 10% to 20% chance of developing disease in his 
lifetime; however, an HIV positive person co-infected with Tb has a greater than 
10% chance of developing the disease within a year [8] and greater than 42% 
chance of death [9]. In 2007, nearly 14.8% of the new Tb cases and 23% of all 
deaths were in HIV positive people [7], an increase from the figures seen in 2006 
[6]. The world’s largest and fastest growing Tb epidemic is in Africa, infecting 
79% of all HIV-positive cases (Figure 1.1 B) [7]. 
 
 In 1993, the WHO declared Tb as a global emergency [10] and in 1994, 
launched the Directly Observed Therapy, Short-course (DOTS). DOTS is the 
most cost effective, highly efficient strategy for controlling Tb, whereby diagnosis 
and registration of every Tb patient is followed by supervised standardized 
treatment. Failure to follow the DOTS program stringently quickly raises the 
number of Tb cases. Evidence of this was seen in Eastern Europe. The 
socioeconomic burden placed by the dismantling of the Soviet Union weakened 
the public health system and thus the DOTS program causing a sudden increase in 
the Tb incidence rate [11]. 
 
 In 2006, the Stop Tb Partnership launched the Global Plan to Stop Tb. 
This program aimed to halt or reverse the prevalence of Tb and death by 2015 and 
eliminate Tb by 2050 by ensuring effective access to diagnosis, treatment and 
cure for all Tb patients [12]. It is estimated that American, East Mediterranean and 
South-East Asian regions may achieve this goal of halving the prevalence of the 
disease and death by 2015 while the Western Pacific region may just be able to 
halve the prevalence of disease. The African and the European regions seem 
unlikely to be able to meet the target of halving either the prevalence or death at 
the current rate [7]. To achieve this goal, greater resources are needed to enhance 
and provide high quality DOTS program, reach those in need, especially the poor, 
improve health system and research for the development of new diagnostics, 
drugs and vaccines [7]. 
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Figure 1.1: Global burden of Tb 
A) Global burden of new Tb cases by country. There are 22 high burden countries with 
India, China, Indonesia, South Africa and Nigeria ranked among the highest. B) The 
global burden of Tb due to HIV epidemic, with the highest burden in South Africa. 
Reproduced with permission from WHO Report, 2009 [7]. 
 
A. Estimated numbers of new TB cases, 2008 
B. Estimated HIV prevalence in new TB cases, 2008 
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1.2.1 Tuberculosis in New Zealand 
 
From 1943 to 1988, the number of Tb cases in New Zealand (NZ) fell from 2, 600 
to 295 annually. However since then, there has been a resurgence of Tb with 
between 300 to 500 cases being reported per year [13]. From 1994 to 2004, NZ 
Tb rate has remained constant at about 10 per 100, 000 people, slightly lower than 
the rate in United Kingdom (UK) but twice that of Australia, Canada and the 
United States of America (USA). This was distributed predominantly in the non-
European and migrant population due to the increase in immigrants from high-risk 
countries, with 64.6% of patients being born overseas [14]. This increase in the 
incidence of Tb rates in the ethnic minorities is usually due to socio-economic 
pressures such as poverty and overcrowding causing a very high transmission rate 
from infected individuals. Fortunately, NZ is not a high-burden country as Tb 
rates here are not caused by HIV and/or multi-drug resistant Tb (section 1.5.2) 
[15]. 
 
 
 
1.3  Mycobacterium tuberculosis 
 
M. tuberculosis was first isolated by the German physician and scientist, Robert 
Koch in 1882 [16]. This microbe is an intracellular obligate aerobic actinomycete 
about 2-6 µm long with a generation time of approximately 20-24 hours under 
optimal conditions [17, 18]. It forms tight, rope-like aggregates in liquid culture 
[19] and creamy irregular raised colonies with condensed filaments in the center 
in solid media [20] which can take up to 7 days or more to form [21]. 
 
 The genus Mycobacterium can be divided into three groups; the slow-
growing pathogenic mycobacteria that is the M. tuberculosis complex (MTBC); 
the slow-growing non-tuberculous mycobacteria and the fast growing non-
tuberculous mycobacteria [22]. The MTBC consists of human pathogens: 
Mycobacterium tuberculosis, Mycobacterium africanum, Mycobacterium canetti, 
a rodent pathogen, Mycobacterium microti, and a wide host range pathogen: 
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Mycobacterium bovis [23]. Unlike most bacterial clonal complexes which have at 
least 1% synonymous single nucleotide polymorphisms (sSNPs), the MTBC 
exhibit between 0.01% to 0.03% sSNPs [24]. Although the members of the 
MTBC display such high genetic homogeneity, they exhibit very different 
epidemiology and host range thus differentiation between the members is 
necessary for correct treatment [25].  
 
Another key difference that separates mycobacteria from other microbes is the 
presence of a highly complex cell wall consisting of a capsule, a core and an inner 
membrane (Figure 1.2). The capsule is made up of free lipids and mycolates such 
as the phosphatidylinositol mannosides (PIMs) and lipoarabinomannan (LAM). 
The core consists of peptidoglycan (PG) and mycolic acid connected by an 
arabinogalactan (AG) polysaccharide, collectively called the mycolyl 
arabinogalactan–peptidoglycan (mAGP) complex. And lastly the inner membrane 
which consists of a lipid bilayer [26]. The presence of such a large amount of lipid 
in the cell wall makes it acid-fast. This is evident when the cells are stained with 
Ziehl-Neelsen stain. They resist decolorization with acid alcohol and retain the 
primary carbol fuchsin stain giving it the characteristic red/pink colour.  
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Figure 1.2: The mycobacterial cell wall  
The upper segment consists of the soluble capsule intercalated with lipids (phthiocerol 
dimycocerosate, cord factor/dimycolyltrehalose, sulfolipids and phosphatidylinositol 
mannosies) while the lower segment consists of the insoluble mAGP complex.  
 
 
1.3.1  Mycobacterium smegmatis 
 
M. smegmatis, first isolated from smegma [27], was discovered by Lustgarten in 
1884 [28, 29]. This microbe is a fast growing opportunistic pathogen [30, 31] of 
the genus Mycobacterium (section 1.3). Like M. tuberculosis, it is a rod-shaped 
acid fast bacilli, however, its generation time is only approximately 2 to 3 hours 
[18] and it forms colonies within 3 to 4 days on solid media [32]. The commonly 
used laboratory strain, M. smegmatis mc
2
155, can also be efficiently transformed 
with foreign DNA and can undergo homologous recombination. M. smegmatis has 
also shown a 100% specificity to anti-Tb drugs and has the most similar profile to 
MDR-Tb compared to other fast growers [33]. For these reasons, in this thesis, M. 
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smegmatis has been used as a surrogate organism for studying mycobacterial 
biology [32-34] and the pathways that are conserved in M. tuberculosis at a much 
faster rate [35]. Significant results were verified in M. tuberculosis, the disease 
causing pathogen. 
 
 
 
1.4  Mycobacterium tuberculosis Pathogenesis 
 
M. tuberculosis pathogenesis and its virulence factors are poorly understood and 
its intracellular location often confers protection from the immune system 
presenting a multifaceted interaction between the pathogen and the host immune 
response upon infection.  
 
The most prevalent form of Tb is pulmonary tuberculosis [36] as the 
common route of infection is via inhalation of aerosol droplets containing the 
tubercle bacilli from an infected person [37]. Upon entering the lungs, the bacillus 
travels to the alveoli where it is phagocytosed by alveolar macrophages [38-40]. 
At this point, there can be several different outcomes of the infection (Figure 1.3) 
depending on the dose of bacteria upon infection and the immune status of the 
host [41]. The first scenario that can take place is the activation of the alveolar 
macrophages by T cells that have recognized mycobacterial antigens [39]. This 
causes the phagosomes within the macrophages to fuse with lysosomes [38] 
resulting in the elimination of the bacteria. However, the rate of this is not known 
and may be very minuscule [42] as complete eradication of the bacilli is very 
difficult to achieve. 
 
The second scenario that can take place is a latent Tb infection. This 
occurs when the alveolar macrophage does not get activated and the bacilli reside 
within the phagosome. The bacteria change the intracellular environment of the 
phagosome by preventing its acidification, thus avoiding normal maturation and 
phagocytosis [38, 43]. The bacteria continue to divide in the macrophage until the 
macrophage lyses. This causes the macrophages in the surrounding tissue to 
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phagocytose the bacilli and this continues as a vicious cycle. It also causes the 
immune system to respond and try to eliminate the bacteria as the lysis of the 
macrophage causes mycobacterial antigen release. This battle between the 
immune system trying to annihilate the bacteria and the bacteria endeavoring to 
survive causes a caseating tubercle [38]. This can lead to the establishment of a 
granuloma. The granuloma is formed from the collection of infected 
macrophages, lymphocytes and fibroblasts developing a fibrous sheath and 
reducing the number of blood vessels penetrating it thus walling off the bacteria 
from the immune system. This is termed a latent Tb infection where there is no 
display of any clinical symptoms [4, 43, 44]. The host response can contain the 
latent Tb infection for life, however, any weakening of the immune system can 
lead to reactivation of Tb [45] thus greatly increasing the chance of clinical 
manifestations in HIV positive people (Figure 1.3).  
 
The last scenario that can arise is infection followed by active disease. The 
bacillus multiplies in the lungs, spreads to the lymph nodes and can disseminate 
into the blood system to the rest of the body [41]. Dissemination of the bacilli in 
the blood vessel can cause disease manifestations on more distant organs like the 
kidneys, bones and brain.  
 
 
 
Figure 1.3: Pathogenesis of Tb infection and disease 
Inhalation of Tb bacilli can have 3 different outcomes. a) It can get eliminated by the 
immune system, b) it can be contained by the immune system in a latent form and c) it 
can lead directly to active disease or d) latent Tb gets reactivated by immune suppression 
later in life to cause active disease.  
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1.5  Tb Treatment 
 
Streptomycin, discovered in 1944, was the first anti-tubercular drug to enter 
clinical use [46, 47]. Soon after this, other drugs used for the treatment of Tb were 
identified. These include p-aminosalicylic acid (PAS, 1946), isoniazid (INH, 
1952), rifampicin (RIF, 1965), ethambutol (ETH, 1968) and pyrazinamide (PZA, 
1970).  
 
The current antibiotic regimen for the treatment of drug susceptible Tb 
consists of multi-drug therapy (MDT) of first-line drugs to reduce drug resistance 
and increase efficacy [48]. The treatment is divided into an initial 2 month 
intensive phase followed by a 4 month continuation phase. The initial therapy 
consists of RIF, INH and PZA together with an introductory phase of ETH and/or 
streptomycin [2, 47-50]. The continuation phase consists of RIF and INH, the two 
most potent first-line drugs used for the treatment of drug susceptible Tb.  
 
 
1.5.1 Mode of Action (MOA) of first-line drugs 
 
RIF targets the DNA-dependent RNA polymerase. It binds to the beta subunit, 
prevents transcription [51] and kills slowly metabolizing bacteria therefore, 
eliminates persistent bacilli [52]. INH inhibits the biosynthesis of mycolic acid, a 
major component of the mycobacterial cell wall (Figure 1.2) and is bactericidal 
against active bacteria in the pulmonary cavities thus, is crucial in early therapy 
[52]. Streptomycin targets the 30S ribosomal subunit and inhibits protein 
synthesis. It has no bactericidal activity in vivo but greatly limits bacterial growth 
therefore is given in the introductory phase [51]. ETH inhibits the arabinosyl 
transferases involved in cell-wall biosynthesis and PZA is used as bactericidal 
agent against M. tuberculosis but the exact functional mechanisms of PZA has not 
yet been elucidated [51]. PZA also works at a lower pH making it important in 
killing bacteria in the acidic caseous necrotic centre [52].  
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The six month treatment regimen (section 1.5) is a major breakthrough 
from the 18-24 month treatment in the early 1960’s [47]. This therapy is 
administered via DOTS to ensure adherence and reduce the emergence of drug 
resistant Tb [48]. However, resource-limited countries with restricted health 
facilities and poor access to anti-tubercular drugs find the adherence to the 6 
month regimen very difficult. This has given rise to multi-drug resistant Tb 
(MDR-Tb). 
 
 
1.5.2  MDR-Tb 
 
MDR-Tb has been reported since the early days of MDT, and is thought to have 
developed due to ineffective drug therapies, inadequate drug supplies and failure 
to adhere to the treatment regimen [53]. MDR-Tb is described as a combined 
resistance to INH and RIF, the two main first-line anti-tubercular drugs [54, 55]. 
The WHO reported approximately 0.5 million cases of MDR-Tb in 2007 with 27 
high-burden countries, 15 of which are from the Eastern European region, 
accounting for 85% of all cases. Of the 0.5 million MDR-Tb cases worldwide, 0.3 
million were reported as new cases and 0.2 million among previously treated 
cases [7].  
 
The WHO launched the DOTS-Plus project in 1999 for the management 
of MDR-Tb. MDR-Tb treatment is based on individual susceptibility thus requires 
reliable drug-susceptibility testing. The treatment for MDR-Tb is considerably 
longer than drug susceptible Tb and the drugs used have more side-effects and is 
less efficacious [54, 56, 57]. The second-line drugs used for therapy are 
aminoglycosides (kanamycin and amikacin), fluroquinolones (ofloxacin and 
ciprofloxacin), polypeptides (capreomycin, viomycin and enviomycin), D-
cycloserine and thionamides (ethionamide and prothionamide); with 
aminoglycosides and fluroquinolones being the most potent of all the second-line 
drugs [58].  
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1.5.3 MOA of second-line drugs 
 
Fluroquinolones exert their effect by inhibiting DNA gyrase, which is required for 
DNA replication, repair and transcription. They also have the ability to penetrate 
macrophages and exert antimycobacterial activity intracellularly. 
Aminoglycosides inhibit protein synthesis by binding to the 30s ribosomal subunit 
as mentioned in section 1.5.1 for streptomycin, an aminoglycoside used as a first-
line drug. The MOA of polypeptides have not yet been elucidated; however, they 
bind to the ribosome and prevent protein synthesis. D-cycloserine is an analog of 
D-alanine which inhibits alanine racemase, an essential enzyme for the synthesis 
of peptidoglycan that is required for cell wall biosynthesis [54].   
 
Apart from the longer treatment regimen for MDR-Tb, it is also associated 
with a higher cost, making adherence to the treatment even more difficult than 
drug susceptible Tb. This has in turn given rise to extensively-drug resistant Tb 
(XDR-Tb). 
 
 
1.5.4  XDR-Tb 
 
In March 2006, the Centers for Disease Control and Prevention reported the 
emergence of XDR-Tb. XDR-Tb is resistant to the most potent first- and second-
line drugs, that is, resistance to RIF, INH and 3 or more of the second-line drugs; 
one or more fluroquinolones and one or more injectables (capreomycin and/or any 
aminoglycosides) [57]. Treatment for XDR-Tb is associated with higher toxicity 
and lower efficacy. The prevalence of XDR-Tb is unknown however 50 countries 
had reported XDR-Tb cases by mid 2008 with the largest number of cases 
reported in South Africa due to the HIV epidemic [59]. In 2006, a town in the 
province of Kwa-zulu Natal had 53 cases of XDR-Tb, 44 of which were tested for 
HIV and were HIV-positive and 52 died within 16 days after sputum sample 
collection [60]. XDR-Tb has become a major problem in the 21
st
 century and 
there are insufficient drugs to target active XDR-Tb [61]. More recently, there 
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have been reports of super XDR-Tb, more commonly know as totally drug 
resistant Tb (TDR-Tb) [62]. 
 
 
1.5.5  Mechanisms of Drug Resistance  
 
Drug resistance is a natural phenomenon and the mechanisms via which bacteria 
develop resistance are diverse and complex. M. tuberculosis resistance occurs due 
to its highly hydrophobic cell wall (Figure 1.2) that is impermeable to most drugs 
and the resistance determinates encoded by its genome [17, 52].   
 
The resistance to RIF is due to mutations in the rpoB gene which is 
responsible for producing the beta subunit of the DNA-dependent RNA 
polymerase. However, there is a small fraction of resistant bacteria that does not 
exhibit this mutation suggesting there are other mechanisms of RIF resistance 
[51]. INH is a pro-drug that is activated by an enzyme called KatG and it inhibits 
an enzyme that is involved in fatty acid biosynthesis called InhA. Resistant to 
INH occurs due to mutations in the either katG or inhA genes [51]. Streptomycin 
resistance occurs due to mutations in the 16s rRNA genes rrs and rpsL, the gene 
encoding ribosomal protein S12 [63]. ETH resistance is acquired via the 
mutations in the embB gene that encodes for the arabinosyl transferases that is 
inhibited by ETH [64]. 
 
Resistance to fluoroquinolones is due to specific mutations in the gyrA and 
gyrB genes that encode for DNA gyrase A and B subunits respectively [65]. 
Aminoglycosides have the same mechanism of resistance as described for 
streptomycin. Since the MOA of polypeptides has not been characterized, the 
mechanism of resistance is not fully understood; however it also changes the 16s 
rRNA and thus may confer cross-resistance from streptomycin [51]. 
 
Despite the impact of global tuberculosis and the prevalence of drug 
resistance, no new classes of drugs have been approved for Tb treatment by the 
US Food and Drug Administration since 1972 [66]. There is an urgent need for 
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new and alternate drugs to target Tb with novel MOA to prevent cross-resistance 
from current anti-tubercular drugs [67].  
 
 
 
1.6  Tb Drug Development 
 
There are a few challenges impeding Tb drug development. Any new drug would 
have to offer an advantage over the current therapy [46]. Specifically, drugs that 
enable a shorter treatment regimen would be ideal. This would improve patient 
adherence, thereby, increasing the likelihood of elimination of the infection and 
decreasing the risk of the appearance of MDR strains [6]. A shorter drug course 
would also reduce the cost of treatment and therefore, enable the expansion of 
treatment programs to cover larger sections of a particular population. New drugs 
also need to be more effective and safe for people who are infected with resistant 
strains of M. tuberculosis. Any new drug should be able to treat latent Tb to help 
eradicate M. tuberculosis from the large number of people carrying the pathogen 
asymptomatically but who can potentially succumb to tuberculosis later in life [6]. 
And lastly, it should not elicit any drug-drug interactions, including with anti-
retroviral drugs (ARVs) used for the treatment of HIV. There are currently a 
number of Tb drugs in the pipeline to try and achieve these goals.  
 
 
1.6.1 Current Tb drugs in the pipeline 
The TB alliance has accumulated the largest pipeline of potential new anti-
tubercular drugs to try and prevent and reverse the number of Tb cases. One of the 
most promising of these drugs is moxifloxacin, a fluoroquinolone which has 
reached Phase III clinical trials. It targets DNA gyrase, an essential enzyme for 
bacterial survival [68, 69] and it has little interaction with cytochrome P450 
enzymes that is involved in the metabolism of some of the ARVs [70]. 
Replacement of INH with moxifloxacin in the 6 month treatment regimen (section 
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1.5) has been shown to eliminate Tb infection in 4 months, decreasing the 
treatment regimen by 2 months [71].  
 
 Other drugs that have reached Phase II clinical trials are TMC207 and PA-
824.  TMC207 is a diarylquinoline with a novel MOA that specifically targets the 
bacterial ATP synthase [72], an enzyme essential for energy homeostasis [73, 74]. 
TMC207 has shown bactericidal activity against drug-susceptible, MDR-Tb and 
XDR-Tb with no cross-resistance to current first-line drugs [75-77]. It also 
eradicates dormant bacilli as effectively as replicating bacilli [74]. A combination 
of TMC207 with either the current first-line (section 1.5) or second-line (section 
1.5.2) treatment regimen led to the successful eradication of infection within two 
months in drug-sensitive mouse model [78].  
 
PA-824, a nitroimidazole with a novel mechanism of action [79], has 
shown activity in a number of  MDR-Tb strains and has sterilizing effects in vivo 
[80]. In addition, it does not possess mutagenic features against genotoxicity 
studies, that is, non-deleterious effect on cellular genetics, and has no significant 
cytochrome P450 interactions [79]. A combination therapy of PA-824 with 
moxifloxacin and pyrazinamide cured the murine model of Tb faster than the 
current first-line regimen of rifampin, isoniazid, and pyrazinamide [81]. These 
drugs, if applicable to humans, can lead to the shortening of the current treatment 
regimen. The discovery of such novel antibacterial agents, their mechanism of 
action and their resistance determinants has been greatly accelerated by the 
advances in technology such as the availability of genomic data.  
 
 
 
1.7  Genomics  
 
Bacteria generally have a double-stranded circular DNA genome with sizes 
varying from 500 kilobase pairs (kbp) to 9,000 kbp [82, 83]. Current high-
throughput sequencing technologies can sanction the assembly of a microbial 
genome within 24 hours [84]. The genome sequence is the starting point of most 
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genetic based scientific research and has many applications. The first and 
foremost advantage is gene prediction that is the identification of the genes 
contained in the genome by looking at the open reading frames (ORFs) [85]. 
However, sequence alone does not provide the functional annotation of a gene. 
 
This leads to the second use of the genomic data that is genome 
annotation. The most common method used for genome annotation is via 
bioinformatics. Bioinformatics provides a means to study genes, proteins and their 
structure and function in silico. It also provides the foundation for rational design 
of experiments to test the in silico hypothesis. There are several different 
methodologies used for gene annotation. Comparative genomics uses sequence 
homology between genomes to explore the distribution, conservation and 
functions of genes based on their similarity [67], [86]. However, functional 
annotation is not always this simple as not all gene sequences are conserved [87]. 
These genes can be annotated via structural genomics as the structure of a protein 
is important for its function comprehension [88, 89]. Structural genomics can 
identify the catalytic and ligand-binding domains present in a protein. This can 
then be used to predict protein-protein and protein-nucleic acid interactions that 
can aid in functional annotation [90]. Nowadays, ab initio gene prediction 
algorithms are used to predict the protein-coding sequence in silico which is then 
verified by a combination of high-performance liquid chromatography and mass 
spectrometry [91].  
 
Genome annotation can in turn lead to the identification of resistance 
determinants, virulence factors, new protein families and estimated metabolic 
aptitudes of an organism [92-94]. This can shed light on the genes that are critical 
for the survival of the bacteria.  The most significant advantage of such genes in 
pathogenic bacteria is the potential to identify novel antimicrobial targets [95, 96]. 
State of the art second-generation genomics technologies are constantly being 
developed to exploit the genomic data for such studies [97].  
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1.7.1 The Mycobacterium Genome 
 
The publication of the complete genome sequence of M. tuberculosis H37Rv has 
opened a whole window of opportunities for drug development. It is being used to 
identify, validate and exploit new targets to discover novel antimicrobials. The 
current anti-tubercular treatment regimen primarily targets cell wall biosynthesis, 
transcription and translation (section 1.5.1 and 1.5.3). The components of other 
essential mycobacterial processes have remained largely unexploited for anti-
tubercular therapy mainly due to lack of information on the molecular 
mechanisms of these processes.  
 
M. tuberculosis H37Rv is the most commonly used laboratory strain [98] 
due to its virulence in animal models, drug susceptibility and its ability to tolerate 
genetic manipulations. The M. tuberculosis H37Rv genome was first sequenced in 
1998 and has since been revised [17, 99, 100]. It is a GC rich genome with 65.6% 
GC nucleotides and 34.4% AT nucleotides containing 4,411,529 base pairs [17]. 
This genome was reported to encode 4,057 genes, 4,007 encoding for proteins and 
50 encoding RNA molecules [17]. This genomic data is regularly updated on the 
Tuberculist website (http://genolist.pasteur.fr/TubercuList/help/current.html) 
which currently reports 4,411,532 base pairs with 4,009 protein coding sequences.  
 
  
 
Figure 1.4: The M. tuberculosis H37Rv genome. Reproduced from Cole et al, 1998 
[17].  
Chapter One: General Introduction 
_______________________________________________________________ 
 
18  
Since the sequencing of the M. tuberculosis H37Rv genome, about 52% of its 
genes have been assigned functions, most of which are based only on comparative 
genomics. Approximately 10% of the unknown genes are unique to M. 
tuberculosis [101]. There are approximately 250 genes for lipid metabolism as 
opposed to 50 in Escherichia coli. This is due to the complex cell wall structure of 
M. tuberculosis as discussed in section 1.3 [89, 102].  
 
Other findings exclusive to the mycobacterial genome are the presence of 
repeat elements (IS6110 and IS1081) and regulatory genes such as two-
component systems and eukaryotic-like serine/threonine kinases. About 10% of 
the genome is dedicated to the Pro-Glu (PE) and Pro-Pro-Glu (PPE) protein 
families with highly conserved N-terminus which currently have not been 
functionally annotated [17]. 
 
From the sequence data, it is predicted that M. tuberculosis is able to 
synthesize all its essential amino acids, vitamins and co-factors and has all the 
enzymes needed for respiration under aerobic and anaerobic conditions [17]. The 
generation and analysis of genomic data has led to the identification of a lot of 
potential drug targets.  
 
 
1.7.2  Drug Targets: essential and conserved genes 
 
The number of genes required to sustain cellular life under favorable conditions 
without external stress is known as the minimal gene set. The genes in the 
minimal gene set are deemed essential. Since essential genes are critical for the 
survival of an organism, they make excellent drug targets. Gene products essential 
for cellular life processes include those involved in transcription, translation, 
DNA replication, cell division, cell membrane and cell wall synthesis, DNA 
recombination and repair, bioenergetics, and macromolecule synthesis.  
 
Some essential genes are also conserved among different bacteria. This 
signifies a selection pressure and may indicate their potential essentiality. A high 
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degree of gene conservation also suggests that mutations are not tolerated in these 
genes. Targeting such conserved genes will reduce the chances of developing 
resistance via genetic variability [67]. Genes that are essential and conserved in 
bacteria but not in eukaryotes are potential targets for broad-spectrum antibiotic 
development [103, 104]. Broad-spectrum antibiotics are clinically useful against 
different strains of the target organism [67] and important for economic and 
diagnostic reasons [105]. Genes that are specific to a small fraction of bacteria are 
potential targets for narrow-spectrum antibiotics [97]. By assessing multiple 
bacterial genomes, essential targets present in clinically relevant species can be 
identified based on their conservation. The identification of such targets has been 
greatly accelerated by in silico technologies and comparative genomics is often 
used to assess the spectrum of these targets between genomes [104-106].  
 
However, identification of a conserved essential gene is not enough to 
deem it a prospective drug target. Interpretation of essential genes can change 
under different conditions [107] as microbes alter their gene expression to ensure 
its survival upon sensing a change in the environment [108] making certain genes 
only essential under certain conditions. For example, a gene essential in vivo 
under stress conditions may not be essential in vitro under optimal conditions. 
These are known as conditionally essential genes [107]. When selecting essential 
genes for drug targeting, it is important that the genes are required under all 
conditions. Thus the vast number of drug targets in any bacterial genomes 
requires a second level of precedence to select an apt target entailing intervention 
with molecular genetic techniques to validate potential targets [101].   
 
 
1.7.3  Target Validation  
 
The first step in targeted drug discovery is the identification and validation of 
drug targets. Target validation determines if the modulation of a target will lead to 
desirable clinical outcomes [109]. If the inhibition or disruption of a particular 
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target leads to non-viable cells, it is deemed an essential gene and thus, a valuable 
target.  
 
There are a number of different methodologies employed for essentiality 
testing. One of the most widely used techniques is transposon mutagenesis. This 
involves the insertion of genetic elements containing a selectable marker and 
transposase that inserts randomly in the genome leading to the disruption of ORFs 
[67]. The advantage of this methodology is that it can be applied to whole 
genomes. The most successful of the techniques used is transposon site 
hybridization (TraSH) where pools of mutants are identified using DNA 
microarrays and genes that are unable to be mutated are deemed essential [110, 
111]. This technique can also be applied to find conditionally essential genes 
(section 1.7.2) where mutants are recovered in some conditions but not all [107].  
 
Other techniques used for establishing gene essentiality involve sequence 
directed mutagenesis which is especially useful for target validation as this can be 
used to characterize each target individually. These include plasmid insertion 
(gene disruption), allelic exchange (gene deletion; marked and unmarked) and 
directed evolution of target DNA (PCR based) [67]. Directed evolution is 
particularly useful to mutate genes in species that are naturally competent to 
uptake DNA. Genes in such species can be mutated in vitro using directed 
evolution and instantaneously introduced into the cells thus removing the cloning 
steps in creating mutants. However, the most fundamental experiments for target 
validations are target modulation studies. This involves conditional gene 
expression techniques like antisense expression (section 4.1.1.1) and microarray 
expression technologies [67].  
 
A key feature of drug discovery today is the ability to utilize high-
throughput screening (HTS). This calls for target validation assays that are easy 
and reliable to accommodate in these HTS strategies. 
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1.8  Targeted Screening  
 
Once a target is validated as being essential, it can be used for screening 
compounds which specifically inhibit its function. Such screening requires the 
development of an efficient in vitro HTS assay for the identification of hits. A hit 
in high throughput drug screening is defined as a drug that gives a positive 
result/desired phenotype that is being screened for in an assay. There are multiple 
assays for HTS. These include cell-free assays like functional and binding assays 
and whole-cell assays [104]. Cell-free functional assays require a known target 
and measure the biological activity whereas binding assays can be applied to an 
unknown target to elucidate the receptor, ligand or antibody binding [112]. 
Binding assays may also give an insight to the function of the unknown gene. 
Each assay has its own advantage but whole-cell assays are preferred as the 
permeability of the drug is ascertained [104] before resources are invested in 
exploring an inhibitor that may be impermeable [113]. However, compounds can 
affect cell growth in a variety of ways thus, a secondary assay is required to 
stipulate the specificity of the inhibitor to the target [97]. Specificity and 
biochemical information is achieved from cell-free based assays with an isolated 
target, making them vital post-screening assays [114]. 
 
More recently, there has been a merging of the targeted approach with the 
whole-cell based assay which can differentiate between specific and non-specific 
inhibition and enable the determination of the bactericidal activity of the drug and 
the druggability of the targets [105]. Such assays involve titrating the expression 
level of the target and identifying potential inhibitors based on the phenotype of 
the cell depending on the function/pathway that is inhibited [97]. These assays 
may provide some evidence of the function of unknown genes and additional 
information like the MOA of compounds [97]. Since these methods define the 
MOA, bioinformatics can be used to identify related targets in mammalian 
systems and the potential toxicity of the drug to mammalian cells which is crucial 
for anti-mycobacterial therapy, given the long treatment regimens. A targeted 
approach can also lead to rational drug design (RDD) using structure-activity 
relationship (SAR) [115]. 
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In summary, there are many different aspects to be considered in the 
development of new anti-tubercular drugs (Figure 1.5). These features have to 
undergo numerous phases of validation and trials before a drug can enter clinical 
use making active research highly desirable to achieve a good pipeline of drugs as 
it is unlikely that one drug alone will conquer the disease. It is also inevitable that 
resistance will evolve over time due to selection pressure from any antibiotic thus 
requiring back-up drugs for the treatment of resistant Tb.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5: Flow chart of target-based drug discovery 
Schematic representation of the processes involved and the outcomes achieved in target-
based drug discovery. It includes the identification of a protein target whose inhibition is 
potentially going to result in the successful eradication of the microbe, an assay that will 
enable screening small-molecule compound libraries in vitro and in vivo for the 
identification of promising inhibitors in model systems and the determination whether the 
findings are extensible to humans; a complex and resource-extensive process.  
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1.9  Aims of this study 
 
The purpose of this study was to identify inhibitory molecules against potential 
drug targets involved in cell division in the M. tuberculosis genome. The aims of 
this thesis to achieve the above mentioned objective were: 
 
 
A. To establish the number of conserved essential genes in the genome of M. 
tuberculosis H37Rv via bioinformatics and literature curation.     
 
B. To validate some of the conserved essential genes involved in cell division 
for their essentiality in the surrogate M. smegmatis.  
 
C. To run high-throughput library screens against various compound libraries 
with the validated target(s).  
 
D. To develope a biochemical assay of the target protein to test for the 
specificity of all significant hits from the high-throughput screens.  
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2.1 Bacterial Strains and Plasmids 
 
 
2.1.1 Bacterial strains 
 
The bacterial strains used in this study are presented in Table 2.1 together with 
their relevant genotype and phenotype. Stocks of all strains were made up in 20% 
glycerol and stored at -80°C.                                                                        
 
 
Table 2.1: Bacterial strains used in this study 
Strain Relevant genotype and phenotype Reference 
E. coli DH5α supE44 ∆lacU169 (F80 lacZ∆M15) 
hsdR17 recA1 endA1 gyrA96 thi-1 
relA1 
Promega, 
(Sydney, 
Australia) 
E. coli LMG194 
 
F- ∆lacX74 galE thi rpsL ∆phoA (Pvu 
II) ∆ara714 leu::Tn10 with SmR, TcR 
Invitrogen, 
(Auckland, NZ) 
E. coli BL21(DE3) F
–
 ompT gal dcm lon hsdSB(rB
-
 mB
-
) 
λ(DE3 [lacI lacUV5-T7 gene 1 ind1 
sam7 nin5]) 
Novagen, 
(Palmerston 
North, NZ) 
M. smegmatis mc
2
155 High-frequency transformation mutant 
of M. smegmatis ATCC 607 
[116] 
M. bovis BCG Strain Pasteur 1173P2 [117] 
M. tuberculosis H37Rv Laboratory strain ATCC 27294 [118] 
M. tuberculosis H37Ra Strain ATCC 25177 [119] 
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2.1.2 Plasmids 
  
All plasmids utilized in this study are listed in Table 2.2 together with their 
relevant characteristics. The plasmid maps of pCR
®
2.1, pBAD/HisB, pET-28a(+) 
and pMind are provided in Appendix 9.1. 
 
Table 2.2: Plasmids used in this study 
Plasmid 
 
Characteristics 
 
Reference 
 
pCR®2.1 TA cloning vector for direct ligation of PCR products, 
pUC origin, T7 promoter/primer site, LacZα fragment, 
M13F and M13R priming site, Ampr, Kanr, 3.9 kb 
Invitrogen 
pBAD/HisB Protein over-expression vector, pBR322 origin, araBAD 
promoter, rrnB transcription termination, araC gene, 
polyhistidine tag, MCS, Ampr, 4.1 kb 
Invitrogen 
pET-28a(+) Protein over-expression vector, pBR322 origin, T7 
promoter, T7 transcriptional start and terminator, 
His·Tag®, MCS, Kanr, 5.369 kb 
Novagen 
pMind Conditional mycobacterium expression vector, CloliE1 
origin, pAL5000 origin, inducible Ptet, MCS, Kan
r, Hygr, 
6.849 kb 
[120] 
pHS201 Mycobacterial- E. coli shuttle vector with a high-copy-
number version of the pAL5000 mycobacterial replicon, 
BCG hsp60 promoter, gfp with a synthetic Shine-Delgarno 
sequence, Kanr, 5.813 kb 
[121] 
pYL GFP BCG- E. coli shuttle vector, two constitutively expressed 
promoters (BCG hsp60 and hsp70), two MCS, Kanr 
[122] 
pSE100 Mycobacterial- E. coli shuttle vector, containing origins of 
replication for E. coli (pMB1) and mycobacteria 
(pAL5000) and a MCS flanked by two transcriptional 
terminators, contains PmyctetO, Hyg
r, 5.538 kb 
[123] 
pMSC1s Single-copy-integrating plasmid which inserts into L5 
attB, tetR under Psmyc, Kan
r 
[123] 
pSHIGH+hsp60 Mycobacterial- E. coli shuttle vector with a high-copy-
number version of the pAL5000 mycobacterial replicon, 
BCG hsp60 promoter, gfpmut2 with a synthetic Shine-
Delgarno sequence, Kanr, 5.6 kb 
[124] 
pCR®2.1_GFP pCR®2.1 vector cloned with a 0.750 kb PCR fragment 
encoding the gfp from pHS201, 4.65 kb 
This work 
pCR®2.1_2357 pCR®2.1 vector cloned with a 1.209 kb PCR fragment 
encoding the MSMEG_2357 gene from M. smegmatis, 
This work 
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5.109 kb 
pCR®2.1_obg pCR®2.1 vector cloned with a 1.458 kb PCR fragment 
encoding the MSMEG_4623 gene from M. smegmatis, 
5.358 kb 
This work 
pCR®2.1_parB pCR®2.1 vector cloned with a 1.056 kb PCR fragment 
encoding the MSMEG_6938 gene from M. smegmatis, 
4.956 kb 
This work 
pCR®2.1_parA pCR®2.1 vector cloned with a 0.972 kb PCR fragment 
encoding the MSMEG_6939 gene from M. smegmatis, 
4.872 kb 
This work 
pCR®2.1_parA+parB pCR®2.1 vector cloned with a 2.087 kb PCR fragment 
encoding the MSMEG_6938 and MSMEG_6939 gene 
from M. smegmatis, 5.987 kb 
This work 
pCR®2.1_parA_600 pCR®2.1 vector cloned with the first 0.6 kb PCR fragment 
encoding the MSMEG_6939 gene from M. smegmatis, 4.5 
kb 
 
pCR®2.1_ParA pCR®2.1 vector cloned with a 1.044 kb PCR fragment 
encoding the Rv3918c gene from M. tuberculosis H37Rv, 
4.944 kb 
This work 
pCR®2.1_ParB pCR®2.1 vector cloned with a 1.035 kb PCR fragment 
encoding the Rv3917c gene from M. tuberculosis H37Rv, 
4.935 kb 
This work 
pSE100_parA_600 Derivative of pSE100 with the first 0.6 kb PCR fragment 
encoding MSMEG_6939 gene from M. smegmatis cloned 
in the SphI/NotI sites 
This work 
pMindGFP Derivative of pMind with a 0.750 kb PCR fragment 
encoding the gfp from pHS201 cloned in the SpeI site, 
7.598 kb 
This work 
pMind2357 Derivative of pMind with a 1.209 kb PCR fragment 
encoding the MSMEG_2357 gene from M. smegmatis 
cloned in the antisense orientation in the PacI site, 8.058 
kb 
This work 
 
pMind_obg Derivative of pMind with a 1.458 kb PCR fragment 
encoding the MSMEG_4623 gene from M. smegmatis 
cloned in the antisense orientation in the NdeI/SpeI sites, 
8.307 kb 
This work 
pMind_parB_GFP Derivative of pMindGFP with a 1.056 kb PCR fragment 
encoding the MSMEG_6938 gene from M. smegmatis 
cloned in the antisense orientation in the NdeI/SpeI sites, 
8.654 kb 
This work 
pMind_parA_GFP Derivative of pMindGFP with a 0.972 kb PCR fragment 
encoding the MSMEG_6939 gene from M. smegmatis 
cloned in the antisense orientation in the EcoRV site, 8.57 
This work 
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kb 
pMind_parA+parB_GFP Derivative of pMindGFP with a 2.087 kb PCR fragment 
encoding the MSMEG_6938 and MSMEG_6939 gene 
from M. smegmatis cloned in the antisense orientation in 
the NdeI/SpeI sites, 9.685 kb 
This work 
pBAD/HisB_ParA Derivative of pBAD/HisB with a 1.044 kb PCR fragment 
encoding the Rv3918c gene from M. tuberculosis H37Rv 
cloned in the BglII/HindIII sites, 5.144 kb 
This work 
pBAB/HisB_ParB Derivative of pBAD/HisB with a 1.035 kb PCR fragment 
encoding the Rv3917c gene from M. tuberculosis H37Rv 
cloned in the BglII/HindIII sites, 5.135 kb 
This work 
pET-28a(+)_ParA Derivative of pET-28a(+) with a 1.044 kb PCR fragment 
encoding the Rv3918c gene from M. tuberculosis H37Rv 
cloned in the BamHI/HindIII sites, 6.413 kb 
This work 
pET-28a(+)_ParB Derivative of pET-28a(+) with a 1.035 kb PCR fragment 
encoding the Rv3917c gene from M. tuberculosis H37Rv 
cloned in the BamHI/HindIII sites, 6.404 kb 
 
This work 
 
 
 
2.2 Media 
 
2.2.1 E. coli 
 
All E. coli strains were cultured in Luria-Bertani broth (LB broth) and 1.5% 
Luria-Bertani agar (LB agar) as per the manufacturers’ instructions with media 
supplements as described in section 2.2.4 and culture conditions as described in 
section 2.3. All media was sterilized via autoclaving at 121°C for 30 minutes in a 
bench-top autoclave on a liquid cycle. 
 
2.2.2 M. smegmatis 
 
All M. smegmatis strains were cultured in LB broth, 1.5% LB agar or Hartman-de 
Bonts (HdeB) minimal media (Appendix 9.5.1) [125] with media supplements as 
described in section 2.2.4 and culture conditions as described in section 2.3. 
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2.2.3 M. tuberculosis H37Ra and M. bovis BCG 
 
All M. tuberculosis H37Ra and M. bovis BCG strains were cultured in 
Middlebrook 7H9 broth and Middlebrook 7H10 agar. All media was 
supplemented with 0.1% (v/v) Tween 80 and 10% (v/v) oleic acid + albumin + 
dextrose + catalase enrichment (OADC; Fort Richard Laboratories) and cultured 
in conditions as described in section 2.3. 
 
2.2.4 Media supplements 
 
Tween 80: Stock solutions of Tween 80 were made to 10% with distilled and 
deionized water (ddH2O) and autoclaved at 121°C for 30 minutes in a bench-top 
autoclave on a liquid cycle. All M. smegmatis culture in rich media had a final 
concentration of 0.1% Tween 80 (LBT). 
 
Glycerol: Stocks of glycerol were made up to 10%, 50% and 80% with ddH2O 
and autoclaved at 121°C for 30 minutes in a bench-top autoclave on a liquid 
cycle.  
 
Antibiotics: All antibiotic stocks were made with ddH2O and filter-sterilized with 
a 0.22 µm Millipore filter and kept at -20°C except hygromycin solution which 
was bought at 50 mg/mL and stored at -4°C. The final concentrations of all the 
antibiotics used are listed in Table 2.3 unless otherwise stated.  
 
Chemicals: Isopropyl-β-D-thiogalactopyranoside (IPTG) and L-arabinose stocks 
made with ddH2O were filtered-sterilized with a 0.22 µm Millipore filter. 5-
bromo-4-chloro-3-indolyl-β-D-galactopyranoside (X-gal) stocks were made with 
100% DMSO. All stocks were kept at -20°C. The final concentrations of all 
chemicals used are tabulated in Table 2.3 unless otherwise stated.  
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Table 2.3: Antibiotics and/or chemicals used in this study 
Antibiotics/ 
Chemicals 
Stocks E. coli        M. smegmatis 
Ampicillin (Amp) 100 mg/mL 200 µg/mL - 
Kanamycin (Kan) 50 mg/mL 50 µg/mL 50 µg/mL 
Hygromycin (Hyg) 50 mg/mL 50 µg/mL 50 µg/mL 
Tetracycline (Tc) 10 mg/mL 0.02 µg/mL 0.02 µg/mL 
IPTG 100 mg/mL 100 µg/mL - 
X-gal 40 mg/mL 40 µg/mL - 
 
 
 
2.3 Culture Conditions 
 
All bacterial strains were cultured (solid and liquid) at 37°C unless otherwise 
stated. All agar plates were incubated in a stationary plate incubator and all liquid 
cultures in flasks, polypropylene tubes and 96 well plates (Raylab) were aerated 
with orbital shaking at 200 rpm. All flasks were sterilized by autoclaving at 138°C 
on a heat/dry cycle with a cotton-wool bung covered with aluminum foil which 
was used as tops during incubations. All 96 well plates were sealed with plate 
seals (Interlab), wrapped in cling film and placed in a plastic bag to prevent 
evaporation from the wells during incubation [124].  
 
 
2.4 Chemicals and Reagents 
 
All chemicals and/or compounds were purchased from Sigma-Aldrich unless 
otherwise stated. IPTG, Xgal, dNTPs, DNA ladder, DNA loading buffer, DNA 
Molecular Marker and Protein Molecular Marker were procured from Bioline 
(Auckland, NZ).  
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2.5 Enzymes 
 
All restriction endonucleases were purchased from Biolab (Auckland, NZ). T4 
DNA ligase was procured from Invitrogen and Bioline, Taq DNA polymerase 
from Qiagen and PCR Master Mix from Bioline. Proteinase K, lysozyme, RNase 
A and DNAse I was obtained from Sigma.  
 
 
 
2.6 Oligonucleotides 
 
Oligonucleotide primers were analyzed for restriction sites and designed using the 
software package Vector NTI Advance 10 (Invitrogen) and were synthesized by 
Invitrogen. The sequences of the primers used in this study are shown in Table 
2.4. Each primer was resuspended in ddH2O as a stock solution at 100 µM and 
working stocks were made from these at 10 µM with ddH2O.  
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Table 2.4: Primers used in this study 
Primer Name Sequence (5’- 3’) 
 GFP 
 
GFP_RBS_F 
 
GFP_R 
CTAGACTAGTTTTAAGAAGGAGATATACATATGAG
TAAAGGAGGA 
CTAGACTAGTTTATTATTTGTATAGTTCATCCATGCC  
 
 Genes from M. smegmatis mc
2
155 
 
MSMEG_4623_F 
MSMEG_4623_R 
CTAGACTAGTATGCCCCGGTTTGTCGACCG 
CTAGCATATGTCACGAGTCCTCTCCTCCCG 
MSMEG_6938_F 
MSMEG_6938_R 
CTAGACTAGTATGAATCAGCCGGCACGCAA 
CTAGCATATGTTACTCGTTCTGGGCGCTCA 
MSMEG_6939_F 
MSMEG_6939_R 
CTAGGATATCATGGGTTCGGGTCAGAACAA 
CTAGGATATCCTACTGCTGGCGCGGCGGCG 
MSMEG_6939_600F 
MSMEG_6939_600R 
CTAGGCATGCATGGGTTCGGGTCAGAACAA 
CTAGGCGGCCGCGTTGATGGTGAGCAGTCCGA 
 
 Genes from M. tuberculosis H37Rv 
 
ParA_F 
ParA_R 
 
CTAGAGATCTGTGAGTGCTCCGTGGGGCCC 
CTAGAAGCTTTCATGGTCGTCCCTTCGCGG 
ParB_F 
ParB_R 
CTAGAGATCTATGACCCAGCCGTCACGCAG 
CTAGAAGCTTTTACAGAGCGTCCCTGTGCA 
 
 DNA from M. tuberculosis H37Rv 
 
ParS_H37Rv_F 
ParS_H37Rv_R 
AGATCGATCGTCGCCGGGAT 
GTCTCGAGAGCGGAGAATGT 
 
 
 
Sequencing primers  
M13F CCCAGTCACGACGTTGTAAAACG 
M13R AGCGGATAACAATTTCACACAGG 
TetROF11 CTTCCGGTGGTGAGTCATAG 
HygR11 AAGTAACAGGGATTCTTGTGTCAC 
P118 ACGATCCGCGACGTGATGAT 
 
All 5’ restriction sites have been underlined and the ribosome binding site on 
GFP_RBS_F primer is in bold. The forward and reverse primers are denoted by an F or 
an R respectively at the end of the primer name. 
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2.7 Bioinformatics 
 
 
2.7.1 Quantification of essential genes in M. tuberculosis H37Rv 
 
Sassetti, et al. identified 614 putative essential genes (Appendix 9.2.1) in M. 
tuberculosis H37Rv under optimal growth conditions via high density transposon 
mutagenesis [126]. These genes were searched for in the literature and in the 
Tuberculosis Animal Research and Gene Evaluation Taskforce (TARGET) 
database (http://webhost.nts.jhu.edu/target/) at Johns Hopkins University. These 
comprehensive literature searches identified any genes that had subsequently been 
mutated and/or deemed non-essential. The genes that met this criterion were 
deleted from the list of 614 essential genes published by Sassetti to generate a new 
set of putative essential genes in M. tuberculosis H37Rv under optimal conditions.  
 
 
2.7.2 Quantification of conserved essential genes in M. tuberculosis H37Rv 
 
The translated sequences of all the genes identified in section 2.7.1 were obtained 
from the National Centre for Biotechnology Information (NCBI) protein database 
(http://www.ncbi.nlm.nih.gov/sites/entrez?db=protein) and submitted to the 
Database of Essential Genes (DEG; http://tubic.tju.edu.cn/deg/) for BLAST 
alignment to analyse if orthologs of these proteins were essential in other bacterial 
species. The presences of an orthologs in the DEG was determined using cut-off 
parameters of 20% identity over the entire length of the query protein and an E 
value of 1e −20 or lower to obtain a list of conserved essential genes in M. 
tuberculosis H37Rv under optimal conditions.  
 
 
2.7.3 Orthologs of conserved essential genes in M. smegmatis mc2155 
 
Genes identified in section 2.7.2 were analysed by means of BLAST alignment at 
the amino acid level with the M. smegmatis mc
2
155 genome available at the 
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Institute for Genomic Research (TIGR; http://tigrblast.tigr.org/cmr-blast/) to 
determine if orthologs of the M. tuberculosis H37Rv proteins existed in the M. 
smegmatis genome.  
 
 
2.7.4 Homology model of the M. tuberculosis ParA  
 
A homology model of M. tuberculosis ParA (NCBI Reference Sequence: 
NP_218434.2) was generated using modeler 9v7. This sequence was used as a 
BLAST search query of the PDB. Of the multiple hits obtained, the pdb2BEJ gave 
the lowest E value. Sequence alignment was carried out via the T-coffee (v7.38) 
webserver (http://www.igs.cnrs-mrs.fr/Tcoffee/tcoffee_cgi/index.cgi). Five 
models (residues G82-P341; magnesium ion and 4 coordinated water molecules) 
were generated using the alignment and the model with the lowest objective 
function was chosen for docking studies.  
 
 
2.7.5 Ligand docking 
 
All ligands (and isomers) were generated in SYBYL-X using the sketcher module. 
The ligands were energy minimized to a low energy starting conformation using 
the Tripos forcefield. Flexible ligand docking was carried out using Gold 4.1 
using chemscore. Threonine 100 was designated as the centre of the ligand 
binding site with a radius of 12 Å. The metal ion was designated as octahedral. 
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2.8 DNA Isolation, Purification and Quantification  
 
 
2.8.1 Purification of mycobacterial chromosomal DNA 
 
Two methods were used for the isolation of M. smegmatis mc
2
155 and M. 
tuberculosis H37Rv chromosomal DNA: phenol/chloroform extraction (section 
2.8.1.1) and ZR Fungal/Bacterial DNA Kit
™
 (Zymo Research- Nelson NZ, section 
2.8.1.2).  
 
 
2.8.1.1  Phenol/chloroform extraction 
 
This method was adapted and modified from Mycobacteria Protocols [127]. M. 
smegmatis mc
2
155 frozen stocks were streaked on LB agar plates and incubated 
(section 2.3) for 72 hours. After 72 hours, a loopful of colonies were inoculated 
into 3 mL LBT in 15 mL polypropylene tubes and cultured overnight (section 
2.3). Approximately 1.5 mL of the overnight culture was pelleted by 
centrifugation at 13, 000 x g for 5 minutes and frozen at -80°C for 4 hours (all 
subsequent centrifugation steps were carried out at 13, 000 x g). After 4 hours, the 
pellet was thawed and resuspended in 400 µL TE buffer (Appendix 9.5.4) by 
vigorous vortexing. A 0.02 volume of 100 mg/ml lysozyme was added to the cells 
and incubated in a water bath at 37°C for 30 minutes. After incubation, a 0.1 
volume of 10% SDS (w/v) and a 0.02 volume of 10 mg/mL proteinase K 
(Appendix 9.5.3) was added to the cell lysate and incubated in a 65°C water bath 
for 15 minutes. After 15 minutes, 400 µL of TE-buffered phenol was added to the 
lysate, mixed gently and centrifuged for 10 minutes. The residual phenol was 
removed from the upper aqueous layer by the addition of 400 µL of chloroform; 
which was mixed gently and again centrifuged for 10 minutes. A 2.5 volume of 
cold ethanol and 0.1 M sodium acetate (pH 5.2) were added to the aqueous layer 
in a fresh microfuge tube, mixed gently and centrifuged for 20 minutes to 
precipitate the DNA. The supernatant was removed and 70% cold ethanol was 
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added to the pellet and centrifuged for 5 minutes. The supernatant was removed 
again and the DNA was dried on a 37°C heating block, resuspended in 200 µL TE 
buffer and stored at -20°C.  
 
 
2.8.1.2  ZR fungal/bacterial DNA Kit ™ 
 
M. smegmatis mc
2
155 was cultured and pelleted (as described in section 2.8.1.1), 
to 50-100 mg (wet weight), washed once in 1x PBS (Appendix 9.5.4), 
resuspended in 750 µL Lysis Solution and added to ZR BashingBead
™
 Lysis tube. 
This was vortexed vigorously for 10 minutes and centrifuged at 13, 000 x g for 1 
minute. Approximately 400 µL of supernatant was transferred to Zymo-Spin
™
 IV 
Spin Filter collection tube and centrifuged at 7, 000 x g for 1 minute. About 1, 
200 µL of Fungal/Bacterial DNA Binding buffer was added to the filtrate and this 
was transferred to Zymo-Spin
™
 IIC column in a collection tube and centrifuged at 
10, 000 x g for 1 minute (this step was carried out twice with 800 µL at a time and 
all subsequent centrifugation steps were carried out at 10, 000 x g). The flow 
through was discarded and 200 µL of DNA Pre-Wash buffer was added to the 
Zymo-Spin
™
 IIC column and centrifuged for 1 minute. 500 µL Fungal/Bacterial 
DNA Wash buffer was added to the Zymo-Spin
™
 IIC column and again 
centrifuged for 1 minute. The Zymo-Spin
™
 IIC column was transferred to a fresh 
1.5 mL microfuge tube and 100 µL of DNA Elution buffer was added to the 
column matrix then centrifuged for 30 seconds. The eluted DNA was stored at -
20°C. 
 
 
2.8.2 Purification of plasmid DNA 
 
Two methods were used for the isolation of plasmid DNA in this study; 
phenol/chloroform extraction (section 2.8.2.1) and Zyppy
™
 Plasmid Miniprep Kit 
(Zymo Research, section 2.8.2.2).  
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2.8.2.1  Phenol/chloroform extraction 
 
Single colonies were picked from LB agar plates and inoculated in 2 mL LB broth 
in 15 mL polypropylene tubes with appropriate antibiotics (Table 2.3) and 
cultured overnight (section 2.3). A 1.5 mL of the overnight cultures were 
transferred to microfuge tubes and centrifuged at 13, 000 x g for 30 seconds (all 
subsequent centrifugation steps were carried out at 13, 000 x g). The pellets were 
resuspended in 100 µL cold Alkaline Lysis Solution I (Appendix 9.5.3) by 
vigorous vortexing. Approximately 200 µL of freshly prepared Alkaline Lysis 
Solution II (Appendix 9.5.3) was added to the bacterial suspensions and mixed via 
inverting the tube. 150 µL of cold Alkaline Lysis Solution III (Appendix 9.5.3) 
was added to the lysate, mixed via inverting the tubes, incubated on ice for 3 
minutes and centrifuged for 5 minutes. One volume of phenol: chloroform (1:1) 
was added to the supernatant, mixed via vortexing then centrifuged for 2 minutes. 
This step was repeated with chloroform. The aqueous layer was transferred to 
fresh microfuge tubes and 2.5 volumes of cold 99% ethanol was added to these. 
The solution was mixed via vortexing and allowed to stand at room temperature 
for 2 minutes before it was centrifuged for 5 minutes. The supernatant was 
removed and all drops of fluid were removed by inverting the tubes on a 
Kimwipe. About 200 µL of cold 70% ethanol was added to the pellets, inverted 
several times and centrifuged for 2 minutes. The supernatant was removed and the 
tubes were stored at room temperature until all the ethanol evaporated. The 
nucleic acid was resuspended in 50 µL TE buffer (Appendix 9.5.4) and stored at -
20°C. 
 
 
2.8.2.2  Zyppy™ Plasmid Miniprep Kit 
 
Approximately 100 µL of 7x Lysis buffer was added to 600 µL of overnight 
cultures (as described in section 2.8.2.1) in 1.5 mL microfuge tubes and mixed via 
inverting the tubes several times. About 350 µL cold Neutralization buffer (with 
100 µg/mL RNase A) was added to the lysate, mixed via inverting the tubes 
several times and centrifuged at 13, 000 x g for 2 minutes (all subsequent 
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centrifugation steps were carried out at 13, 000 x g for 30 seconds). The 
supernatant was transferred to Zymo-Spin
™
 II columns in collection tubes and 
centrifuged, washed with 200 µL Endo-Wash buffer, centrifuged again and re-
washed with 400 µL Zyppy
™
 Wash buffer via centrifugation with the flow-
through being discarded between each centrifugation step. The columns were 
transferred to a clean microfuge tubes and the plasmid was eluted with either 30 
µL Zyppy
™
 Elution buffer or 30 µL ddH20 by centrifugation and stored at -20°C. 
 
 
2.8.3 Gel purification of DNA 
 
DNA from agarose gels were purified using Zymoclean
™
 Gel DNA Recovery Kit 
(Zymo Research). DNA fragments were excised out of the gel using a scalpel and 
transferred to pre-weighed microfuge tubes. 3 volumes of ADB buffer was added 
to each volume of agarose gel and incubated on a heating block at 37-55°C for 5-
10 minutes until all the gel dissolved. The solution was transferred to Zymo-
Spin
™
 columns in collection tubes and centrifuged at 13, 000 x g for 30 seconds 
and washed twice with Wash Buffer by centrifugation (all centrifugation steps 
were carried out at 13, 000 x g for 30 seconds). The columns were transferred to 
new microfuge tubes and the DNA was eluted with 6-10 µL ddH2O by 
centrifugation and stored at -20°C.  
 
 
2.8.4 Purifying salts and enzymes from DNA 
 
Plasmid DNA extracted via phenol/chloroform extraction (section 2.8.2.1) was 
desalted on nitrocellulose membrane filters (Biolab; section 2.8.4.1) or run 
through the DNA Clean and Concentrator
™
 column (Zymo Research, section 
2.8.4.2). The DNA Clean and Concentrator
™ 
Kit was also used to clean PCR 
products (section 2.9.1) before ligation reactions (section 2.9.2) and enzymes from 
restriction digests (section 2.9.6). Plasmid DNA purified using Zyppy
™
 Plasmid 
Miniprep Kit was not desalted as the flow-through via the column removed all 
salts.  
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2.8.4.1  Nitrocellulose filters 
 
Nitrocellulose membrane filters (Biolab) were placed on petri dishes filled with 
ddH20 with the matt surface on the water and the gloss side up. Approximately 50 
µL of phenol/chloroform extracted plasmid DNA was placed on top of the filter 
and was dialysed for 30 minutes to remove all salts. After 30 minutes, the 
plasmids were recovered from the filter (~ 48 µL), transferred to sterile microfuge 
tubes and stored at -20°C. 
 
 
2.8.4.2  DNA Clean and Concentrator Kit™ 
 
One volume DNA Binding buffer was added to DNA samples, mixed via 
vortexing and transferred to the Zymo-Spin
™
 columns in collection tubes. The 
tubes were centrifuged at 13, 000 x g for 30 seconds (all centrifugation steps were 
carried out at 13, 000 x g for 30 seconds). The flow-through was discarded and 
200 µL of Wash buffer was added to the columns and centrifuged. This step was 
repeated once and the DNA was eluted out with 6-10 µL ddH2O via centrifugation 
into fresh microfuge tubes and stored at -20°C.  
 
 
2.8.5 DNA quantification 
 
All nucleic acid was quantified using NanoDrop
®
 ND-100 Spectrophotometer 
(NanoDrop Technologies, Auckland, NZ) using NanoDrop
®
 3.1.0 software. The 
pedestal was cleaned and initialized with ddH2O and blanked with the solution the 
DNA was dissolved in (TE buffer, elution buffer or ddH2O). A 1 µL  of the 
sample was placed on the pedestal and read at 260 nm in ng/µL.  
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2.9 Genetic Manipulation  
 
2.9.1 Polymerase Chain Reaction (PCR) 
 
PCRs were performed using eppendorf Mastercycler
®
 gradient (Global Science) 
in PCR tubes using either Taq DNA polymerase (Table 2.6) or PCR Master Mix 
(Table 2.7). The annealing temperatures and the templates used for each primer 
set are given in Table 2.8. All PCR cycles were carried out as shown in Table 2.5 
except for the amplification of MSMEG_parA+parB with primers 
MSMEG_6939_F and MSMEG_6938_R which had an extension time of 120 
seconds in the 30 x cycle.  
 
 
Table 2.5: PCR cycles used for basic amplification 
 
 
 
 
 
 
 
 
 
 
 
Cycle Temperature Time No. of cycles 
Initial 
denaturation 
94°C 2 mins  1 x 
 
Denaturation 
Annealing  
Extension  
94°C 
As shown in Table 2.8 
72°C 
 
30 sec 
30 sec 
60 sec 
 
30 x 
Final extension 72°C 10 mins 1 x 
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Table 2.6: Reagents and concentrations used with Taq DNA Polymerase 
 
 
 
 
Table 2.7: Reagents and concentrations used with PCR Master Mix 
 
 
 
 
 
 
 
 
 
 
 
 
 
Reagent Stock conc. Final conc. 
Primer_F 10 µM 0.4 µM 
Primer_R 10 µM 0.4 µM 
CoralLoad Buffer 10 x 1 x 
Taq 250 U 1 U 
MgCl2 25 mM 1.5 mM 
DMSO 100% 5% 
Template 100 – 200 ng/uL 40 – 80 pg 
Reagent Stock conc. Final conc. 
Primer_F 10 µM 0.4 µM 
Primer_R 10 µM 0.4 µM 
BioMix Red 2 x 1 x 
DMSO 100% 5% 
Template 100 – 200 ng/uL 40 – 80 pg 
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Table 2.8: PCR annealing temperatures used per primer set 
 
* The pMind vectors had various inserts that were screened (section 2.9.5.3) using 
different annealing temperatures which was suitable for both the forward and the reverse 
primers.  
 
 
2.9.2 DNA ligations 
 
Two different T4 DNA ligase were used in this study. TA cloning of PCR 
fragments (Table 2.9) was carried out using the T4 DNA ligase supplied with the 
pCR
®
2.1 TA Cloning Kit (Invitrogen). All other ligation reactions, that is, 
cohesive end ligations (Table 2.10), were carried out using T4 DNA ligase 
purchased from Bioline. All TA ligation reactions were ran with a negative 
control with no vector. All cohesive end ligation reactions had a negative control 
with no vector and a control with the digested but unligated vector to identify the 
percentage of false positives in the transformations (section 2.9.3.2). 
Primer Name Anneal
. temp. 
Template 
MSMEG_6939_600F; 
MSMEG_6939_600R 
55°C M. smegamtis mc
2
155 
P118; MSMEG_6939_600R 40°C pSE100_parA_600 
GFP_RBS_F; GFP_R 54°C pHS201 
MSMEG_6938_F ; MSMEG_6938_R 53°C M. smegamtis mc
2
155 
MSMEG_6939_F; MSMEG_6939_R 53°C M. smegamtis mc
2
155 
MSMEG_2357_F; MSMEG_2357_R 52°C M. smegamtis mc
2
155 
MSMEG_2509_F; MSMEG_2509_R 58°C M. smegamtis mc
2
155 
MSMEG_4623_F; MSMEG_4623_R 56°C M. smegamtis mc
2
155 
MSMEG_6327_F; MSMEG_6327_R 53°C M. smegamtis mc
2
155 
ParA_F; ParA_R 57°C M. tuberculosis H37Rv 
ParB_F; ParB_R 55°C M. tuberculosis H37Rv 
ParS_H37Rv_F; ParS_H37Rv_R 45°C M. tuberculosis H37Rv 
TetROF11;  HygR11 44°C pMind* 
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Table 2.9: Reagents and concentrations used for TA cloning 
 
 
 
 
 
 
The above ligation reactions were prepared in PCR tubes and made-up to a total 
volume of 10 µL with ddH2O and incubated in the eppendorf Mastercycler
®
 
gradient at 16°C overnight before transformations (section 2.9.3.2).  
 
 
 
Table 2.10: Reagents and concentrations used for cohesive end ligation 
 
 
 
 
 
 
 
The above ligation reactions were prepared in PCR tubes and made-up to a total 
volume of 10 µL and incubated in the eppendorf Mastercycler
®
 gradient at 16°C 
for 30 minutes before transformations (section 2.9.3.2). 
 
 
2.9.3 Transformations into  E. coli 
 
E. coli was transformed with vectors and ligation reactions into calcium 
competent cells (section 2.9.3.1) with heat-shock (section 2.9.3.2).  
 
 
 
Reagent Stock conc. Final conc. 
T4 DNA Ligase 4 U/µL 0.4 U/µL 
Ligation Buffer 10 x 1 x 
pCR
®
2.1 vector 25 ng/µL 25 ng 
PCR product - 50 - 100 ng 
Reagent Stock conc. Final conc. 
T4 DNA Ligase 10 U/µL 0.5 U/µL 
Ligation Buffer 10 x 1 x 
ATP solution 10 x 1 x 
Vector 10 – 20 ng/µL 10 ng 
Insert 50 – 200 ng/µL 90 ng 
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2.9.3.1  Preparation of calcium competent cells 
 
E. coli frozen stocks were streaked on LB agar plates and incubated overnight 
(section 2.3). Single colonies from the overnight plates were inoculated into 10 
mL LB broth in 50 mL polypropylene tubes and cultured overnight (section 2.3). 
The overnight cultures were sub-cultured in 100 mL LB broth (1:10) in 250 mL 
flasks and cultured with vigorous shaking (section 2.3) until the optical density at 
600 nm (OD600) reached ~ 0.5. OD600 of the cultures were measured in 10 mm 
path length cuvettes using a Thermo Heλios γ Spectrophotometer (all cultures 
were diluted with the appropriate media to give an OD600 reading ranging between 
0.05-0.5 for accurate reading in the spectrophotometer). These mid-logarithmic 
phase cells were transferred to 50 mL polypropylene tubes and stored on ice for 
30 minutes. The cells were harvested by centrifugation at 4, 000 x g for 10 
minutes at 4°C (all subsequent centrifugation steps were carried out at 4, 000 x g 
for 10 minutes at 4°C). The supernatant was decanted and the pellet was 
resuspended in 50 mL cold sterile 0.1 M CaCl2. This was incubated on ice for 20 
minutes and the cells were recovered by centrifugation. The cell pellets were 
resuspended in 2 mL cold sterile 0.1 M CaCl2 with 14% glycerol and 50 µL 
aliquots of these were stored into microfuge tubes and were either used for heat-
shock transformations (section 2.9.3.2) and/or stored at -80°C. 
 
 
2.9.3.2  Heat-shock transformation 
 
Calcium competent cells (section 2.9.3.1) were taken out of -80°C and thawed on 
ice for 5 minutes. Approximately 150 µL cold sterile 0.1 M CaCl2 was added to 
the cells and 10 µL of the ligation reactions (section 2.9.2) or 50 ng/µL of purified 
plasmid DNA (section 2.8.2) were added to the cells, incubated on ice for 20 
minutes and heat-shocked at 42°C on a heating block for 90 seconds. The tubes 
were incubated on ice for 5 minutes after heat-shock before 800 µL LB broth were 
added to the cells. These transformations were recovered in LB at 37°C for 60 
minutes in a stationary incubator. After 60 minutes, the cells were spun at 13, 000 
x g for 30 seconds, 900 µL of the supernatant was discarded and the pellet was 
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resuspended in the remaining 100 µL media and plated on LB agar plates with 
appropriate antibiotics (Table 2.3).  
 
 
2.9.4  Transformations into M. smegmatis 
 
M. smegmatis was transformed with vectors using electro-competent cells (section 
2.9.4.1) via electroporation (section 2.9.4.2).  
 
2.9.4.1  Preparation of electro-competent cells 
 
M. smegmatis was cultured overnight as described in section 2.8.1.1 in 10 mL 
LBT in 50 mL polypropylene tubes. The overnight cultures were sub-cultured into 
100 mL LBT (1:10) in 250 mL flasks until the OD600 reached between 0.5 to 1.0. 
These mid-log phase cells were transferred to 50 mL polypropylene tubes and 
stored on ice for 20 minutes. The cells were harvested by centrifugation at 4, 000 
x g for 20 minutes at 4°C (all subsequent centrifugation steps were carried out at 
4, 000 x g for 20 minutes at 4°C). The supernatant was decanted and the pellet 
was resuspended in 50 mL cold sterile 10% glycerol, incubated on ice for 10 
minutes and recovered by centrifugation. The cell pellet was resuspended in 20 
mL cold 10% glycerol, recovered by centrifugation and resuspended in 4 mL 10% 
glycerol. Approximately 200 µL of this suspension was aliquoted out into 
microfuge tubes and were either used for electroporations (section 2.9.4.2) and/or 
stored at -80°C. 
 
 
2.9.4.2  Electroporation 
 
Electro-competent cells (section 2.9.4.1) were taken out of the -80°C freezer and 
thawed on ice for 5 minutes. Approximately 200 µL of cold sterile 10% glycerol 
was added to the cells before they were transferred into chilled 0.2 cm electrode 
gap electroporation cuvettes (Raylab, Auckland, NZ). Between 0.5-5 µg purified, 
desalted plasmid DNA (section 2.8.2 and section 2.8.4 respectively) were added 
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to the cuvettes and incubated on ice for 2 hours. After incubation, the cuvettes 
were placed in the electroporation chamber and subjected to a single pulse of 2.5 
kV, capacitance of 25 µF and the pulse-controller resistance at 1000 Ω using a 
Gene Pulser Xcell
™
 Electroporation System (Bio-Rad). After electroporation, the 
cells were transferred into microfuge tubes, 600 µL LB broth was added to these 
and incubated at 37°C for 6-16 hours. After incubation, the cells were harvested 
by centrifugation at 13, 000 x g for 30 seconds, 900 µL of supernatant was 
removed and the cells were resuspended in the remaining 100 µL media and 
plated on LB agar plates with appropriate antibiotics (Table 2.3).  
 
 
2.9.5 Identification of recombinant clones 
 
Recombinants clones were initially identified via colony screening (section 
2.9.5.1). Clones with the correct inserts were cultured overnight (section 2.3) in 
LB with appropriate antibiotics (Table 2.3) from which plasmids were extracted 
(section 2.8.2). 
 
 
2.9.5.1  Colony screening 
 
Colonies were picked from agar plates and used as templates in the PCR reactions 
with the appropriate primers (Table 2.4) and their respect annealing temperatures 
(Table 2.8) using the PCR protocols shown in section 2.9.5.3. Approximately 5 
µL PCR products were run on 1% agarose gels (section 2.9.8) and the presence of 
the correct size PCR product verified that the insert was present in the colony. 
Clones verified with inserts were prepared using either of the protocols in section 
2.8.2 for further analysis. 
 
 
 
 
Chapter Two: Materials and Methods 
_______________________________________________________________ 
 
47  
2.9.5.2  PCR products in pCR®2.1 
 
Identification of recombinant clones in pCR
®
2.1 vector (Appendix 9.1) was done 
via blue/white selection on LB agar plates supplemented with Amp
+
, Kan
+
, 
IPTG
+
, X-Gal
+
 (refer to Table 2.3 for conc.). White colonies signified insertion of 
the PCR product. To verify this, single colonies were picked for colony screening 
(section 2.9.5.1) and also inoculated into 3 mL LB Amp
+
, Kan
+
 broth in 15 mL 
polypropylene tubes to be cultured overnight for plasmid preparation (section 
2.8.2), restriction analysis (section 2.9.6) and DNA sequencing (section 2.9.9) to 
confirm the insertion of the correct PCR product. Restriction analysis verified that 
the correct enzyme sites from the PCR primers (Table 2.4) had been integrated 
and agarose gel electrophoresis (section 2.9.8) was used to confirm that the 
correct size fragment was inserted before plasmids were sent for sequencing. 
DNA sequencing (section 2.9.9) was performed using primers M13F and M13R 
(Table 2.4) and it verified the exact nucleotide sequence of the insert. 
 
 
2.9.5.3  Orientation PCR 
 
Orientation PCRs were performed when DNA fragments containing the same 
restriction sites on both ends were used for cloning into the pMind vector, that is, 
GFP into the SpeI site, parA into the EcoRV site, and MSMEG_2357 into the 
PacI site (Table 2.4). The orientations of the inserts were screened using an 
external primer designed from the sequence of the plasmid (TetROF11 and/or 
HygR11) and an internal primer designed from the sequence of the insert (Table 
2.4). 
 
 All orientation PCR reactions were denatured for 2 minutes at 94°C followed 
by 15 cycles of denaturation for 30 seconds at 94°C, 30 seconds at annealing 
temperatures shown in Table 2.8 for the respective gene primers used and 60 
seconds of extension at 72°C. This was followed by 15 cycles of denaturation for 
30 seconds at 94°C, 30 seconds of annealing at 44°C for the external primer and 
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60 seconds of extension at 72°C, followed by a final extension for 10 minutes at 
72°C (Table 2.11). 
 
 
Table 2.11: PCR cycles used for orientation screens 
 
 
 
2.9.6 Restriction digests 
 
All restriction digests were performed with the appropriate New England Biolabs 
(NEB) buffers supplied with the enzyme. Appropriate buffers for double digests 
were searched in the Double Digest Finder, NEB 
(http://www.neb.com/nebecomm/doubledigestcalculator.asp). Approximately 1x 
BSA was added to some enzyme digests as recommended by the manufacturer.  
 
All restriction digests (Table 2.12) for the analysis of insertions into 
vectors were made up to a total volume of 10 µL with ddH2O and incubated at 
37°C for 4 hours before running the digests on a 1% agarose gel (section 2.9.8). 
Cycle Temperature Time No. of cycles 
Initial denaturation 94°C 2 mins  1 x 
 
Denaturation 
Annealing  
Extension  
94°C 
As shown in Table 2.8 
72°C 
 
30 sec 
30 sec 
60 sec 
 
15 x 
Denaturation 
Annealing  
Extension  
94°C 
44°C 
72°C 
 
30 sec 
30 sec 
60 sec 
 
15 x 
Final extension 72°C 10 mins 1 x 
Chapter Two: Materials and Methods 
_______________________________________________________________ 
 
49  
All restriction digests performed to obtain cohesive end DNA fragments for 
ligation reactions (section 2.9.2) were incubated overnight at 37 °C.  
 
Digests used to extract DNA fragments from vectors were made up to a 
total volume of 50 µL with ddH2O and incubated overnight at 37°C and run on a 
1% agarose gel (section 2.9.8) to separate the extracted DNA fragment from the 
plasmid DNA before being gel purified (section 2.8.3). All vectors that were 
digested to ligate DNA fragments into were made up to a total volume of 20 µL 
with ddH2O and put through the DNA Clean and Concentrator
™
 column (Zymo 
Research, Section 2.8.4.2) after the overnight incubation to purify the DNA of 
enzymes and salts from the buffers. 
 
 
Table 2.12: Reagents and concentrations used for restriction digests  
 
 
 
 
 
 
 
 
 
2.9.7 Dephosphorylation 
 
Vectors digested with the same restriction site for ligation of DNA fragments 
were first dephosphorylated using calf intestinal phosphatase (CIP). Digested 
vectors were clean and concentration (section 2.8.4.2) and quantified (section 
2.8.5). Approximately 10 units of CIP was incubated with 1 µg of DNA at 37°C 
for 4 hours. After 4 hours the reaction was clean and concentrated again and used 
in ligation reactions (section 2.9.2) 
 
 
Reagent Stock conc. Final conc. 
Restriction 
Enzyme 
10, 000 U/µL 0.5 U/µL 
NEBuffer 10 x 1 x 
BSA 10 x 1 x 
Vector 50 – 200 ng/µL 25 - 100 ng 
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2.9.8 Agarose gel electrophoresis 
 
1% agarose gels were prepared using 1g of agarose dissolved in 100 mL 1 x TAE 
buffer (Appendix 9.5.4) via microwaving. Approximately 100 mL of 1% agarose 
was mixed with 10mg/ml ethidium bromide, poured into a gel cast with combs 
and set at RT for 30 minutes. 5 µL of DNA ladder and DNA with 5x DNA 
loading buffer (1: 4) were loaded on the gel and ran at 100-120 V for 60-90 
minutes. Gels were visualized using a High Performance UV transilluminator. Gel 
photos were taken with an Olympus C-5060 Wide Zoom digital camera and 
analyzed using UVP LS (Life Sciences) Software.  
 
 
2.9.9 DNA sequencing  
 
DNA sequencing reactions were sent to The Allan Wilson Centre for Molecular 
Ecology and Evolution Genome Services (Palmerston North, NZ) in PCR tubes 
containing 300 ng of plasmid DNA, 3.2 pmol of the appropriate primer and 
ddH2O to make the reaction up to 15µL. The chromatograms received from the 
sequencing reactions were analyzed using Vector NTI Advance 10 software 
(Invitrogen).  
 
 
2.9.10 Curing plasmids 
 
M. smegmatis-pMind_parA+parB_GFP colonies were picked from LB Kan
+
, 
Hyg
+
 plates and cultured overnight in 10 mL LBT (section 2.3) in 50 mL 
polypropylene tubes. These were subcultured into 100 mL LBT in 250 mL flasks, 
grown overnight, subcultured again (1:10) into 100 mL LBT in 250 mL flasks and 
grown overnight. Serial dilutions of the last overnight cultures were plated out 
onto LB agar plates. Singles colonies were picked from these serial dilution plates 
and patched onto LB and LB Kan
+
, Hyg
+
 plates. Colonies that lost resistance were 
used as cured strains.  
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2.10 Protein Over-expression, Purification and Quantification 
 
2.10.1 Protein over-expression optimization  
 
Protein over-expressions were carried out in E. coli LMG194 with the 
pBAD/HisB vector and in E. coli BL21 (DE3) with the pET-28a(+) vector. Both 
these vectors were cloned with the wild-type parA and parB genes from M. 
tuberculosis H37Rv under the transcriptional control of the arabinose promoter 
for the pBAD/HisB vector and the T7 promoter for the pET-28a(+) vector (Table 
2.2).  
 
 
2.10.1.1 Expression of recombinant protein in E. coli LMG194 
 
E. coli LMG194 expression strains were overexpressed in various conditions to 
try to obtain soluble Par proteins. E. coli LMG194 transformed with 
pBAD/HisB_LacZ was used as a positive control.  
 
Expression strains were taken from the -80°C freezer and streaked onto LB 
agar Amp
+
 plates and incubated overnight (section 2.3). Single colonies were 
picked from these plates and cultured into 3 mL LB Amp
+
 overnight (section 2.3). 
Approximately 50 µL of the overnight cultures were subcultured into 10 mL LB 
Amp
+
 in 50 mL polypropylene tubes and subjected to the conditions below: 
 
I. The first experiment was carried out at 37°C. The subcultured cells were 
grown to an OD600 of 0.5 and induced with 0.2% L-arabinose for 4 hours. 
(Initial experiments with varying concentrations of L-arabinose (0.0002% - 
0.2%) at different time points was carried out to determine the concentration 
of L-arabinose and the time required for optimal over-expression).  
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II. The second experiment was carried out exactly as described in I above 
except after the OD600 reached around 0.5, the cultures were cooled to 18°C 
and induced overnight with 0.2% L-arabinose at 18°C.   
 
III. The third experiment was carried out in high salt media. The starter cultures 
were grown overnight at 37°C in LB with 0.5 M NaCl, subcultured as 
described above in LB containing 0.5 M NaCl and 1 mM betaine, grown till 
the OD600 reached around 0.5 and induced overnight at 37°C with 0.2% L-
arabinose.  
 
IV. The fourth experiment was carried out as described in III above with a few 
modifications. The subcultured cells were grown till the OD600 reached 0.9, 
heatshocked at 47°C in a waterbath, induced with 0.2% L-arabinose for 20 
minutes in the 47°C waterbath before it was transferred to 25°C for 
overnight expression [128].  
 
V. The fifth experiment was carried out in auto-inducing media ZYP-5052 
(Appendix 9.5.2) [129]. Overnight starter cultures were subcultured in ZYP-
5052 and grown overnight at 37°C in the absence of the L-arabinose.  
 
 
2.10.1.2  Expression of recombinant protein in E. coli BL21 
 
E. coli BL21(DE3) expression strains were cultured and expressed similar to E. 
coli LMG194 expression strains (section 2.10.1.1) except all media had Kan 
instead of Amp and all cultures were induced with 0.5 mM IPTG instead of 0.2% 
L-arabinose except in autoinducing media which did not require an inducer.  The 
fifth condition mentioned above (section 2.10.1.1) with ZYP-5052 auto-induction 
media gave the most soluble protein. This was scaled up to 500 mL over-
expression cultures for protein isolation.  
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2.10.2  Purification of recombinant protein 
 
Approximately 500 mL of overexpressed cultures (section 2.10.1.2) were pelleted 
in 50 mL polypropylene tubes and were lysed via resuspending the pellet in: 
 
1. 20 mL Bug Buster® Protein Extraction reagent (Novagen) for 20 minutes 
on a rocking platform at room temperature (RT). 
2. 20 mL cold 1x bind buffer (Novagen) and French pressed (Thermo 
Scientific) three times at 1000 psi.  
3. 30 mL cold 1x bind buffer* (Novagen) and sonicated (Ultrasonic 
processor W-380) for 3 minutes in one second bursts with a power output 
ranging from 50-70% in tubes packed with crushed ice.  
 
The cell lysate was transferred to 50 mL polypropylene Sorvall tubes and the 
cellular debri was removed from the soluble fraction via centrifugation at 14, 000 
in a Sorvall RC-5C centrifuge (Thermo Scientific) for 30 minutes at 4°C. The 
supernatant was column purified using the Ni-NTA His•Bind® Resin and 
His•Bind® Purification kit (Novagen).  
 
Approximately 3 mL His•Bind® resin was added to the chromatography 
column and settled via gravity. The column was washed with 4.5 mL ddH2O with 
the peristaltic pump flow rate set at 3 mL/minute throughout the purification 
process. This was followed by 8 mL of 1x charge buffer, 4 mL of 1x bind buffer, 
20 mL of soluble fraction, 20 mL of 1x bind buffer, 8 mL of 1x wash buffer and 9 
mL of 1x elution buffer. The eluate was collected in 1.5 mL fractions and ran on 
SDS gels (section 2.10.5). The most concentrated fraction was desalted (section 
2.10.3) and used in the biochemical assays (section 2.11). 
 
* ParA protein immediately precipitated upon elution from the column with 
elution buffer. To prevent this, 10% glycerol (v/v) was used in all buffers for 
purification of ParA. 
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2.10.3  Desalting Proteins 
 
All protein was desalted using 5 mL HiTrap™ desalting columns (GE 
Healthcare). The desalting column was clamped and attached to a 50 mL syringe 
and equilibrated with 25 mL 50 mM Tris-HCl pH 7.5 (Appendix 9.5.4) at a flow 
rate of 3 mL/min. Approximately 1.5 mL of purified protein fraction was put 
through the column and the protein was eluted out in 2 mL 50 mM Tris-HCl pH 
7.5 and stored at 4°C.  
 
Once again all buffers used for desalting ParA had 10% glycerol (v/v). Desalted 
ParA was stored in 50% glycerol at -20°C.  
 
 
2.10.4  Protein quantification  
 
All protein was quantified using the DC Protein Assay (Bio-Rad). Four dilutions 
(0.25-1.5 mg/mL) of BSA was prepared in 50 mM Tris-HCl pH 7.5 as standards. 
5 µL of proteins and standards were aliquoted into a 96 well plate in triplicate. 
Approximately 25 µL of reagent A and 200 µL of reagent B was added to each 
well containing protein samples or standards respectively and incubated at RT for 
15 minutes. This was read at 750 nm.  
 
 
2.10.5  SDS-PAGE 
 
About 4.5 mL of 12% separating gel (Appendix 9.5.5) was poured between gel 
plates (Bio-Rad), covered with 700 µL 100% isopropanol and set at RT for 30 
minutes. After 30 minutes the isopropanol was decanted off and 4% stacking gel 
(Appendix 9.5.5) was poured on top of the separating gel, the combs put in place 
and set at RT for 45 minutes. The combs were removed after 45 minutes. The 
wells were washed gently with water to remove unpolymerized acrylamide and 
the apparatus was placed in the gel tank (Bio-Rad) and filled with 1x SDS running 
buffer (Appendix 9.5.4).  
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Approximately 1 mL bacterial pellets were resuspended into 1 mL of 2% 
SDS. About 20 µL of these samples and/or 20 µL of soluble fraction or purified 
protein were added to 10 µL 3x sample buffer (2:1) (Appendix 9.5.4) and boiled 
at 95°C in the thermocycler (eppendorf Mastercycler
®
 gradient) for 10 minutes 
before being loaded onto the gel. Approximately 10 µL (small wells) or 20 µL 
(big wells) of samples were loaded in the wells with 5 µL protein molecular 
weight marker (also boiled with sample buffer) and run at 200 V for 60 minutes.  
 
Once the bromophenol blue ran off the end of the gels, the gels were carefully 
removed from between the glass plates and stained for 30 minutes in coomassie 
stain (Appendix 9.5.3) on a rocking platform at RT. After 30 minutes, the gels 
were rinsed 3 times in water and destained (Appendix 9.5.3) for 2 hours with one 
change of destain after an hour. After 2 hours, the gels were rinsed in water and 
left overnight in water for complete destaining. The gels were scanned with a 
Personal Densitometer SI (Molecular Dynamics) and the images were processed 
using Image J (NIH).  
 
 
2.10.6  Polyclonal Antibody Production  
 
Approximately 5mL of 1 mg/mL purified ParA protein (section 2.10.2) was sent 
to the Pocono Rabbit Farm and Laboratory Inc. (PRF&L, Pennsylvania, USA) to 
raise polyclonal antibodies against ParA in a SPF white female rabbit. The rabbit 
was initially immunized with Complete Freund’s Adjuvant (CFA) followed by 
Incomplete Freund’s Adjuvant (IFA) for all subsequent injections with 50 µg to 
200 µg of immunogen (Table 2.13). The immunogen was diluted to 0.25 mL with 
sterile saline and combined with 0.25 mL of the adjuvant, mixed thoroughly to 
form a stable emulsion before it was either injected beneath the skin of the rabbit 
(subcutaneously (SC)) in the area around the shoulders or intradermally (ID) into 
the hind haunches near the rear legs for a maximum of two times. Blood was 
collected from the central ear artery with a 21-gauge needle and allowed to clot 
and retract at 37°C overnight. The serum was decanted and clarified by 
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centrifugation at 2, 500 rpm for 15 minutes. The schedule of immunization and 
bleeds are shown in Table 2.13.  
 
 
Table 2.13: Schedule for the production of ParA antibodies 
 
 
 
2.10.7  Western Blotting 
 
SDS-PAGE was run as described in section 2.10.5 except Amersham ECL Plex™ 
fluorescent rainbow marker (GE Healthcare) was used instead of the standard 
protein molecular weight marker. Amersham Hybond-LFP membrane and 
blotting paper (GE Healthcare) were cut to the size of the gel. The membrane was 
activated in methanol for 30 seconds before being equilibrated in the transfer 
buffer (Appendix 9.5.4) with the gel for 20 minutes. All blotting paper and foam 
pads were soaked in transfer buffer before assembly. The blotting sandwich was 
assembled in transfer buffer with forceps from the negative electrode with a foam 
pad followed by 3 pieces of blotting paper, gel, PVDF membrane, 3 pieces of 
blotting paper and another foam pad. All air bubbles were rolled off with a roller 
and the assembly was closed, placed in the tank with an ice pack, filled with 
transfer buffer and ran at 4°C for 2.5 hours at 37 V. All western blot apparatus 
used in this experiment were from Bio-Rad. 
 
Days Procedure – immunogen used (µg) Adjuvant description 
0 Preimmune Bleed – 4 mL - 
0 Inject ID – 200 µg CFA 
14  Inject ID – 100 µg IFA 
28  Inject SC – 100 µg IFA 
42 Small bleed - 4 mL - 
56  Inject SC – 50 µg IFA 
70 Small bleed - 4 mL - 
84  Inject SC – 50 µg IFA 
98  Final Bleed - 4 mL - 
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 After transfer, the membrane was rinsed in 1x PBS (Appendix 9.5.3) and 
blocked with 3% low-fat milk in 1x PBS for 1 hour at RT. All wash steps and 
incubation periods were carried out at RT on a rocking platform. After an hour, 
the blocked membrane was washed twice for 5 minutes in 1x PBST (Appendix 
9.5.3) and incubated with a 1:1000 dilution of the polyclonal antibody (section 
2.10.6) in 1x PBST for 2 hours. After incubation with the primary antibody, the 
membrane was washed four times for 5 minutes in 1x PBST and incubated with a 
1:500 dilution of Amersham ECL™ Plex goat-anti-rabbit IgG Cy3 (GE 
Healthcare) in 1x PBST for 1-2 hours. After incubation with the secondary 
antibody, the membrane was washed four times for 5 minutes with 1x PBST 
followed by two final washes with 1x PBS for 5 minutes. The transferred 
fluorescent labelled protein was scanned with a Fujifilm FLA-5100 imaging 
system (Alphatec) using ImageReader FLA-5000 series V1.0 software.  
 
 
 
2.11 In vitro ATPase Assay 
 
The biochemical assay performed with the purified ParA protein was modified 
and adapted from various published sources [130-132] to identify the time frame 
and the protein concentration that resulted in a linear relationship with respect to 
the ParA activity. The reaction for the assay was set-up as shown in Table 2.14 
and made up to a total volume of 100 µL with ddH2O in 96 well plates. All assays 
were incubated at 37°C unless otherwise stated. The hydrolysis of ATP in the 
reaction was determined by quantifying the amount of inorganic phosphate (Pi) 
released using the brilliant green assay, a modified protocol of the malachite green 
assay from McQuade et. al., 2009 [133] (section 2.11.1). 
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Table 2.14: Concentration of reagents used in the ParA ATPase assays 
 
 
 
 
 
 
 
 
 
* The initial concentration of ParA varied in different preps 
 
 
2.11.1 Brilliant green assay 
 
The release of Pi upon ATP hydrolysis was measured using a colourmetric assay. 
Approximately 20 µL of Reagent A (4.2% ammonium molybdate in 4 M 
sulphuric acid) was added to the ATPase assay and mixed briefly. This was 
followed by the addition of 20 µL Reagent B (0.045% brilliant green in ddH2O) 
and again mixed briefly. The reaction was incubated at RT for 2-5 minutes and 
read at 650 nm.  
 
 
 
2.12  Antisense Assays 
 
2.12.1  Growth curves 
 
All antisense expression vectors created via insertion of various genes into the 
pMind vector in the antisense orientation under the transcriptional control of the 
tetracycline-inducible promoter (Table 2.2) were electroporated into M. 
smegmatis (section 2.9.4.2) and subjected to growth assays.  
 
Reagents Initial conc. Final conc. 
Tris-HCl pH7.5 1 M 50 mM 
DTT 100 mM 1 mM 
MgCl2 100 mM 1 mM 
KCl 1 M 50 mM 
BSA 10 mg/mL 0.1 mg/mL 
ATP 10 mM 0 – 1 mM 
ParA * 1 µg 
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Growth assays were conducted in rich (LB broth), carbon and nitrogen 
starvation medias (HdeB minimal media; Appendix 9.5.1) with appropriate media 
supplements (section 2.2.4) and culture conditions (section 2.3) in 96 well plates 
in a total volume of 100 µL. The promoter was induced with a titration of 
tetracycline from 0- 40ng/mL and growth was monitored via measuring the OD590 
of the cultures using the Wallac EnVision 2102 Multilabel Reader and Wallac 
EnVision Manager software (version 1.12) (Perkin Elmer). Induction of the 
promoter and antisense expression was confirmed via measuring the relative 
fluorescence in strains that contained a gfp sequence downstream of the antisense 
sequence (Table 2.2) using the multilabel reader with an excitation wavelength of 
485 nm and an emission wavelength of 510 nm.  
 
M. smegmatis strain hosting pMindGFP vector was used as controls in the 
antisense assays. The plate was divided into 2 parts; columns 1-6 with no Tc and 
columns 7-12 with 20 ng/mL Tc (the optimal concentration for promoter 
induction).  
 
 
2.12.1.1  Rich media 
 
M. smegmatis colonies transformed with the antisense vectors were picked from 
LB Kan
+
, Hyg
+
 agar plates (refer to Table 2.3 for conc.) and cultured overnight 
(section 2.3) in 5 mL LBT Kan
+
, Hyg
+
 until they reached mid-logarithmic phase 
with OD600 ranging from 1 to 1.5. The mid-log phase cultures were sub-cultured in 
LBT Kan
+
, Hyg
+
 and Kan
+
, Hyg
+
, Tc
+
 with the starting OD590 of 0.01 in 96 well 
plates as described in section 2.12.1 and monitored for OD590, the number of CFU 
(section 2.12.2), and/or fluorescence. Cells were also analyzed with 4',6-
diamidino-2-phenylindole (DAPI) staining (section 2.12.3) at 144 hours.  
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2.12.1.2  Nutrient starvation media (Appendix 9.5.1) 
 
M. smegmatis colonies transformed with the antisense vectors were picked from 
LB Kan
+
, Hyg
+
 agar plates and cultured overnight in 5 mL HdeB oxygen 
starvation media (O2
-
) with Kan
+
, Hyg
+
 until they reached mid-logarithmic phase 
with OD600 ranging from 0.5 to 1.0. The mid-log phase cultures were sub-cultured 
in carbon and nitrogen starvation (C
-
 and N
-
) medias with Kan
+
, Hyg
+ 
and Kan
+
, 
Hyg
+
, Tc
+
 with a starting OD590 of 0.05 in 96 well plates as described in section 
2.12.1 and monitored for OD590, the number of CFU (section 2.12.2) and/or 
fluorescence. Cells were also analyzed with DAPI staining (section 2.12.3) at 72 
hrs. 
 
 
2.12.2  Colony forming units (CFU’s) 
 
Cells were removed at 0, 24, 72 and 144 hours of the growth assays to calculate 
the CFU/mL of the cultures. About 20 µL of cells were serially diluted with 180 
µL 0.15% NaCl and 100 µL of various serial dilutions were plated on LB agar 
plates. These plates were incubated at 37°C for 72 hours and colonies were 
counted from plates that had between 50 -150 colonies. CFU/mL was calculated 
using the formula:  
 
CFU/mL = number of colonies (n) × dilution factor of plate (10
n
) 
       volume of culture on plate (0.1 mL) 
 
 
2.12.3  DAPI staining 
 
All cells were stained with ViaGram™ Red+ Bacterial Gram Stain and Viability 
Kit (Molecular Probes). Approximately 50 µL of cells were spun down at 13, 000 
x g for 1 minute (all subsequent centrifugation steps were carried out at 13, 000 x 
g for 1 minute), the supernatant was removed and the cells were washed with 50 
µL BSA-saline solution (0.25% BSA: 0.15 M NaCl). This was spun down and 
resuspened in fresh BSA-saline solution. About 2.5 µL of 2 mg/mL WGA 
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conjugate was added to the cells and incubated at RT for 10 minutes, spun down 
and resuspended in BSA-saline solution. Approximately 2.5 µL of DAPI stain: 
SYTOX green working solution in water (1:1:20) was added to the resuspended 
cells and incubated again at RT for 10 minutes. About 10 µL the stained cells 
were transferred onto slides, covered with a cover slip and observed under oil 
immersion using the Olympus Provis AX70 microscope. Cell lengths were 
measure using the calibrated eye piece graticule.  
 
 
 
2.13  Differential Susceptibility Assays 
 
 
Differential susceptibility assays were carried out with M. smegmatis strains 
transformed with vectors pMind_parA_GFP and pMind2357. These strains were 
screened against 3 compound libraries, LOPAC (Library of Pharmacologically 
Active Compounds; Sigma Aldrich), Spectrum Collection (MicroSource 
Discovery Systems, Inc.) and NIH Diversity Set (NIH) in three different culture 
conditions, LBT, C
-
 and N
-
 (Table 2.15). All assays were conducted in triplicate.  
 
 
Table 2.15: Compound library screens against anitsense strains 
Library Strain LBT C
-
 N
-
 
LOPAC M. smegmatis_pMind_parA_GFP 3x 3x 3x 
 M. smegmatis_pMind2357 3x 3x 3x 
 
Spectrum 
Collection 
M. smegmatis_pMind_parA_GFP 3x 3x 3x 
 M. smegmatis_pMind2357 3x 3x 3x 
 
NIH M. smegmatis_pMind-parAGFP 3x 3x 3x 
 M. smegmatis_pMind2357 3x 3x 3x 
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2.13.1.1  Assay set-up 
 
All screens were performed in 96 well plates in a total volume of 100 µL as 
described previously [124]. Column 1 was filled with 100 µL ddH2O to minimize 
evaporation from the plates during incubation and column 12 had duplicates of 
various controls, that is, negative control (media), cell growth control, solvent 
control and positive control (ethambutol at 50 µM). All compound libraries were 
resuspended in DMSO thus DMSO was used as solvent control in all assays 
(Figure 2.1).  
 
Approximately 50 µL of media with Kan
+
, Hyg
+ 
Tc
+
 (Table 2.3) was 
transferred to columns 2 to 12. Exactly 2 µL of library compound from 1 mM 
working plates were dispensed into wells from column 2 to column 11 using the 
Cybi-Well liquid handler (CyBio) covering 80 compounds per plate with a final 
concentration of 20 µM per well.  
 
About 20 mL cultures of the strains to be screened were grown overnight in 50 
mL polypropylene tubes to mid-log phase in either LBT Kan
+
, Hyg
+ 
for LBT 
assays or in HdeB O2
-
 Kan
+
, Hyg
+ 
for C
-
 and N
-
 assays (section 2.3). The 
overnight cultures were subcultured with the appropriate media, that is, LBT, C
-
 
and N
-
 with Kan
+
, Hyg
+ 
Tc
+
 to get a starting OD600 of 0.15 in 10 mm path length 
cuvettes (Thermo Heλios γ Spectrophotometer). Approximately 50 µL of the 
subcultured cells were aliquoted into all columns wells with cells (Figure 2.1). 
The plates were sealed and incubated as described in section 2.3 for 72 hours. 
OD590 and GFP fluorescence measurements were taken after the incubation period 
as described in section 2.12.1.  
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Figure 2.1: Plate map used to screen compound libraries 
 
 
2.13.1.2  Data Analysis 
 
All data from the library screens were compiled and analysed in excel worksheets. 
Wells that exhibited a greater than 40% inhibition in the M. 
smegmatis_pMind_parA_GFP strain without having an effect on the M. 
smegmatis_pMind2357 control strain were taken as hits and the cells from these 
wells were analyzed via microscopy (Olympus Provis AX70) for GFP and with 
DAPI stain (section 2.12.3). These cells were compared to the corresponding 
wells of M. smegmatis_pMind2357 strain.  
 
 
2.13.1.3  Statistical analysis  
 
All differential susceptibility assays used for HTS of compound library had their Z 
factors calculated [134] to evaluate the quality of the assays where the sample was 
cells grown in 2% DMSO with 20 ng/mL Tc giving maximum signal and the 
control was the antibiotic control giving minimal signal using the formula:  
 
 
Z =   1-  3 (SD of sample + SD of control) 
                         |mean of sample – mean of control| 
 
 
 
 
 
 
 
 
 
 
 
A 
B 
C 
D 
E 
F 
G 
H 
1     2     3     4    5      6    7     8     9    10   11  12 
ddH2O  
 
compounds + cells 
 
media 
 
media + cells 
 
media + cells + DMSO 
 
media + cells + Eth 
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2.14 Dose-response Assays 
 
Compounds that were validated as inhibitors of ParA in the biochemical assay 
(section 2.11) were analyzed for their IC50 and MIC values in M. smegmatis-
pSHIGH_hsp60 in LBT, C
-
 and N
- 
medias (supplemented with Kan
+
) and in M. 
bovis BCG-pYL GFP (supplemented with Kan
+
) and M. tuberculosis H37Ra in 
Middlebrook 7H9 broth (section 2.2.4). M. smegmatis-pSHIGH_hsp60 strains 
were cultured (section 2.3) overnight in appropriate medias. M. bovis BCG-
pMOD12_hsp70 and M. tuberculosis H37Ra were cultured for 16 days. All cells 
were diluted to a starting OD600 of 0.05 and 50 µL of these were dispensed into 50 
µL of two-fold serially diluted drugs in the appropriate media. All assays were set-
up in 96 well plates in a total volume of 100 µL and incubated at 37°C for 4 days 
for M. smegmatis and 14 days for M. bovis BCG and M. tuberculosis H37Ra. IC50 
and MIC values were determined from OD590 and/or GFP readings. All dose-
response assays were performed in triplicate and all data were analyzed with 
SigmaPlot 11 (SYSTAT) using four-parameter logistic standard curve analysis to 
determine IC50 and MIC values.  
 
 
 
2.15 Stationary Bactericidal Assays 
 
Stationary bactericidal assays were carried out with M. smegmatis-pSHIGH+hsp60 
in LBT, C
-
 and N
- 
medias supplemented with Kan
+
. All LBT assays had starter 
cultures grown in LBT Kan
+
 for 8 days. After 8 days, the cultures were diluted 
down to an OD600 of 0.5 with PBS. All starvation assays had starter cultures either 
grown in C
-
 or N
- 
media for 10 days. After 10 days, the cells were spun down and 
resuspended in PBS to an OD600 of 0.5. 50 µL of these cells were used in standard 
two-fold dilutions in PBS for dose-response assays in a total volume of 100 µL. 
All plates were exposed to drugs for 96 hours at 37°C. After 96 hours, viability of 
the cells was measured by adding 30 µL of 0.02% (w/v) resazurin. This was 
further incubated for another 24 hours at 37°C. After 24 hours, the assay plates 
Chapter Two: Materials and Methods 
_______________________________________________________________ 
 
65  
were read with the Wallac EnVision 2102 Multilabel Reader at excitation 
wavelength of 530 nm and emission wavelength of 590 nm. All bactericidal assays 
were performed in triplicate and all data were analyzed with SigmaPlot 11 
(SYSTAT) using four-parameter logistic standard curve analysis to determine IC50 
and MIC values.  
 
 
 
2.16 Cytotoxicity Assays 
 
Cytotoxity assays were carried out using cancer cell line HL-60. The cells were 
maintained in RPMI supplemented with 10% fetal calf serum (FCS) and penicillin-
streptomycin at 100:10:1. All assays were set-up in 96 well plates in a total volume 
of 100 µL. 50 µL of 10, 000 cells per well were dispensed into two-fold serially 
diluted drugs and cultured at 37°C in a 5% CO2 incubator for 48 hours. Cell 
viability was measured by adding 10 µL of Alamar blue reagent. This was further 
incubated for 4 hours at 37°C and read at OD750 and/or fluorescence at excitation 
wavelength of 570nm and emission wavelength of 585 nm. All cytotoxicity assays 
were performed in triplicate and all data were analyzed with SigmaPlot 11 
(SYSTAT) using four-parameter logistic standard curve analysis to determine IC50 
values.  
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3.1 Introduction 
 
The availability of whole genome sequences has lead to a new era in drug 
development, with bioinformatics often being the primary step in the drug 
discovery programme today [135, 136]. In silico technologies are routinely used 
for the identification of novel targets by predicting the putative functions [137, 
138] and/or the metabolic activity of these targets [67, 135, 139]. This is a more 
rapid and inexpensive method compared to the traditional methods of target 
validation using a series of experiments, that is, cell-based assays and loss-of-
function phenotypes using knock-out mutants. These experiments are still 
required at later stages of target validation [135] but the targets identified via in 
silico technologies save a lot of time and money before the validation experiments 
are carried out [67, 140]. This chapter reviews potential drug targets identified in 
via bioinformatics analyses.    
 
 
3.1.1 Comparative genomics 
 
Haemophilus influenzae Rd KW20 was the first bacterial genome sequenced by 
The Institute of Genomic Research (TIGR) in 1995 [141]. Since then, genome 
sequencing data has increased exponentially with approximately 2, 605 different 
bacterial genomes being sequenced, most of these publicly available at the 
Genomes OnLine Database (GOLD; http://www.genomesonline.org/gold.cgi) as 
well as at the individual sequencing centres. The availability of these genomic 
data has led to genome mining, where genes are assigned functions based on 
sequence homology and conservation between genomes. It also revealed some of 
the differences between genomes. This is particularly relevant to pathogenic 
bacteria as these differences may shed light on the variety of mechanisms which 
are associated with their unique virulence and clinical manifestations. 
 
It is now been widely accepted that bacterial genomes contain a core set of 
genes encoding proteins that have essential cellular functions [67, 142, 143]. 
These genes can be easily and rapidly identified using comparative genomics. 
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Such genes present a set of novel broad-spectrum antimicrobial targets as they are 
vital to the survival of the microbe. However, ideal targets have to fulfil certain 
parameters making them difficult to ascertain, that is, they should have a known 
function so a biochemical assay can be developed to be used in the HTS [135, 
144]. Most importantly ideal targets should be absolutely imperative for the 
organisms survival [104, 145] so targeting it will result in the elimination of the 
microbe to prevent recurrence of disease after therapy [67].  
 
 
3.1.2 Identification of novel targets using a genomics approach 
 
There is a great need to identify new antimicrobials with novel MOA [146] and/or 
different cellular targets to prevent cross-resistance from existing antibiotics 
[104]. To date there has been no novel antitubercular drugs introduced for therapy 
in over 3 decades [110] reflecting the amount of work that is required for 
antitubercular drug discovery. This has led the drug discovery industry to move 
from selecting targets that are well-characterized to target-driven discovery of 
lead compounds [140, 147]. Currently, there are approximately only 40 bacterial 
targets that are being exploited for drug targeting leaving a potentially vast 
number of novel targets from other essential components to be discovered [148].  
 
With target-based drug discovery, one of the major limitations is target 
selection [104]. Genome sequencing and in silico technology have provided a new 
dimension to the target selection paradigm. These technologies have not yet 
produced any new FDA approved antibiotics but have led to the identification of 
inhibitors to specific targets for lead optimization. It takes at least 12-15 years for 
antibiotic candidates to go through drug development to FDA approval [109]. 
Since most pathogenic genome data has become publicly available from 2000 
onwards, it is unrealistic to expect many antibiotics from target-based drug 
discovery yet; however, the dawn for this era may very well be near. Another 
reason for the low number of FDA approved antibiotics from target-based drug 
discovery is due to the lack of investment in the field after the discovery of most 
antibiotics in the mid 1960s [105].  
Chapter Three: Target Selection 
_______________________________________________________________ 
 
69  
Some genomics-driven targets that had led to the identification of novel inhibitors 
are: 
 The inhibition of polypeptide deformylase (PDF). Comparative genomics 
revealed that PDF is conserved in a broad-spectrum of pathogenic bacteria 
[135] and genomic technologies showed it to be an essential enzyme for 
protein biosynthesis and maturation [149]. PDF’s are inhibited by 
actinonin, a naturally occurring antibacterial agent [135, 150]. This 
information of the lead compound has been used for rational drug design 
to synthesize derivatives of actinonin to increase potency and the spectrum 
of target organisms. Two of its derivatives, LBM415 [151] and BB-83698 
[152], have reached phase III clinical trials [153].  
 The inhibition of dihydrofolate reductase (DHFR). DHFR produces folate 
cofactors that are required for the synthesis of purines and some amino 
acids [154]. Genome sequences of DHFR have been used to produce over 
100 crystal structures of the protein that has aided in the identification of 
its inhibitors. They are inhibited by diaminopyrimidines and the structural 
information has been used to synthesize a derivative of 
diaminopyrimidines, iclaprim, which has shown potency against 
trimethoprim, methicillin, vancomycin resistant pathogens and has 
undergone phase III clinical trials [155, 156]. 
 The inhibition of various enzymes involved in bacterial fatty acid 
biosynthesis (FAB) pathway, an essential metabolic process for bacterial 
survival [157]. Genomics led to the identification of all the enzymes 
involved in this pathway in clinically important pathogens and this 
information has been used to develop inhibitors via various rational drug 
development schemes: 
o diazaborines and triclosan - inhibitor of the enoyl-acyl carrier 
protein (ACP) reductase (FabI) [158] 
o cerulenin - inhibitor of beta-ketoacyl-ACP synthase I and II (FabB 
and FabF) 
o thiolactomycin - inhibitor of FabB, FabF and beta-ketoacyl-ACP 
synthase III (FabH) 
o platensimycin – inhibitor of FabF and FabB [159, 160] 
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Thus genomics and molecular techniques have revolutionized the drug discovery 
process and can lead to the identification of a collection of novel validated 
molecular targets. This, coupled with HTS can produce a range of structurally 
diverse compounds as leads to counteract disease and drug resistance.  
 
 
 
3.2 Objectives of chapter three 
 
The goal of this chapter was to prioritize potential broad-spectrum drug targets in 
M. tuberculosis. 
 
There are various strategies that can be employed for prioritizing drug 
targets which are dependent upon the type of targets being selected for and the 
parameters set out for the their identification [161]. The type of targets being 
selected for in this study was broad-spectrum targets. The aims to achieve this 
were:  
 
I. To identify all genes required for growth under optimal (nutrient-rich) 
conditions, experimental data from Sassetti at. el. [162] 
II. To determine if the genes required for growth under optimal conditions are 
essential 
III. To distinguish if the identified essential genes were conserved and essential 
in other microbes by comparative genomics.  
 
The genes identified in this study are referred to as putative essential targets as 
they will require further experimentation to support their essentiality in M. 
tuberculosis H37Rv. This list does not include genes that may be essential for 
latency, infection and/or genes that are specific to mycobacteria. 
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3.3 Results 
 
3.3.1 Quantification of essential genes in M. tuberculosis H37Rv 
 
The foremost criteria for selecting essential genes in this chapter is based on the 
work by Sassetti, et al. [162]. The study by Sassetti identified 614 putative 
essential genes (Appendix 9.2) in M. tuberculosis H37Rv under optimal growth 
conditions via high density transposon mutagenesis [126]. Since the publication of 
the work by Sassetti, 58 of the 614 proposed essential genes have been mutated 
and deemed non-essential by other researchers. A comprehensive literature search 
was conducted to identify all the genes that have been considered non-essential 
from the genes identified by Sassetti. These genes are given in Table 3.1 together 
with their functional group and gene annotations.  
 
 
3.3.1.1  Genes mutated from the list published by Sassetti 
 
One of the primary sources of M. tuberculosis mutants is the TARGET database 
at Johns Hopkins University. Of the 614 genes mentioned in the work by Sassetti, 
48 were published as being able to sustain transposons in the TARGET database. 
Besides the TARGET database, other research groups have also managed to 
mutate some of the 614 genes via transposon mutagenesis and site-directed 
mutagnesis.  
 
Consequently, after the literature search, a total of 58 genes were excluded 
from the 614 putative essential genes required for growth under optimal 
conditions (Table 3.1). This reduced the number of putative essential genes to 
556. These remaining 556 genes were put through comparative genomics analysis 
(section 3.3.2) to identify the number of conserved essential genes required by M. 
tuberculosis for growth under optimal conditions.  
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Table 3.1: List of genes mutated from the 614 putative essential genes published by 
Sassetti et. al.   
Functional category No. of genes 
mutated 
H37Rv Annotations 
a) 
Amino acid 
metabolism 
 
6 
 
Rv0118c, Rv0337c, Rv1005c, Rv1187, 
Rv1188, Rv1248c 
Energy metabolism 2 Rv1448c, Rv2702 
Lipid metabolism 5 Rv0400c, Rv0404, Rv2967c, Rv3139, Rv3564 
Co-factor metabolism 3 Rv0425c, Rv1391, Rv3111 
Transcription 5 Rv0339c, Rv0668, Rv1708, Rv3198c, Rv3201c 
DNA replication/repair 2 Rv0949, Rv1420 
Cell division 1 Rv2748c  
Cell structure 2 Rv3793, Rv0112 
Membrane 
translocation 
 
6 Rv0411c, Rv0450c, Rv1348, Rv1456c, 
Rv2041c, Rv2833 
Molecular 
chaperones/proteases 
 
3 Rv0384c, Rv2110c, Rv3417c 
Regulatory 2 Rv1027c, Rv3132c 
Unknown functions 11 Rv0127, Rv0311, Rv0588, Rv0755c, Rv0875c, 
Rv0955, Rv1303, Rv1753c, Rv2739c, 
Rv2837c, Rv3660c 
b) 
Amino acid 
biosynthesis 
 
 
1 
 
Rv2855 
Co-factor metabolism 3 Rv2338c, Rv3109, Rv3112 
Transcription 1 Rv0894 
Cell structure 1 Rv3597c 
Unknown functions 
 
3 Rv1490, Rv3113, Rv3343c 
c) 
Regulatory 
 
1 
 
Rv0982 [163] 
a) - genes mutated via transposon mutagenesis at Johns Hopkins University 
b) - genes mutated via transposon mutagenesis by McAdam et. al. [164] 
c) - genes mutated via site-directed mutagenesis by Pang et. al. [163, 165] 
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3.3.2 Quantification of conserved essential genes in M. tuberculosis H37Rv 
 
The aim of this study was to identify a set of broad-spectrum targets thus gene 
conservation was taken into account. To isolate conserved genes that might be 
essential in M. tuberculosis H37Rv, I performed comparative genomics with the 
556 genes from section 3.3.1 against the genes available at the Database of 
Essential Genes [146] using the criteria outlined in section 2.7.2. This database 
contains essential genes from 14 prokaryotes including M. tuberculosis H37Rv 
(Table 3.3).  
 
Protein sequences of the 556 putative essential genes were used for 
protein-protein BLAST alignment against the DEG proteins. This confirmed 261 
genes as fulfilling the cut-off (20% identity) of conserved genes in this study. 
Table 3.2 shows the list of conserved essential genes as prioritized drug targets in 
M. tuberculosis H37Rv together with their functional group.  
 
 
Table 3.2: List of broad-spectrum targets in M. tuberculosis H37Rv 
Functional category No. of 
conserved 
essential 
genes 
H37Rv Annotations 
Amino acid metabolism 
 
 
 
 
 
 
 
Nucleotide metabolism 
 
 
Lipid metabolism 
 
 
 
Co-factor metabolism 
 
 
 
Energy metabolism 
 
 
 
 
 
 
30 
 
 
 
 
 
 
 
12 
 
 
18 
 
 
 
14 
 
 
 
38 
 
 
 
 
 
 
Rv0422c#, Rv0500, Rv1293#, Rv1464#, Rv1601+, Rv1603+, 
Rv1609, Rv1612+, Rv1652#, Rv1655#, Rv1659, Rv1850*, 
Rv2121c+, Rv2192c*, Rv2220, Rv2231c*, Rv2537c*, Rv2538c#, 
Rv2539c#, Rv2540c*, Rv2753c#, Rv2987c+, Rv2995c, 
Rv2996c#, Rv3025c, Rv3356c, Rv3708c, Rv3709c+, Rv3778c#, 
Rv3799c 
 
 
Rv0772, Rv0780, Rv0808, Rv1017c, Rv1381, Rv1389, 
Rv1699, Rv2883c, Rv2977c*, Rv3411c, Rv3752c#, Rv3913# 
 
Rv0562, Rv0675, Rv0973c, Rv1018c, Rv1193#, Rv1350, 
Rv1661, Rv1662, Rv2182c, Rv2500c, Rv2682c, Rv3140, 
Rv3285, Rv3332#, Rv3398c, Rv3581c#, Rv3582c#, Rv3800c# 
 
Rv0510, Rv0524, Rv0542c#, Rv0555#, Rv0558#, Rv1409*, 
Rv1416*, Rv2217, Rv2218, Rv2225*, Rv3602c*, Rv3608c+, 
Rv3609c, Rv3713                  
 
Rv0526#, Rv0527#, Rv0529, Rv0462, Rv1023, Rv1092c#, 
Rv1098c, Rv1308, Rv1309, Rv1310, Rv1311*, Rv1326c, 
Rv1392, Rv1436, Rv1437, Rv1438, Rv1449c, Rv1465*, 
Rv1617, Rv1622c+, Rv1631#, Rv1695#, Rv1713, Rv1712+, 
Rv1714#, Rv2215, Rv2364c, Rv2421c, Rv2447c, Rv2786c, 
Rv3043c, Rv3255c#, Rv3257c, Rv3396c, Rv3436c, Rv3441c#, 
Rv3559c, Rv3634c 
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DNA replication/repair 
 
 
 
Transcription 
 
 
Translation 
 
 
 
 
 
 
 
 
 
 
Cell division 
 
 
Cell structure 
 
 
 
 
Membrane translocation 
 
 
 
Molecular 
chaperones/proteases 
 
Unknown functions 
 
13 
 
 
 
12 
 
 
63 
 
 
 
 
 
 
 
 
 
 
9 
 
 
20 
 
 
 
 
13 
 
 
 
8 
 
 
11 
 
 
Rv0001, Rv0005#, Rv0058#, Rv1547+, Rv1629#, Rv1701#, 
Rv2343c#, Rv2986c#, Rv3014c, Rv3048c, Rv3051c, Rv3646c#, 
Rv3721c# 
 
Rv0667#, Rv1297#, Rv1390+, Rv2444c+, Rv2511, Rv2703#, 
Rv2710, Rv2841c, Rv2925c#, Rv3246c#, Rv3457c, Rv3907c 
 
Rv0041, Rv0640, Rv0651, Rv0682, Rv0683#, Rv0684, Rv0685, 
Rv0700, Rv0701, Rv0702, Rv0704, Rv0705, Rv0707, Rv0708, 
Rv0710#, Rv0714, Rv0715, Rv0716, Rv0718, Rv0719, Rv0720, 
Rv0721, Rv1007c, Rv1014c, Rv1292, Rv1298, Rv1299, 
Rv1406, Rv1630, Rv1641, Rv1649, Rv1650#, Rv1689#, 
Rv2130c, Rv2357c, Rv2441c, Rv2442c, Rv2448c, Rv2534c, 
Rv2555c#, Rv2580c, Rv2614c, Rv2727c#, Rv2839c, Rv2845c, 
Rv2882c, Rv2889c#, Rv2890c, Rv2904c, Rv2906c#, Rv2992c#, 
Rv3009c, Rv3011c, Rv3105c#, Rv3336c, Rv3443c, Rv3458c#, 
Rv3459c, Rv3462c, Rv3579c#, Rv3580c, Rv3598c, Rv3834c 
 
Rv0014c#, Rv0015c, Rv0284#, Rv2150c, Rv2154c, Rv2440c, 
Rv3610c, Rv3817c, Rv3918c 
 
Rv0993+, Rv1315+, Rv2152c+, Rv2153c*, Rv2155c+, Rv2156c*, 
Rv2157c*, Rv2163c, Rv2165c#, Rv2245, Rv2246, Rv2361c, 
Rv2746c, Rv2881c, Rv2981c*, Rv3032, Rv3423c*, Rv3464, 
Rv3627c#, Rv3712# 
 
Rv0732#, Rv1349, Rv1463, Rv2093c, Rv2397c, Rv2398c#, 
Rv2399c#, Rv2477c, Rv2832c, Rv2846c, Rv2916c, Rv3240c, 
Rv3781+ 
 
Rv0352#, Rv0440, Rv1223, Rv2373c#, Rv2457c, Rv2460c, 
Rv3418c, Rv3596c 
 
Rv1229c#, Rv1461#, Rv1462#, Rv1711#, Rv2166c#, Rv2188c, 
Rv2869c#, Rv2897c#, Rv3177#, Rv3422c, Rv3921c 
 
 
Further information on the known or predicted function of the individual conserved 
essential genes is given in the supplementary Table S1 (Appendix 9.2.2). Genes marked 
with a hash symbol (#) were also identified as targets by Raman et al. [140], genes 
marked with a plus sign (+) were identified as targets by Anishetty et al. [166] and genes 
marked with an asterisk (*) were identified as targets by both the above mentioned 
studies (section 3.4.3).  
 
3.3.3 Orthologs of conserved essential genes in M. smegmatis  
 
The model organism used in this study for experimentation was M. smegmatis 
mc
2
155; therefore orthologs of all the genes in Table 3.2 were searched for and 
identified in M. smegmatis. The M. smegmatis gene annotations corresponding to 
the M. tuberculosis genes are also provided in supplementary Table S1 (Appendix 
9.2.2). 
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3.4 Discussion 
 
This chapter highlights the importance of target identification in the drug 
discovery process. It presents a list of broad-spectrum candidates in M. 
tuberculosis generated by comparative genomics. This list consists of conserved 
essential genes thus providing a starting point for drug discovery for broad-
spectrum antibiotics. 
 
 
3.4.1  Essential genes 
 
The best targets are genes that are essential for the cellular maintenance of the 
microbe [104]. Thus the first step in identifying potential targets in M. 
tuberculosis in this study was determining gene essentiality. The gold standard for 
identifying essential genes is to determine if the gene can be knocked out [167]. 
Thus, in accordance with the first and second condition discussed in the aims of 
this chapter, we looked at the data presented by Sassetti et. al. [162]. This study 
identified 614 essential genes in M. tuberculosis via high density transposon 
mutagenesis and transposon site hybridization (TraSH) that could not be knocked 
out under optimal growth conditions [107].  
 
The justification for looking at genes under optimal conditions was to 
uncover the inventory of housekeeping genes that is responsible for essential 
biosynthetic, metabolic and regulatory processes, which may be all that is 
required by a cell under optimal conditions when all the mandatory nutrients are 
provided. If this is the case and these genes are indispensable under favourable 
conditions, the likelihood of them being essential under all growth conditions, that 
is, nutrient deprived conditions, is high as opposed to conditionally essential 
genes (section 1.7.2). Targeting conditionally essential genes may not be as 
effective in therapy as constitutively essential genes because if the metabolic state 
of the cell changes, the conditional genes may not be required leaving the drug 
without a target and rendering therapy useless. Apart from genes required for 
growth, it would also be ideal to have a set of targets for the latent bacilli where 
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the bacteria is not growing actively, however, latency is very poorly understood 
and latent bacilli do not cause active disease therefore for the scope of this study, 
the emphasis was on targeting genes that are essential for growth.  
 
The study by Sassetti et. al. also compared the 614 essential genes 
identified under optimal conditions against the genome sequence of 
Mycobacterium leprae and found that 78% of these genes were retained in M. 
leprae [162]. This has huge implications as M. leprae has been found to have 
undergone reductive evolution, shedding a lot of its genes and only keeping the 
genes that are critical for its survival. This has led the M. leprae genome to be 
about half the size of the M. tuberculosis genome [168]. Because of this genome 
reduction, only 40% of the M. tuberculosis genes are conserved in M. leprae 
[169]. Thus a 78% conservation of the 614 genes in M. leprae identified as being 
essential in M. tuberculosis strengthens the hypothesis that these genes may very 
well be essential in M. tuberculosis [137].  
 
Since the focus of this study was in the identification of broad-spectrum 
targets and in accordance with the third condition of this chapter, a comparative 
analysis of the genes identified as being essential in M. tuberculosis (section 
3.3.1) against other more divergent bacterial species (Table 3.3) available at DEG 
was performed.  
 
 
3.4.2 Broad-spectrum targets 
 
Protein sequences between M. tuberculosis and the microbes available at DEG 
(Table 3.3) were compared as these are more analogous than primary sequence 
due to codon degeneracy [147]. The rationale for comparing the putative protein 
sequences of essential mycobacterium genes against the protein sequences of 
essential genes in other bacterial species was to identify the ubiquitous essential 
genes as potential broad-spectrum targets.  
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Several genome comparison studies have revealed that a very small 
number of genes maybe required for a pathogen to survive [67, 170]. Mushegian 
et al. compared the smallest bacterial genome, Mycoplasma genitalium with 
another bacterial genome, Haemophilus influenzae [170]. This study found that 
over 70% of the genes, that is, a total of 240 genes, in the minimal gene set 
derived from the sequences of M. genitalium and H. influenzae are conserved, 
[111, 170]. These two genomes are relatively small; however in this study we 
found 261 genes that were common between 14 different bacterial species (Table 
3.2). This follows a pattern in that the number of conserved genes does not vary 
much between different genome sizes. However, several studies tried to validate 
the genes identified as being essential by Mushegian et al. [171-173] and found 
that there is a high level of redundancy due to non-orthologous gene 
displacement. This phenomenon is portrayed when the same function is fulfilled 
by an related or paralogous protein in different organisms [174]. This places 
emphasis on the need for target validation.  
 
The importance of target validation was demonstrated in another study 
where 347 conserved genes were being validated for essentiality and as potential 
broad-spectrum targets in Streptococcus pneumoniae via high-throughput gene 
disruption. Of the 347 conserved genes, only 113 were presumed as being 
essential as they were unable to grow after gene disruption [161]. Comparative 
genomics studies like these have shown that there might be approximately 250 to 
350 essential broad-spectrum targets [67, 161]. However, these figures may be an 
over estimation as target validation experiments demonstrate that not all genes 
identified as being essential is actually essential as was shown for S. pneumoniae. 
Validation studies may also disprove some of the genes shown as being essential 
in DEG (Table 3.3) as these organisms were analysed using whole genome 
analysis and such analysis techniques are prone to some degree of error. This was 
demonstrated in this study with M. tuberculosis where some of the genes 
identified as being essential by Sassetti et. al via a whole genome analysis were in 
fact found to be non-essential by other researchers (Table 3.1).  
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Table 3.3: Organisms in DEG 
Organism No. of essential genes  Reference 
Acinetobacter baylyi ADP1 499 [175] 
Bacillus subtilis 168 271 [176] 
Escherichia coli MG1655 712 [177, 178] 
Francisella novicida U112 392 [179] 
Haemophilus influenzae Rd 
KW20 
642 [171] 
Helicobacter pylori 26695 323 [180] 
Mycobacterium tuberculosis 
H37Rv 
614 [162] 
Mycoplasma genitalium G37 381 [181] 
Mycoplasma pulmonis UAB CTIP 310 [182] 
Pseudomonas aeruginosa 
UCBPP-PA14 
335 [183] 
Salmonella typhimurium LT2 230 [184, 185] 
Staphylococcus aureus N315 302 [1, 186, 187] 
Streptococcus pneumoniae 244 [161] 
Vibrio cholerae 5* [188] 
* The 5 genes identified as being essential in V. cholerae is not a true representative of all 
the essential genes present in this organism as this study only characterized a total of 16 
mutants. 
 
 
Another study that used the same criteria as defined in our study found 306 
essential genes in Pseudomonas aeruginosa [189]. This is slightly higher than 
what was identified in this study with M. tuberculosis however, their cut-offs for 
identifying homologs in the DEG database was lower than the cut-offs set in the 
current study.  
 
This current study also performed a comparative analysis of the 261 
conserved essential targets from M. tuberculosis H37Rv (Table 3.2) with the M. 
smegmatis mc
2
155 genome and found that all these proteins were present in M. 
smegmatis with high amino acid identity (supplementary Table S1- Appendix 
9.2.2). This provides additional justification that these genes may be required for 
essential cellular processes in mycobacteria.  
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3.4.3  Comparison to other studies in M. tuberculosis 
 
Irrespective of the criteria chosen to identify targets by any researcher, the end 
goal is to achieve a list of targets whose impairment will lead to the eradication of 
the microbe [95]. A good example of using different criteria to generate distinct 
target lists is given in a study by Hasan et. al. where three different lists of 
prioritized drug targets for M. tuberculosis were generated, each conformed to a 
different criterion [137]. This study used all of the MTB genes as targets whereas 
our study gives a more focussed list of targets where some genes were eliminated 
as potential targets. Thus, the list of genes from Table 3.2 was compared to other 
studies that followed a similar method of identifying targets where genes not 
falling under the selected criteria were excluded.  
 
This analysis revealed that about 34% of the genes identified in this study 
were also established as targets by another research group [140]. This study used a 
number of different filters to ours to eliminate genes at various stages of analysis. 
It also looked at genes that were specific to M. tuberculosis and related to 
persistence and resistance as well as broad-spectrum targets and came up with a 
total of 451 high-confidence targets. In contrast, our analysis only identified 261. 
However, this is to be expected as our list only contains broad-spectrum targets, 
addition of mycobacterial specific and/or persistence genes would most certainly 
increase this figure.  
 
A second study that looked at potential drug targets in M. tuberculosis 
confirmed 13% of the genes identified in this study as targets [166]. However, this 
study by Anishetty et. al. only performed a comparative analysis of all the 
enzymes in M. tuberculosis from the Kyoto Encyclopedia of Genes and Genomes 
(KEGG) metabolic pathway database against proteins from humans. In doing so, 
they discounted any potential target that is not an enzyme or may be an enzyme 
but is not yet characterised in the KEGG database. This may account for the low 
percentage of comparable targets between thier study with our study.  
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It is also worth noting that some of the genes identified in our study (Table 
3.2) already had their cognate inhibitors identified and are currently used for Tb 
treatment. Rv0667 (RpoB) is the known target for rifampicin [190], one of the 
main first-line anti-tubercular drug and Rv0683 (RpsL) is a known target for 
streptomycin [191], another first-line anti-tubercular drug. Rv2981c (Ddl) and 
Rv3423c (Alr) are known targets for D-cycloserine, a second-line Tb drug [192] 
and Rv0005 (GyrB) is the known target to fluoroquinolones [68], another second-
line drug. The fact that this method identified already known targets of currently 
used anti-tubercular drugs proved that the method used in this study extracted 
creditable targets for future drug development.   
 
 
3.4.4  Uniqueness of this study 
 
There are a few ideas in this study that deviate from the routinely used 
bioinformatics checklist for target identification. Firstly, the targets identified in 
this study were not compared for human analogues as it is common to find some 
degree of homology between bacterial enzymes against the eukaryotic genome 
[67]. Important as this is, there have been reported cases where despite a 
significant homology between the eukaryotic and prokaryotic proteins, drugs did 
not have the same level of toxicity. For example the staphylococcal gene encoding 
isoleucyl-tRNA synthetase is 38% identical to its human homolog, falling well 
within the range to inhibit both prokaryotic and eukaryotic proteins however; 
mupirocin, an analog of isoleucine which competitively inhibits amino acid 
activation by isoleucyl tRNA synthetase and thus inhibits protein synthesis [193], 
has been successfully used as an antibiotic for many years [193, 194]. This is due 
to two amino acid substitutions in the active site weakening the mupirocin 
interaction in humans and preventing the inhibition of the mammalian enzyme 
[195]. This proves that antibiotic selectivity cannot be based on protein sequence 
homology alone and single amino acid substitutions can have significant changes 
to antibiotic binding affinities [67]. An additional example of this is given by the 
inhibition of bacterial DHFR but not the highly similar human enzyme by 
trimethoprim and its derivatives. [196, 197].  
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 Another common feature used in identifying targets is comparing it to 
metabolic and/or structural databases. However, with this method, unusual 
proteins underrepresented in the databases or proteins of unknown functions are 
eliminated. This results in missing out in the identification of completely novel 
functions that may constitute potential new antibacterial targets with unique MOA 
and/or new classes of antibiotics, something that we are in the hunt for. 
 
 
3.4.5 Summary 
 
Notably, bioinformatics is routinely used for the discovery, selection and 
prioritization of drug targets to combat disease. This chapter presents a focussed 
list of broad-spectrum targets for M. tuberculosis identified via bioinformatics 
with support from experimental data by various researchers. It also illustrates the 
functional classes of these genes. This provides the basis for selecting unique 
targets and/or pathways to identify antibiotics with novel mode of action to 
overcome current resistant mechanisms. 
 
Such step-wise prioritization and elimination of genes using simple 
biological criteria is an efficient way to reduce the number of genes to an 
experimentally manageable level. These genes can be validated in more traditional 
low-throughput methods and the results can be used to make informed decision on 
where investment should be made for drug development.  
 
 
 
Chapter Four: Target Validation 
_______________________________________________________________ 
 
82 
 
 
 
 
 
 
 
CHAPTER FOUR 
 
 
Target Validation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter Four: Target Validation 
_______________________________________________________________ 
 
83 
4.1 Introduction 
 
Recent drug discovery has been driven largely by genomics-based approaches. 
The primary barrier to drug discovery prior to the availability of genomic data 
was the small number of potential drug targets that were characterized. Genomics 
has removed this target identification barrier from the few characterized genes to 
the whole genome [198]. The targets identified via in silico genomics have to be 
validated to determine if their alteration is going to have a therapeutic effect 
[109]. This includes the exploration of target gene function which in turn can be 
used to develop suitable assays for high-throughput antimicrobial screening. 
These rational target-based screening programs combine genomic data with 
genome-based technologies to isolate and/or validate potential targets [67]. One of 
the most commonly used methods for modulating target protein function is 
blocking gene expression at the RNA level, a method that was implemented in 
this study.  
 
 
4.1.1 Approaches to target validation 
 
Essential and conserved genes make excellent drug targets as their conservation 
signifies some canonical function required for growth or survival as opposed to 
species specific roles [114]; however, target selection requires genetic 
manipulation for validation. There are various strategies applied for target 
validation [161, 171, 185, 186, 199] (section 1.7.3 and Table 3.3), all of which use 
the genomic data that has become available to analyse the essential processes 
required for growth.  
 
Gene disruption validates gene essentiality where loss of function is 
associated with loss of viability [67] but this technique does not give the 
functional annotation of the targets as mutation of essential genes is lethal to cells 
[200]. Some gene disruption techniques can also be misleading as they may have 
polar effects on the downstream genes if the target is present in a polycistronic 
operon. If the downstream genes are essential, such conditions will lead to a null 
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phenotype that is not related to the target. This would require further genetic 
manipulation to overcome, thus making it unsuitable for genome scale high-
throughput analysis and inferior to other techniques like allelic mutagenesis [67, 
201].  
 
Since lethal mutants cannot be analysed further, controlled gene 
expression studies have become a useful tool for studying essential genes [185]. 
Gene expression studies allows the regulation of the target where it can be titrated 
up or down, giving more perspective on gene functionality based on the 
phenotype achieved from these titrations [202]. Such studies can expose the 
cellular pathways of genes with unknown functions and most importantly these 
studies can subsequently be used in HTS to find inhibitors against the target. 
 
Gene regulation studies include the incorporation of inducible promoters 
used for direct modulation of target gene expression and antisense technology for 
indirect modulation of target gene expression (section 4.1.1.1). With direct gene 
modulation, conditional mutants can be created either by replacing the native 
promoter with an inducible promoter or an inducible promoter can be used to 
control a complementary copy of the gene while the gene is removed from the 
genome. Both of these systems can be used to regulate the level of gene 
expression in a dose-dependent manner with respect to the inducer [114]. The 
most commonly used of these inducible systems are based on bacterial response 
regulators that bind to specific operator sequences which can be modulated to 
induce or repress gene expression with specific inducing molecules [203].  
 
 
4.1.1.1  Antisense Technology 
 
The key feature of molecular biology consists of genetic information being 
transcribed from DNA into RNA which is then translated into proteins (Figure 
4.1A). Antisense technology exploits these two essential processes. Antisense 
gene regulation is a sequence-specific inactivation of protein production without 
affecting the gene. In nature, there are cis-encoding and trans-encoding antisense 
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molecules that regulate gene expression [204]. There are three different 
mechanisms via which antisense inhibition works in bacterial cells (Figure 4.1B). 
The most common and natural mechanism involves binding of the antisense 
molecule to complementary messenger RNA (mRNA) forming a duplex. This 
prevents the translation of the protein and leads to the degradation of the double-
stranded RNA (dsRNA) by dsRNA-specific-RNases [205]. The second 
mechanism involves the dsRNA covering the ribosome recognition sites and 
causing steric hindrance at the ribosome and thus preventing translation [204]. 
The third mechanism involves the formation of DNA:RNA heterodimers which 
are degraded by RNases [204, 205]. 
 
Antisense inhibition provides a means to down-regulate gene expression 
giving rise to loss of function phenotype thus this technology can also be used for 
functional annotation. However, the efficiency of loss of function depends on the 
length, structure and intracellular concentration of the antisense molecule [206]. 
This technique has been used on single essential genes for functional annotations 
in a number of microbes including the hisD gene in M. smegmatis, the ahpC gene 
in M. bovis, the sgp gene in Streptococcus mutans and the srrAb in 
Staphylococcus aureus [200, 207-209]. It has also been used with a whole genome 
for the identification of the conditional essential gene expression profile in 
Staphylococcus aureus [185, 186]. Successful use of antisense technology has 
also been applied to identifying inhibitors of specific targets in HTS [159] 
 
The molecular and genetic functions of many essential genes have not yet 
been studied as deletion mutants are difficult to study making conditional mutants 
a necessity for the study of essential genes [123]. Antisense is a commonly used 
technique for such studies as it removes a lot of laborious lab work which is 
associated with creating genome mutations. Therefore, this study utilized 
antisense RNA expression to validate some of the targets identified via the 
bioinformatics analysis for essentiality and viability.  
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Figure 4.1: Gene expression 
A) Normal gene expression in a prokaryotic cell. Double-stranded DNA (dsDNA) duplex 
unfolds and gets transcribed into mRNA and the mRNA gets translated into protein at the 
ribosome. B) Mechanisms of gene regulation using the expression of antisense RNA. 
This can be either achieved using a cis-encoded antisense sequence or a trans-encoded 
antisense sequence a) a vector containing the antisense sequence of the gene of interest is 
integrated at a pre-determined site in the genome to develop a conditional mutant. This 
system uses the normal cellular machinery and the inducible promoter from the integrated 
vector to transcribe antisense RNA. This is complementary to the sense strand of the 
DNA and binds to ssDNA upon replication thus preventing transcription and mRNA 
formation which in turn leads to decrease in protein production. b) The antisense 
molecule is provided in trans in a vector; once again the vector uses cellular machinery to 
transcribe antisense RNA which is complementary to the mRNA thus binds to it forming 
dsRNA and prevents translation and protein production as dsRNA is unstable and gets 
degraded. c) dsRNA that reaches the ribosome is unable to fully transcribe as it 
encounters steric hindrance, again preventing translation thus leading to a decrease in 
protein production.  
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4.1.1.2  Cell division 
 
The focus of this thesis is in validating drug targets that are essential in the cell 
division process. A step-by-step progression of cell division involves DNA 
condensation and replication, chromosome partitioning to opposite poles of the 
cells, Z-ring assembly and septum formation at midcell followed by cytokinesis to 
generate daughter cells with identical genetic material [210-212]. This is a 
complex process necessitating the need for spatial and temporal coordination of 
an array of proteins however little is known about the factors regulating these 
processes in mycobacteria [210, 212-215]. Thus it was hypothesized that 
elucidating the fundamental genes involved in cell division may present novel 
targets with alternate MOA to current Tb treatment as cell division proteins are 
underexploited targets for drug discovery.  
 
 
4.2 Objectives of chapter four 
 
The goal of this chapter was to validate some of the conserved essential genes 
identified in chapter 3 that were involved in the cell division process as potential 
anti-tubercular targets. This would be achieved by assessing if down-regulation of 
these genes has any effect on the viability of the cells.  
 
It was hypothesized that decreasing an essential gene product will affect a 
cells survivability as an essential gene product signifies that it is absolutely vital 
for the cell [167]. 
 
To explore this hypothesis, 3 different M. smegmatis genes identified as 
being essential for cell division were selected. These were cloned into a plasmid 
in the antisense orientation under a tetracycline inducible promoter upstream of a 
GFP sequence to develop a trans-encoded antisense RNA expression system. All 
strains were subjected to growth assays under different culture conditions and 
monitored for:  
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 GFP expression; to ensure antisense induction 
 Optical density (OD); to monitor growth rate 
 CFU; to monitor the number of separable and viable cells  
 Cell morphology; to observe any discernable phenotypic difference upon 
antisense induction 
 
The outcomes from the above investigations were used to discern if the putative 
essential genes tested in this work were viable candidates for targeted drug 
screening.  
 
 
 
4.3 Results 
 
4.3.1 Construction of expression vectors 
 
All PCR products were cloned into the pCR
®
2.1 TA cloning vector (Appendix 
9.1A) and transformed into E. coli DH5α cells. Transformants were selected and 
plasmids were isolated from these clones and sequenced. The correct sequences 
were then digested out of pCR
®
2.1 using appropriate restriction enzymes and 
cloned into equally restricted pMind (Appendix 9.1D).  
 
This study utilized the tetracycline inducible vector, pMind (Appendix 
9.1D) for antisense gene expression. pMind uses a tetracycline-regulated efflux 
system isolated from a Corynebacterium
 
glutamicum plasmid. It contains a 
transcriptional repressor (TetR) and an operator region (tetO) containing the 
promoter sequence and repressor binding site [120]. The repressor protein 
sterically prevents transcription by binding to the operator sequence between the 
inducible promoter and the gene product in the absence of the inducer 
(tetracycline). Transcription can be de-repressed by the addition of tetracycline 
which binds to the repressor and prevents it from binding to the operator.  
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This vector was used as described by Blokpoel et. al. [120] with a few 
modifications. To monitor expression from the promoter upon induction with 
tetracycline, a gfp sequence was amplified from the pHS201 vector [121] using 
the primers GFP_RBS_F and GFP_R (Table 2.4) and cloned into the SpeI site 
(MCS) to act as a reporter. Since both the forward and reverse primers had the 
same enzyme sites, an orientation PCR was carried out to ensure that the gfp 
sequence had been inserted in the correct direction using the primers TetROF11 
and GFP_R (Figure 4.2; section 2.9.5.3). Clones with the correct inserts were 
isolated and this plasmid was called pMindGFP. This was electroporated into M. 
smegmatis and used as a control in later experiments.  
 
 
 
 
 
Figure 4.2: Orientation PCR of pMindGFP  
1% agarose gel showing PCR product of pMindGFP amplified with primers TetROF11 
and GFP_R with lane 1 showing HyperLadder I and lanes 2, 4 and 11 showing positive 
insertion of the gfp sequence in the correct orientation. The gfp sequence is ~ 750 bp. The 
insert shown in the gel is ~ 850 bp since a 100 bp sequence was added onto the PCR 
product by the TetROF11 primer as this is an external primer, that is, from the plasmid 
outside of the GFP sequence (Figure 4.4).  
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4.3.1.1  Construction of antisense vectors 
 
All genes of interest were amplified from M. smegmatis mc
2
155 genomic DNA 
using their respective primers (Table 2.4) and sub-cloned in the antisense 
orientation in either pMind or pMindGFP from pCR
®
2.1 (section 4.3.1). The 
inserts in the vectors were verified with various primer sets and verified plasmids 
were electroporated in M .smegmatis. 
 
 
 
 
Figure 4.3: pMindGFP vector 
pMindGFP vector showing the placement of the ORF for the target gene in the antisense 
orientation (pink) upstream of the GFP reporter (purple). Vector created using 
PlasMapper [216].  
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Figure 4.4: PCR product of genes cloned into pMind and pMindGFP 
1% agarose gels showing DNA ladders and PCR products derived from M. smegmatis 
that were cloned in the antisense orientation into the pMind and pMindGFP vectors. The 
PCR products are slightly larger than the gene size as the external primer and the GFP 
gene added more sequence to the M. smegmatis gene products. A) PCR product from 
pMind_obg with primer set TetROF11 and MSMEG_4623_F (gene size ~ 1.5 kbp). B) 
PCR product from pMind_parB_GFP with primer set MSMEG_6938_R and GFP_R 
(gene size ~ 1 kbp). C) PCR product from pMind_parA_GFP with primer set 
MSMEG_6939_R and GFP_R (gene size ~ 1 kbp). D) PCR product from 
pMind_parA+parB_GFP with primer set MSMEG_6938_R and GFP_R (combined gene 
size of set parA and set parB ~ 2 kbp). These were also verified with external primers 
TetROF11 and HygR11 (data not shown) and with DNA sequencing. The reason for 
using the same primer sets for the verification of the parB and MSMEG_parA+parB 
fragments was because of the gene arrangement of parA and parB. Figure 4.5 illustrates 
this gene arrangement and the position of all the primers. The cloning sites used for each 
of these fragments are given in Table 2.2.  
 
 
 
 
Chapter Four: Target Validation 
_______________________________________________________________ 
 
92 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5: Gene arrangement of parA and parB 
A) This diagram illustrates the gene arranged of parA and parB as in the mycobacterium 
genome and the primer binding sites of the various primers used in this study for the gene 
amplification, PCR screening and DNA sequencing. B) This diagram shows the two 
genes (parA and parB) cloned in the antisense orientation in the pMind vector under the 
tetracycline inducible promoter (Ptet) upstream of the operator sequence (Po). The gfp 
sequence was cloned downstream of the gene sequences. It also shows the primer binding 
sites for GFP (GFP_RBS_F and GFP_R) and the external primers used for orientation 
PCR (TetROF11 and GFP_R) and DNA sequencing (TetROF11 and HygR11). This 
vector was called pMind_parA+parB_GFP.  
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4.3.2 Electroporation into M. smegmatis  
 
All the above constructs were electroporated in M. smegmatis (section 2.9.4.2), 
plated on agar plates with appropriate antibiotics for transformant selection and 
incubated at 37°C. All plates had 1-3 mm colonies after 72 hours except for the 
plate containing M. smegmatis electroporated with the pMind_parA+parB_GFP 
vector. Figure 4.6 shows the difference between the electroporation plates of 
strains that had the vectors pMindGFP, pMind_parB_GFP, pMind_parA_GFP 
and pMind_parA+parB_GFP. All strains created were used in antisense 
expression assays except M. smegmatis-pMind_parA+parB_GFP. This strain was 
further characterized (section 4.3.7).  
 
 
 
 
Figure 4.6: Electroporation of M. smegmatis 
These plate photos were taken at 72 hours showing M. smegmatis electroporated with A) 
pMindGFP, B) pMind_parB_GFP, C) pMind_parA_GFP and D) 
pMind_parA+parB_GFP. The growth of the M. smegmatis-pMind_parA+parB_GFP 
strain was severely inhibited when both parA and parB genes were placed in the antisense 
orientation in the same vector. This was performed in triplicate.  
A  B 
  
    
 D 
  
    
C 
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4.3.3 Determination of optimal tetracycline concentration 
 
Before the strains created in this study could be used in antisense RNA expression 
assays, the optimal inducer concentration had to be established. This was 
determined by conducting growth assays of M. smegmatis-pMindGFP in rich 
media (LBT) (section 2.12.1.1). A titration of 0–40 ng/mL of Tc was used in this 
assay and the OD590 and GFP emission were monitored every 24 hours (Figure 
4.7).  
 
As can be seen in Figure 4.7A, there were no obvious differences between 
the OD590 of the cultures containing different concentrations of Tc indicating that 
Tc concentration as high as 40 ng/mL could be used in the assays however, the 
GFP signal dropped at high Tc concentrations (Figure 4.7B). The GFP signal was 
used to determine the concentration of Tc to be used for antisense induction as it 
is a more sensitive measure than OD. From these results, 20 ng/mL of Tc was 
considered as the optimal concentration to achieve maximum expression from the 
Tet promoter and was used for all future experiments unless otherwise stated.  
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Figure 4.7: Determination of optical inducer concentration 
Growth curve of M. smegmatis-pMindGFP in LBT with varying concentrations of Tc at 
different time points plotted against A) OD590 and B) relative fluorescence units (RFU) 
and C) RFU difference between 0 ng/mL and 20 ng/mL. Statistical analysis using a two-
tailed T-test showed an insignificant difference in fluorescence with all concentrations of 
Tc compared to 0 ng/ml except 20 ng/mL (p = 0.05; Figure 4.7C). Results from four 
independent experiments with triplicates always showed 20 ng/mL of Tc with the highest 
GFP expression level. All results are representative of mean values of triplicates ± SE. 
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4.3.4  Induction of antisense transcript 
  
To prove that the antisense transcript was being transcribed by the promoter, all 
strains harbouring the gfp sequence were cultured in LBT with or without Tc for 
72 hours. The gfp sequence was cloned downstream of the antisense fragments 
(Figure 4.4) thus expression of GFP would indicate that the antisense transcript 
was being produced. M. smegmatis-pMind was used as a negative control. As can 
be seen from Figure 4.7, there was incomplete repression of the promoter in the 
absence of the inducer. However, there was increase in GFP expression upon 
induction of the promoter.  
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Figure 4.8: Induction of antisense transcript  
This graph shows M. smegmatis electroporated with various pMind vectors (indicated on 
the graph) in the absence (■) and presence ( ) of tetracycline. The strains with the pMind 
vector showed no change in fluorescence with or without Tc. All the strains with the 
pMindGFP vector show some fluorescence in the absence of the tetracycline (incomplete 
repression of the promoter) but this increased upon the addition of tetracycline showing 
that there is expression being induced from the promoter. * represents p value > 0.05 and 
** represents p value < 0.05. All results are representative of mean values of triplicates ± 
SE. 
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4.3.5 Antisense assays 
 
Growth assays with different culture conditions were carried out (section 2.12.1) 
with the various strains created in this study (Table 4.1) to determine if down 
regulation of the conserved essential genes had any effect on cell growth, viability 
and morphology. All cultures were analysed by measuring the OD every 24 hours 
for 11 days. CFU and cell morphology were analysed at time 0 and at late 
exponential phase as the cultures were entering stationary phase. Two 
independent experiments were carried out for each assay; however, results are 
shown from just one experiment. All statistical analysis was carried out on data 
from the late exponential phase when the number of CFU were determined and 
cell morphology was analysed. All data is compared to the M. smegmatis-
pMindGFP control.  
 
 
Table 4.1: Strains used for antisense assays 
 
 
 
 
 
 
This table shows all the strains that were used in the antisense expression assays and the 
annotations used to denote these strains in the graphs.  
 
 
 
 
 
 
 
 
 
 
Strains Annotation 
M. smegmatis-pMindGFP gfp 
M. smegmatis-pMind_obg obg 
M. smegmatis-pMind_parB_GFP parB 
M. smegmatis-pMind_parA_GFP parA 
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4.3.5.1  Antisense expression under rich culture conditions (LBT) 
 
The above mentioned strains (Table 4.1) were cultured in rich media (LBT) with 
and without Tc. Analysis of results were carried out at 144 hours with all cultures 
supplemented with Tc. At 144 hours in the 1
st
 experiment, there was 
approximately a 25% growth inhibition seen with all cultures compared to M. 
smegmatis-pMindGFP control (Figure 4.9A). In the 2
nd
 experiment, only the M. 
smegmatis-pMind_parA_GFP cultures showed a 33% inhibition (data not shown). 
These results were verified with CFU data (Figure 4.10).  
 
In the 1
st
 experiment, the M. smegmatis-pMindGFP control cultures had 
2.31 x 10
12
 CFU/mL compared to M. smegmatis-pMind_obg cultures which had 
3.41 x 10
10 
CFU/mL, a 67 fold decrease (Figure 4.10B). There was no significant 
difference in the number of CFU in the M. smegmatis-pMind_parB_GFP cultures 
however; M. smegmatis-pMind_parA_GFP cultures had 7.83 x 10
9 
CFU/mL, a 
295 fold decrease compared to the control (Figure 4.10B). In the 2
nd
 experiment, 
there was a decrease in the number of CFU in the M. smegmatis-pMind_obg (100 
fold) and the M. smegmatis-pMind_parA_GFP (400 fold) cultures at 144 hours 
with no difference in the number of CFU in the M. smegmatis-pMind_parB_GFP 
cultures compared to the control cultures (data not shown). 
 
Consequently, expressing antisense RNA of the various genes in rich 
media gave varying results with respective to OD and the number CFU. All 
strains showed very little inhibition with OD; however there were significant 
reductions in the number of CFU with two genes, obg and parA with parA having 
the most significant effect. All strains were also analysed for any morphological 
differences with DAPI stain but there were no significant changes in the 
morphology of the cells between all strains (Appendix 9.3.1).  
 
 
 
 
 
Chapter Four: Target Validation 
_______________________________________________________________ 
 
99 
 
Time (hrs)
0 50 100 150 200 250 300
O
D
5
9
0
 i
n
 L
B
T
 w
it
h
o
u
t 
T
c
0.0
0.1
0.2
0.3
0.4
0.5
Time (hrs)
0 50 100 150 200 250 300
O
D
5
9
0
 i
n
 L
B
T
 w
it
h
 T
c
0.0
0.1
0.2
0.3
0.4
0.5
 
 
Figure 4.9: Growth curves of cultures in LBT 
Growth curves of M. smegmatis strains electroporated with vectors GFP (●), obg (○), 
parB (▼) and parA (Δ) cultured in LBT A) without Tc and B) with 20 ng/mL Tc. As can 
be seen from these two graphs, there were no differences between the strains without 
antisense induction. There was a slight reduction in OD with antisense induction at late 
exponential phase however; upon reaching stationary phase these differences were not 
significantly maintained. All results are representative of mean values of quintuplicates ± 
SE. 
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Figure 4.10: Number of viable cells in LBT 
The above graphs show the CFU/mL of M. smegmatis strains electroporated with vectors 
GFP (■), obg ( ), parB ( ) and parA ( ) cultured in LBT with 20 ng/mL Tc at A) 0 
hours and B) 144 hours (late exponential phase, refer to Figure 4.9). At time 0, all 
cultures had approximately the same number of cells except for parA which had a slightly 
higher inoculum however this difference was insignificant. At 144 hours, there was ~ a 2 
log reduction in the number of CFU between the control strain and the antisense strains 
M. smegmatis-pMind_obg and M. smegmatis-pMind_parA_GFP. * represents p value > 
0.06 and ** represents p value < 0.03. 
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4.3.5.2  Antisense expression under carbon starvation (C-) conditions  
 
The above experiment was carried out in carbon limited media with and without 
Tc. Analysis of results was carried out at 72 hours with all cultures supplemented 
with Tc.  At 72 hours in the 1
st
 experiment, only the OD of the M. smegmatis-
pMind_parA_GFP cultures showed a 10% inhibition compared to the M. 
smegmatis-pMindGFP control (Figure 4.11B). M. smegmatis-pMind_parA_GFP 
cultures also took twice as long to reach the stationary phase OD compared to all 
other cultures (Figure 4.11B). This was consistent with what was seen in the 2
nd
 
experiment; M. smegmatis-pMind_parA_GFP cultures exhibited a 24% inhibition 
with a longer exponential phase (data not shown). These results were verified with 
CFU data.  
 
The CFU data from the 1
st
 experiment showed no change in the number of 
CFU between all cultures and the control except for the M. smegmatis-
pMind_parA_GFP cultures (Figure 4.12B). M. smegmatis-pMind_parA_GFP 
cultures showed approximately a 14 fold reduction the number of CFU. This was 
confirmed in a 2
nd
 experiment which only showed a decrease in the number of 
CFU with the M. smegmatis-pMind_parA_GFP cultures (data not shown). The 
cells were also analysed for morphological difference with DAPI stain at 72 hours 
(Appendix 9.3.2). There were no differences in the cellular morphology between 
all cultures except for the cells from the M. smegmatis-pMind_parA_GFP 
cultures. These were ~ 3 µM smaller than the cells in the control culture.  
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Figure 4.11: Growth curves of cultures in C
- 
media 
Growth curves of M. smegmatis strains electroporated with vectors GFP (●), obg (○), 
parB (▼) and parA (Δ) cultured in C- media A) without Tc and B) with 20 ng/mL Tc. 
There were no significant differences between all the strains without antisense induction; 
however upon induction the M. smegmatis-pMind_parA_GFP strain took twice as long to 
reach the stationary phase OD compared to all other strains. It can also be seen that M. 
smegmatis-pMind_parA_GFP and M. smegmatis-pMind_obg cultures were maintained at 
a slightly lower OD in the early stationary phase compared to the 2 control strains 
however, this difference was not significant once the cells entered late stationary phase. 
All results are representative of mean values of quintuplicates ± SE. 
A 
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Figure 4.12: Number of viable cells in C
-
 media 
The above graphs show the CFU/mL of M. smegmatis strains electroporated with vectors 
GFP (■), obg ( ), parB ( ) and parA ( ) cultured in C- media with 20 ng/mL Tc at A) 0 
hours and B) 72 hours. At time 0 all cultures had approximately the same number of cells 
however at 72 hours, the CFU for the antisense strain M. smegmatis-pMind_parA_GFP 
was approximately 1 log lower than all other strains which is comparable with what was 
observed in the growth curve by OD. * represents p value > 0.1 and ** represents p value 
< 0.05. 
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4.3.5.3 Antisense expression under nitrogen starvation (N-) conditions  
 
The above experiment was carried out in nitrogen limited media with and without 
Tc. Analysis of results was carried out at 72 hours. Growth experiments in N
-
 
media showed the most pronounced effect on the OD of the cells (Figure 4.13). In 
the absence of antisense induction, the basal level of antisense expression of all 
essential genes from incomplete repression of the promoter had some effect on the 
cells (Figure 4.13A). However, upon antisense induction this effect was much 
more pronounced (Figure 4.13B). M. smegmatis-pMind_obg cultures were 
inhibited 44% while M. smegmatis-pMind_parA_GFP cultures were inhibited 
32% compared to the M. smegmatis-pMindGFP cultures at 72 hours. The growth 
of M. smegmatis-pMind_parB_GFP cultures were approximately 40% enhanced 
compared to the M. smegmatis-pMindGFP cultures. The above experiment was 
repeated and results compared. Both experiments showed consistent results. These 
results were verified with CFU data (Figure 4.14). 
 
The number of CFU of the cultures in N
-
 media was not consistent with the 
OD data. Even though cultures of all the strains showed an effect with OD 
compared to the OD of the control strain (Figure 4.13), the number of CFU were 
approximately the same as the control for all cultures except the M. smegmatis-
pMind_parA_GFP cultures (Figure 4.14B). These cultures showed a 6.7 fold 
decrease in the number of CFU. This was confirmed in a 2
nd
 experiment which 
also showed an effect with OD with all cultures consistent with the 1
st
 experiment 
but only a decrease in the number of CFU with the M. smegmatis-
pMind_parA_GFP cultures (data not shown). Expressing antisense RNA of the 
different genes under N
- 
media gave varying results with respective to OD and the 
number CFU. All cultures exhibited a difference with OD; however there were no 
significant differences in the number of CFU between all cultures except for the 
cultures expressing antisense RNA of parA. The cells were also analysed for 
morphological difference with DAPI stain at 72 hours. All cells were slightly 
elongated in N
-
 media and M. smegmatis-pMind_obg and M. smegmatis-
pMind_parA_GFP cells had irregularly located foci along the length of the cells 
(Appendix 9.3.3).   
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Figure 4.13: Growth curves of cultures in N
- 
media 
 
Growth curves of M. smegmatis strains electroporated with vectors GFP (●), obg (○), 
parB (▼) and parA (Δ) cultured in N- media A) without Tc and B) with 20 ng/mL Tc. 
Under nitrogen starvation, there was some growth inhibition of obg and parA antisense 
strains without induction. Statistical analysis using a two-tailed T-test showed a non-
significant difference without induction (p value > 0.03). This difference was more 
pronounced after induction showing a significant difference between the control and the 
obg and parA antisense strains. Statistical analysis using a two-tailed T-test gave a p 
value < 0.0008 for M. smegmatis-pMind_obg and M. smegmatis-pMind_parA_GFP. M. 
smegmatis-pMind_parB_GFP antisense control strain grew better than all strains, even 
the control, p value = 0.001. All results are representative of mean values of 
quintuplicates ± SE. 
A 
B 
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Figure 4.14: Number of viable cells in N
-
 media 
The above graphs show the CFU/mL of M. smegmatis strains electroporated with vectors 
GFP (■), obg ( ), parB ( ) and parA ( ) cultured in N- media with 20 ng/mL Tc at A) 0 
hours and B) 72 hours (late exponential phase, refer to Figure 4.13). At time 0 all cultures 
had approximately the same number of cells. However at 72 hours, the number of CFU 
for the antisense strains M. smegmatis-pMind_parA_GFP was approximately 1/3 a log 
lower than all other strains. The CFU data did not concur with the OD data with M. 
smegmatis-pMind_obg which showed a reduction upon antisense induction in two 
independent experiments. * represents p value > 0.3 and ** represents p value < 0.004. 
 
 
A 
B 
* 
 * 
   ** 
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4.3.6 Measuring protein levels  
 
Antisense induction of parA decreased the viability of the cells under all culture 
conditions tested. Thus it was hypothesized antisense induction of parA led to a 
down-regulation of ParA that caused this effect. To test this hypothesis, antibodies 
were raised against the ParA protein to measure the level of protein present in the 
cell lysates with and without expression of parA antisense RNA. Purified ParA 
protein was sent to the Pocono Rabbit Farm and Laboratory Inc. for antibody 
production (section 2.10.6).  
  
Upon receipt of the antibodies, western blots were performed with various 
dilutions (section 2.10.7) however no bands resolved at ~ 40 kDa, the expected 
size of the ParA protein (data not shown). There was however a prominent non-
specific band resolved at 31 kDa and several other non-specific bands of other 
molecular weight. 
 
To identify if there was not enough protein in the lysate to be detected by 
the antibodies or if the antibodies raised were non-specific, the ParA protein was 
over-expressed in E. coli and the cell lysate was run on SDS-PAGE and used for 
western blotting. This western blot illustrated that the antibodies raised were non-
specific as there was an abundant of overexpressed protein transferred on to the 
membrane (Figure 4.15). Thus the level of ParA protein down-regulated upon 
antisense expression of parA could not be measured in this study.  
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Figure 4.15: Western blot showing non-specific binding 
The above Western blot contains: lane 1- a protein molecular marker, lane 2- cell lysates 
of E. coli-pBAD/HisB, lane 3- cell lysate of over-expressed E. coli-pBAD/HisB_ParA 
and lane 4- purified ParA protein. As can be seen in lane 3 (red circle), there was 
sufficient ParA protein (over-expressed) transferred on the membrane however, it did not 
bind the antibodies but showed non-specific binding. Since the ParA antibodies showed 
non-specific binding, it was unable be used in determining the level of ParA upon 
antisense expression in the M. smegmatis cells.  
 
 
 
4.3.7 Characterization of M. smegmatis-pMind_parA+parB_GFP 
 
M. smegmatis-pMind_parA+parB_GFP colonies took at least 3 weeks to grow 
sufficiently to be picked from plates to be cultured in broth (Figure 4.6). After 3 
weeks, the colonies were cultured in LBT Kan
+
Hyg
+
. These cultures grew 
overnight to an OD600 of ~ 0.3. This was unexpected and it appeared that these 
strains had mutated that allowed it to overcome the growth defect that was 
experienced by the cells when grown on solid media.  
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In order to identify where such mutation(s) might have occurred, the 
pMind_parA+parB_GFP vector was isolated from the M. smegmatis cells to 
detect if the mutation(s) were extrachromosomal. The original 
pMind_parA+parB_GFP vector electropoarted into M. smegmatis was called O 
and the vectors recovered from M. smegmatis after electoporations were called 
R1, R2 and R3. The inserts in these vectors were amplified with various primer 
sets (Figure 4.16) and sequenced. The vectors were also re-electroporated into WT 
M. smegmatis (Figure 4.17) and cured M. smegmatis strains (Figure 4.19), that is, 
the strains that had the pMind_parA+parB_GFP vector eliminated from the cells 
(Figure 4.18).  
 
 
Figure 4.16: PCR products of pMind_parA+parB_GFP 
1% agarose gels showing PCR products of pMind_parA+parB_GFP vectors O*, R1*, 
R2* and R3*. A) All lanes labelled 1 contain PCR products from the primer set 
TetROF11 and GFP_R and all lanes labelled 2 contain PCR products from the primer set 
HygR11 and MSMEG_6938_R. The original vector (O) shows ~ 3 kbp insert that is to be 
expected from the 1.056 kb parB fragment, 0.972 kb parA fragment and 0.750 kb GFP 
fragment together however, recovered vectors (R1, R2 and R3) showed non-specific 
binding with these primer sets and none of the PCR’s gave the correct size insert band. B) 
PCR products from primer set GFP_RBS_F and GFP_R of vector O, R1, R2 and R3 
showing the correct size insert of GFP in all 4 vectors. 
*O = original vector, R1 = recovered vector 1, R2 = recovered vector 2 and R3 = 
recovered vector 3. 
A 
B 
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Figure 4.17: Electroporation of M. smegmatis 
These plate photos show M. smegmatis electroporated with pMind_parA+parB_GFP 
vectors A) O* B) R1* C) R2* and D) R3*. The growth of the strain with original 
pMind_parA+parB_GFP (O) exhibited inhibition as reported in Figure 4.6 however; cells 
electroplated with the recovered vectors (R1, R2 and R3) overcame this difficulty 
implying that these vectors had mutated. This was performed in triplicate and all plates 
exhibited similar results. *O = original vector, R1 = recovered vector 1, R2 = recovered 
vector 2 and R3 = recovered vector 3. 
 
 
 
 
Figure 4.18: Cured M. smegmatis strain 
M. smegmatis-pMind_parA+parB_GFP colonies grown in LBT and plated on LB agar as 
described in section 2.9.10 were patched onto A) LB B) LB Kan
+
Hyg
+
 plates. The loss of 
antibiotic resistance signified that the strains were cured of the pMind_parA+parB_GFP 
vector.  
 A B 
C D 
A B 
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Figure 4.19 Electroporation of cured M. smegmatis 
These plate photos show cured M. smegmatis strain electroporated with 
pMind_parA+parB_GFP vectors A) O* B) R1* C) R2* and D) R3*. This was performed 
in triplicate with 3 cured strains, all exhibiting the same result.  
*O = original vector, R1 = recovered vector 1, R2 = recovered vector 2 and R3 = 
recovered vector 3. 
 
 
 
As can be seen from Figure 4.19, the cured cells were phenotypically similar to 
the WT cells (Figure 4.17) when electroporated with the same vectors where the 
original vector caused growth inhibition and the recovered vectors overcame this 
defect. This suggests that the mutation(s) arising due to the presence of the 
antisense fragment of parA and parB together in one vector were not 
chromosomal but extrachromosonal. All four vectors (O, R1, R2 and R3) were 
sent for DNA sequencing to verify this. The primers TetROF11, 
MSMEG_6938_F, MSMEG_6939_R and HygR11 (Figure 4.5) were used for 
sequencing. The two internal primers were used as the expected sequence was ~ 3 
kbp; too long to give legible sequence for the whole length by the external primers 
alone. The original pMind_parA+parB_GFP vector (O) gave the expected 
             C            D 
        
      B A 
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sequence of parA, parB and gfp that was cloned into the pMind vector with the 4 
primers (data not shown).  
 
All three recovered vectors (R1, R2 and R3) gave the correct gfp sequence 
that was originally cloned with the HygR11 primer (data not shown). This was 
also confirmed by PCR (Figure 4.16B) where primers GFP_RBS_F and GFP_R 
gave the expected product size of gfp. The TetROF11 primer gave ~ 100 bp that 
read into the end of the parB gene before numerous mutations were found (Figure 
4.20). The MSMEG_6938_F and MSMEG_6939_R primers gave illegible 
sequences with R1, R2 and R3. This could be explained by the fact that most of 
the sequences past the last 100 bp of the parB gene were mutated so failed to get 
recognised by these primers. 
 
Since electroporating the vector hosting the sequence of parA and parB in 
the antisense orientation gave rise to mutations in the sequence, all M. smegmatis 
antisense strains were cultured overnight and the antisense vectors were recovered 
and sequenced from these to identify if the original sequences of the cloned genes 
underwent mutations like the parA+parB gene fragment. All other sequenced 
vectors showed that the genes originally cloned in were maintained without 
mutations after being electroporated into M. smegmatis.   
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Figure 4.20: Sequence alignment of parA+parB 
The above is an alignment of the original parA+parB_GFP sequence with approximately 
600 bp of the sequences obtained from the TetROF11 primer from the vectors R1, R2 and 
R3. The first 100 bp is only present in R1, R2 and R3 as this is the sequence from the 
pMind vector from the TetROF11 primer (Figure 4.5); parA+parB_GFP only contains 
sequences of parA, parB and gfp. The second 100 bps that is perfectly aligned with the 
parA+parB_GFP sequence is the end of the parB. Everything downstream of the 
perfectly aligned 100 bps has undergone extreme mutations. These mutations do not seem 
to follow any particular pattern so the individual residues that might be crucial for these 
genes could not be identified.  
‘*’ denotes bases that are identical in all vectors, ‘-’ denotes deleted bases and ‘.’ denotes 
bases that are identical to the original sequence.  
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4.4 Discussion  
 
This chapter aimed to validate some of the homologues of the genes identified as 
potential broad-spectrum targets in chapter 3 in the surrogate M. smegmatis using 
conditional gene silencing with antisense RNA. Of particular interest to this study 
was validating as yet uncharacterized proteins that may be involved in cell 
division to generate novel targets for anti-tubercular therapy. The two cell division 
genes identified as potential broad-spectrum targets in this study, ftsZ and ftsH 
(supplementary Table S1), have extensive research being invested on them to 
characterize these proteins and identify their inhibitors and their mechanisms of 
inhibition [217-223] and thus were discounted in this study.  
 
 For the scope of this project, I looked at other genes that are known or 
thought to be associated with cell division in M. tuberculosis. The conserved 
essential gene list presented nine such genes (Table 3.2). Three of these genes, 
Rv2440c, Rv3917c and Rv3918c, believed to be involved in chromosome 
partitioning, were chosen to be evaluated in this study.  
 
 
4.4.1  Gene modulation  
 
The system used for target validation in this study was gene modulation via a 
tetracycline-inducible vector pMind. This was used for conditional antisense RNA 
expression however there was one drawback with this system. This vector has 
been reported to exhibit incomplete repression of the promoter by the repressor in 
the absence of the inducer, showing approximately a 10 fold higher luminescence 
when uninduced compared to a vector that lacked the tetRO region [120]. This 
was also observed in this study when GFP expression was detected without 
induction of the promoter upon placement of the gfp sequence under its control 
(Figure 4.8). There are a number of reasons why this vector may be leaky. Firstly, 
the tetA promoter may be a very strong mycobacterial promoter and the binding of 
TetR to tetO is not able to effectively suppress transcription of GFP. 
Alternatively, there could be background GFP expression due to readthrough from 
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promoter sequences within the plasmid backbone. Thus this system was 
thoroughly evaluated before being used in the target validation experiments to 
ensure that there were no repercussions due to partial expression under repressed 
conditions. Firstly, all the vectors constructed and electroporated in M. smegmatis 
were isolated from M. smegmatis and sequenced to ensure the maintenance of the 
antisense sequence. Secondly, it was demonstrated that there was an increase in 
GFP expression from the promoter upon induction with tetracycline validating 
that this system could be used for target modulation. Thirdly, only freshly 
electroporated cells were used in the experiments to prevent any acquisition of 
mutations over time in these strains. This is a commonly used technique to 
prevent suppressor mutations [224]. This system had also been successfully used 
previously to down regulate essential genes [120]. Another more tightly regulated 
system was also attempted in this study but this method proved unsuccessful in 
generating the mutants (section 4.4.1.1).  
 
GFP expression was measured to monitor expression from the promoter 
upon induction however it was not used for the growth analysis of the cultures 
even though it is a more sensitive measure than OD. This was because we were 
looking at genes involved in cell division and it has been known that perturbing 
proteins essential to this process gives filamentous phenotype [215]. These 
elongated cells will emit higher fluorescence compared to regular sized cells 
which may not necessarily correlate with an increase in the number of cells. While 
OD gave an approximate measure of the number of cells present in the cultures, 
this was not used as an absolute measure either for the same reason mentioned 
above; elongated cells giving greater absorbance. CFU were used to give the most 
accurate measure of the number of viable cells present in the cultures as this has 
been used as the gold standard for proof of cell viability. All CFU data presented 
in this study is exclusive to strains in the presence of tetracycline. The number of 
CFU without tetracycline is not fully reflective of the CFU in the absence of the 
antisense RNA as there is some expression from the promoter at all times (Figure 
4.8). All data was compared against the M. smegmatis-pMindGFP control with 
tetracycline to determine if there were any differences upon antisense induction of 
an essential gene. Section 4.4.1.2 and 4.4.1.3 discusses the genes that were tested 
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in this work together with their roles and their potential contribution to the cell 
division process.  
 
 
4.4.1.1  Addressing incomplete repression 
 
An important factor that needs to be addressed for any inducible gene regulation 
system is its ability to be tightly regulated. Since gene expression from the pMind 
vector was not very tightly regulated, a different vector was looked at for gene 
regulation, pSE100 (Figure 4.21) [225]. This system creates conditional mutants 
using a suicide vector that contains approximately 600 bp of the gene of interest 
from the start codon, downstream of the TetR-responsive promoter, PmyctetO. This 
undergoes homologous recombination in the chromosome and replaces the native 
gene promoter with Pmyc1tetO. A second vector, pMC1s with the promoter Psmyc is 
used to constitutively express TetR which binds to the operator region and 
prevents transcription of the gene from PmyctetO. Upon induction, the inducer 
binds to repressor and relieves transcription repression allowing gene expression.  
 
This conditional knockout system of controlling gene expression was 
attempted with parA where the first 600 bp of the gene was amplified using 
primers MSMEG_6939_F, MSMEG_6939_600R and cloned into pSE100. The 
insertion was verified with primers P118 and MSMEG_6939_600R and DNA 
sequencing (data not shown). This vector, pSE100_parA_600, was electroporated 
into M. smegmatis. Numerous attempts were made to acquire mutants that had 
undergone homologous recombination with no success thus this approach was 
abandoned.  
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Figure 4.21: Conditional mutant system (adapted from Ehrt et. al.) [123] 
This diagram illustrates the conditional knock-out system that uses the pSE100 suicide 
plasmid to replace the native promoter with PmyctetO which is controlled by TetR. It also 
shows primer binding sites for MSMEG_6939_600F, MSMEG_6939_600R, 
MSMEG_6939_R and P118 (Table 2.4).  
 
 
4.4.1.2  Obg 
 
MSMEG_4623 is the M. smegmatis homologue of Rv2440c (Appendix 9.2.2), a 
ribosome associated GTPase of the obg subfamily of proteins that is essential for 
bacterial viability [226, 227]. The Obg subfamily of protein is one of the P-loop 
small GTPases that is highly conserved in many organisms from bacteria to 
human and is named after its best investigated member - the Obg protein of 
Bacillus subtilis. It is implicated to be involved in cell growth, morphological 
differentiation, chromosome partitioning, replication initiation and stress 
response, however the explicit function of the gene is not known [226, 228]. In B. 
subtilis the obg protein is co-transcribed in a bicistronic operon with SpoOB 
pSE100 
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Pmyc1tetO 
1st 600 bp of 
essential gene 
Genomic  
600 bp gene 
 Essential gene 
P118 
   tetR 
pMC1s 
Psmyc 
  hyg 
    hyg 
           
 
MSMEG_ 
6939_F 
 
  
 
       
 
 
  
MSMEG_ 
6939_600R 
 
MSMEG_ 
6939_R 
Essential gene 
gDNA 
Chapter Four: Target Validation 
_______________________________________________________________ 
 
118 
(sporulation protein) and is essential during exponential growth [229]. It also 
activates transcription factors that induce the general stress regulon in response to 
environmental stress [230]. In E. coli, the temperature sensitive mutant of the Obg 
homologue had been found to be involved either directly or indirectly in 
chromosome partitioning and underwent cell elongation [231]. Similarly, in 
Vibrio harveyi, an Obg-like GTP-binding protein is involved in regulation of 
chromosomal functions where mutant cells are filamentous with unpartitioned 
chromosome; a phenotype which is associated with impaired chromosome 
partitioning [232]. In M. tuberculosis, this gene is co-expressed with various other 
genes which are associated with the ribosome and protein biosynthesis (data 
obtained from the NIAID BioHealthBase BRC online at 
http://www.biohealthbase.org).  
 
 In this work, antisense RNA of the M. smegmatis obg GTPase was 
expressed under various culture conditions. In the rich media, there were a 
significantly lower number of viable cells at late exponential phase (Figure 4.10). 
This may imply that obg is required for exponential growth in M. smegmatis as 
down-regulating it in rich media affected its viability. In nitrogen starvation 
media, there was a significantly low OD but this was not reflected in the number 
of CFU. However, the cells did display filamentous cellular morphology with 
irregularly distributed foci along the length of the cell (Appendix 9.3.3) giving an 
indication that this gene may be required for chromosomal partitioning in M. 
smegmatis; however this would have to be confirmed with further 
experimentation.  
 
 GTP-binding proteins play a role in diverse cellular processes and, as 
mentioned above, the Obg protein is involved in various cell cycle regulations 
thus the effects upon down-regulating Obg may arise from a combination of 
different actions. Since Obg is associated with protein biosynthesis in 
mycobacteria, down-regulation of this gene may lead to a down-regulation of the 
co-expressed protein biosynthesis genes. If this is the case and Obg is required in 
exponential growth as was indicated in rich culture conditions, such a situation 
will render it non-essential when metabolism is down-regulated. This could 
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explain why there was no difference in the number of cells under nutrient 
starvation conditions as the cells may have sensed the environmental stress and 
slowed down metabolism, a common response to starvation conditions [108] thus, 
not requiring the Obg protein as it aborted exponential growth.  
 
 
4.4.1.3  ParA and ParB  
 
MSMEG_6939 is the M. smegmatis homologue of Rv3918c (Appendix 9.2.2), a 
probable chromosome partitioning protein called ParA. In mycobacterium, like in 
most other bacterial species, the parA gene is located near the chromosomal
 
origin 
of replication (oriC) in an operon with another gene, parB (MSMEG_6938 in M. 
smegmatis and Rv3917c in M. tuberculosis) and cis-acting parS sites which are 
located upstream of the parAB operon [165, 233-235].  
 
 
 
 
 
 
Figure 4.22: The parAB genome region in mycobacteria 
The diagram shows the genome arrangement of the parAB region in mycobacteria around 
the oriC region. The arrows at the start sites of parA and gidB indicate the parS sequences 
that bind ParB [165, 234].  
 
 
The chromosomal encoded par system has been studied based on the model of the 
P1 plasmid [236, 237]. Plasmid partitioning is an active process that requires the 
separation and maintenance of replicated DNA at subcellular locations [238]. This 
energy is derived from the ATPase activity of ParA which has a nucleotide 
binding domain. ParA is recruited to the partition nucleoprotein complex (ParB-
parS) via its interaction with ParB which stimulates ATP hydrolysis [237]. ParB 
binds the centromere-like parS sites which in turn binds membrane bound 
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gidB 
 
dnaA 
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proteins [239, 240]. This process aligns the newly replicated plasmid towards the 
cell poles to ensure equipartitioning during division. 
 The binding of the parABS for accurate partitioning has been demonstrated 
in a number of different bacterial species however they do not all function in the 
same manner [130]. In P. aeruginosa, the ParA protein is not essential but is 
required for faithful chromosome segregation in the exponential growth phase and 
is down-regulated in the stationary phase and deletion of ParA leads to anucleated 
and filamentous cells [224]. In P. putida however, the deletion of the parAB genes 
show no defects in rich media but had anucleate cells in minimal media [241]. 
The ParAB proteins have been shown to be essential for chromosomal 
partitioning in Caulobacter crescentus [242], where ParB binds to parS sequence 
and initiates cell division by regulating ParA ATPase activity [243, 244].  
Streptomyces coelicolor, the best characterized member of the 
actinomycete genus has a complex chromosomal partitioning system where 
multigenomic aerial hyphae is converted into chains of unigenomic spores 
requiring synchronous segregation of multiple chromosomes [165, 245]. Deletion 
of either parA or parB gene in S. coelicolor does not affect the growth but causes 
deficiency in DNA partitioning. Elimination of ParA affected chromosome 
segregation and septation in S. coelicolor as ATP-bound ParA is crucial for 
interaction with ParB and thus chromosomal segregation which is followed by 
septation (section 4.4.1) [165]. ParA protein has also been reported to act as a 
transcriptional repressor on the par operon [246]. ATP-bound ParA is thought to 
stimulate chromosomal segregation by associating with the ParB-parS 
nucleoprotein complex whereas ADP-bound ParA binds to operator sequence and 
acts as a transcriptional repressor [244, 246, 247].  
 
The activity of ParAB has not yet been characterized in M. tuberculosis 
however both genes have been shown to be indispensable in M. tuberculosis 
H37Rv [126]. In M. smegmatis however, parB has been designated non-essential 
where deletion of the parB gene only caused a longer lag phase and produced 
anucleate cells [165]. Jakimowicz et. al. also showed that ParB binds to two oriC-
proximal parS sites for the formation of the nucleoprotein complex [165].  
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In this study, antisense RNA of both MSMEG_6938 (ParB) and 
MSMEG_6939 (ParA) were expressed under various culture conditions and 
monitored. Upon expression of ParB antisense, there was no effect in the growth, 
the number of CFU or cellular morphology of the cells in any culture conditions 
compared to the M. smegmatis-pMindGFP control. This work commenced before 
the publication by Jakimowicz et. al that demonstrated the ParB was not essential 
in M .smegmatis[165]. The data in this study confirmed what was demonstrated 
by Jakimowicz et. al. It revealed that down-regulation of ParB had no effect on 
cell viability demonstrating that ParB was not essential for cell division in M. 
smegmatis.  
 
Expression of ParA antisense however, had various effects under all 
culture conditions tested. In rich media, the number of CFU was approximately 2-
4 log lower (Figure 4.10B). Under carbon starvation conditions, cells that 
expressed ParA antisense were slower in reaching the exponential phase and took 
twice as long to reach stationary phase compared to all other strains (Figure 
4.11B). The CFU in carbon starvation for ParA antisense expressing cells were 
also lower (Figure 4.12B) and the cells were smaller in size compared to all other 
strains (Appendix 9.3.2). Decreased in cell length has been associated with cell 
division in older cultures where biosynthetic process slow down and division 
starts before the cells have doubled their starting length [248]. Exhibition of this 
phenotype only in the ParA antisense expressing strain may indicate cells going 
into stationary phase due to stress other than carbon starvation, that is, potential 
decrease in the ParA protein concentration. In nitrogen starvation conditions, 
antisense expression of ParA affected the growth, CFU and cellular morphology 
of the cells (Figure 4.13, 4.14 and Appendix 9.3.3 respectively). The growth and 
CFU were lower than the control and the cells had multiple foci along it when 
stained with DAPI stain, a phenotype that is usually associated with improper 
chromosome partitioning.  
 
This study demonstrated that ParA is essential for cell division in M. 
smegmatis and plays a far more essential role in chromosome partitioning than 
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ParB. ParA may be required in exponential phase growth as it had the lowest 
number of CFU under rich media where the cells are actively dividing. The 
growth of the parA antisense expressing strain was also compromised in the 
exponential phase under carbon starvation conditions (Figure 4.11B) further 
supporting that ParA may be essential for exponential growth in M. smegmatis. 
This was also demonstrated in another study that quantified mRNA levels of parA 
and parB and found that the mRNA levels for both these genes reduced from the 
exponential phase to late exponential and the levels were very low at stationary 
phase [234]. This may explain why the difference in the OD seen at the early 
growth phases under antisense inducing conditions was not significantly 
maintained at late stationary phase as the ParA protein was not highly required 
thus decreasing its level did not have a significant effect (Figure 4.9B and 4.11B). 
It was also shown by Casart et. al. that parA levels were maintained at a higher 
level at all growth phase than parB in M. smegmatis [234].  
 
It has been established that mycobacteria slow-down transcription, energy 
metabolism, lipid biosynthesis and cell division upon nutrient starvation [249]. A 
study by Betts et. al. also showed that ParA and ParB were down-regulated upon 
nutrient starvation in M. tuberculosis; ParA 2 fold more than ParB. This 
demonstrates that these proteins are not as highly required in nutrient starvation 
conditions when cell division has slowed down compared to rich growth 
conditions when cells are actively dividing. Upon expression of ParA antisense 
under nutrient limitation conditions in this study, the number of CFU was lower 
than the controls. However, this was not as significant as it was shown under rich 
culture conditions as cells sense nutrient deprivation by their stress sensors and 
start to shut down/slow metabolism [249]. This would prevent them from 
undergoing division as actively as in rich media thus the cells would not require 
ParA in very high quantities. Therefore, these strains would not be expected to 
exhibit a very significant difference in CFU under starvation conditions upon 
decreasing the ParA protein concentration which is consistent with what was seen 
in this study. Since ParA is already down-regulated twice as much as ParB under 
nutrient depriving conditions [249], a further down-regulation with antisense 
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RNA may lead the cells to show a more severe effect which may explain why the 
effects upon antisense expression of ParA were discernable compared to ParB.  
Interestingly, expression of parA and parB antisense together had severe 
effects on the cells. This was shown by the M. smegmatis-
pMind_parA+parB_GFP strain which had the antisense of both the genes placed 
in one vector (Figure 4.6). The cells were unable to sustain the basal level of 
antisense expression from the promoter in the absence of the inducer and 
underwent suppressor mutations to overcome this (Figure 4.20). This was not 
totally surprising as expression of parA antisense showed defects; however down-
regulation still leaves some molecules to carry out its functional process. Further 
down-regulation of the protein it may bind to (ParB) for functional activity would 
reduce the activity of ParA to a minuscule level leading to exaggerated phenotypic 
effects. The fact that this was not tolerated by the cells further confirms the 
essentiality of ParA.  
 
The above section discussed some of the putative roles of the various 
genes down-regulated in this work. Most hypotheses are based on genes that are 
co-expressed as these are likely to have a functional relationship. Transcriptional 
co-regulation can sometimes indicate interaction between proteins and the 
association of regulatory patterns of known proteins with unknown proteins can 
suggest a linkage [198] especially in the case of physically interacting proteins, 
proteins belonging to the same pathway or genes demonstrating synthetic 
lethality. Currently, it is not known what genes specifically affect the growth of 
mycobacteria, however; it is unlikely that one single gene will be able to control 
the growth rate as the pathways that drive this process are interconnected to other 
pathways, that is, signalling pathways that will try and prevent cellular demise 
[210]. Thus, affecting one gene will most likely display pleiotropic effects.  
 
Further experimentation is required to elucidate the precise role of these 
genes as there are a lot of factors that can influence how a cell behaves in whole 
cell-based assays with stresses like nutrient starvation and gene down-regulation. 
Nevertheless, this study sheds some light on the genes tested and whether they are 
essential under the conditions tested. The only gene that showed an effect upon 
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antisense RNA induction under all culture conditions was parA. It had a lower 
CFU than the control strain at late exponential phase in all culture conditions 
when the initial number of cells for all strains was the same showing that parA 
may be essential for growth in M. smegmatis.  
 
 
4.4.1.3.1 Chromosome partitioning in mycobacteria  
 
Bacterial genome segregation is tightly coupled with replication where the newly 
synthesized origin seperates towards the opposite poles to form daughter cells 
[165]. This process, while crucial, is not very well understood. This study together 
with data presented by other recent studies indicates that the Par proteins are 
involved in this process. Results from this chapter demonstrate that ParB is not 
essential in M. smegmatis which was also demonstrated by Jakimowicz et. al. 
[165]. However, Jakimowicz et. al. established that while ParB is not essential, 
absence of ParB created by deletion mutants lead to significant growth inhibition 
and segregation defect where 10% of M. smegmatis cells were anucleate. Recent 
report of another actinomycete, C. glutamicum showed that deletion mutants of 
either ParA or ParB in C. glutamicum also resulted in DNA-free cells [250]. Their 
study also showed that ParB localises to the poles which is indistinguishable from 
the localization of the origin. The origin is known to have multiple parS sites 
which has been shown to bind to ParB in vitro [250] and thus may indicate that 
ParB-parS colocalize to the poles together. ParB localization to the poles has also 
been reported in M. smegmatis [251] and M. smegmatis ParB binds to two oriC-
proximal parS sites for the formation of the nucleoprotein complex. This binding 
of ParB to parS has been proven in plasmid partitioning (section 4.4.1.3) and 
since ParB is able to bind to parS in M. smegmatis, it may behave in a similar 
manner [165]. Both C. glutamicum and M. smegmatis ParB is occasionally seen at 
the midcell location and C. glutamicum ParB associates with the FtsZ protein 
which is present at the cytokinetic ring at the midcell. It is hypothsized that the 
ParB-parS complex is directed to midcell as this will be the position of the new 
poles.  
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Donovan et. al. also showed that ParB is able to interact with ParA and 
ParA has subcellular localization in C. glutamicum [250]. It is hypothesized that 
ParA binds to the nucleocomplex and pulls it to the pole which requires the 
ATPase activity of ParA. Similar results were also seen in C. crescentus [252]. M. 
smegmatis ParA is found at the poles, at quarter-cell and at midecell position and 
is believed to oscillate from pole to pole as is seen for Soj (ParA homolog) in B. 
subtilis and C. crescentus [251, 252]. This study demonstrated that ParA may be 
essential in M. smegmatis as antisense expression of ParA affected the viability of 
the cells under all culture conditions and resulted in elongated cells with multiple 
foci under nitrogen limited conditions.  
 
 
4.4.1.3.2 Chromosome partitioning in B. subtilis 
 
B. subtilis also encodes homologues of the ParA and ParB protein, Soj and Spo0J 
respectively [238]. Unlike most bacterial species, inactivation of soj does not 
produce any chromosomal defects on its own however, it is required for 
chromosomal partitioning in conjunction with the structural maintenance of 
chromosome (SMC) protein where the absence of both these genes leads to a 
increase in anucleate cell production [238]. Interestingly, Spo0J mutants produce 
a 100 fold more annucleate cells than wild type [253]. Spo0J binds to the parS 
sites [254] and this nucleoprotein is required for the efficient recruitment of the 
SMC complex (condensin) to the origin [255, 256]. The condensin consists of 
SMC homodimer binding to the ScpA kleisin and ScpB [255]. The recruitment of 
the condensin to the origin by Spo0J-parS organizes the origin region. Defects in 
equipartitioning of DNA have been attributed to the loss of the SMC–ScpA–ScpB 
complex [238] thus in B. subtilis, Soj/Spo0J and Smc/ScpAB complex are 
required for proper chromosome partitioning [255]. However, Soj has been found 
to regulate the initiation of replication by regulating DnaA [257]. DnaA 
recognizes the origin and forms a complex that allows loading of the helicase for 
DNA replication. This study by Murray and Errington hypothesize that the effects 
on sporulation seen with Soj mutants may be secondary due its effect on DNA 
replication via DnaA [257].  
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4.4.1.3.3 Chromosome partitioning in E. coli 
 
The E. coli genome does not contain homologues of the Par proteins but encodes 
an SMC-like condensation complex consisting of 3 subunits, MukB, MukE and 
MukF. MukB has an N-terminal domain with ATP/GTP-binding (ATPase and 
GTPase activities) and C-terminal domain with DNA-binding activity [258]. It 
forms a complex with MukE, a kleisin subunit, via binding to MukF [259]. MukF 
exhibits sequence homology to ScpA while MukE is similar to ScpB [260]. These 
proteins are believed to be essential for chromosome partitioning in E. coli [261] 
as deletion of any of the genes leads to annucleate cells [262]. MukB has been 
reported to colocalize to the poles with the origin region of the chromosome thus 
MukB may be responsible for organisation the origin [262]. Interestingly, MukB 
interacts with topoisomerase IV and promotes it relaxation activity in vitro [261]. 
Similar to what was postulated in B. subtilis, this may indicate that the 
chromosome partitioning defects seen may be a result of chromosome replication 
defect.  
 
A majority of bacterial species encode either of the SMC complex 
(SMC/ScpA/ScpB or MukBEF). M. tuberculosis contains a homolog of these two 
proteins (Rv2922c) that has not been evaluated in relation to DNA replication 
and/or chromosome partitioning. Interestingly, it has been shown that ParA is co-
expressed with translation elongation factors, beta subunit of the DNA-directed 
RNA polymerases and transcription termination factor Rho 
(http://www.biohealthbase.org) thus a down-regulation of ParA may also lead to 
the down-regulation of these crucial factors involved in DNA replication which 
will in turn cause a decrease in cell division and is not directly related to 
chromosome partitioning. Looking at the relationship between this and the Par 
proteins may shed more light on this vital process in mycobacteria.  
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4.5 Summary 
 
The aim of this chapter was to validate the essentiality of some of the putative 
essential genes involved in the cell division process via antisense RNA expression 
as antisense-knock down can be used to demonstrate gene product essentiality 
[148]. An important aspect of target validation is to identify genes that are 
essential under all growth conditions [105]. This is of significance as bacterial 
cells continuously monitor the availability of nutrients and/or the presence of 
exogenous stress and have developed complex regulatory networks that enable 
quick responses [263, 264]. These responses include differential expression of 
transcriptional regulators that leads to modulation of gene expression allowing the 
bacteria to adapt to the various stimuli [263].  
 
This study took homologues of three putative essential M. tuberculosis 
genes that may be involved in chromosome partitioning (obg, parA and parB) to 
test in M. smegmatis. Of the three genes tested, only parA demonstrated that it 
may be essential for the viability of the cells under the various culture conditions 
tested; nutrient rich, carbon starvation and nitrogen starvation conditions. It also 
exhibited a null phenotype upon antisense expression with parB which is believed 
to encode the protein that may aid in the ATPase activity of the protein encoded 
by parA. Down-regulation of obg only showed an effect under rich culture 
conditions but not under nutrient limitation conditions demonstrating that it is not 
vital for the viability of the cells at all times.  
 
 The final goal was to identify a gene that may be required under all 
conditions as a potential target for screening for anti-tubercular drugs. This 
chapter illustrated that parA may be a viable target for drug screening. 
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5.1 Introduction 
 
Broad cell-based screens have led to the identification of a number of antibiotics. 
However, a major draw-back of these screens is the lack of information on the 
biochemical targets of the antibiotics identified. This creates a series of problems 
downstream and has resulted in the drug discovery industry moving towards 
targeted drug discovery [46, 67, 115, 147, 198].  
 
 
5.1.1 Parameters of a drug screen 
 
As discussed in section 1.8, there are various different assays that can be used for 
target-based HTS and this calls for a number of different parameters to be 
evaluated for the selection of the best screening method. The most obvious of 
these is the antimicrobial activity of the molecules. For a molecule to display 
antibacterial effects, it has to overcome membrane permeability, evade efflux 
pumps, prevent degradation in the cell and reach its target in the active form [95]. 
Cell permeability is particularly a concern with antimycobacterial compounds as 
mycobacteria are known to have a complex cell wall (Figure 1.2) making them 
impermeable to most antibiotics [265]. These attributes are overlooked in cell-free 
biochemical screens and hits require further modification involving expensive 
medicinal chemistry to accommodate these measures [97]. This makes cell-based 
assays a superior choice over cell-free assays for initial screening. Another 
advantage of such whole-cell assays is the ability to screen for compounds in 
multiple culture conditions [124]. Minimal media conditions are an appropriate 
choice since M. tuberculosis dwells in granulomas where there is believed to be a 
limitation of nutrients [266]. 
 
 A significant factor that needs to be considered with a targeted screen is 
the selectivity of the compounds to the target. This aspect can be quickly and 
easily addressed using bioinformatics and genomics where similar targets in other 
microbes and mammals can be identified. Known targets can also be used in mode 
of action studies and can be used to uncover heritable resistance determinants. 
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Both of these are difficult to elucidate in broad cell-based assays when the target 
is unknown. This requires a lot more post-screening labour [147] thus making 
target based assays a preferred option.  
 
By far, the most important feature of targeted screens in today’s drug 
development program is ability to use the MOA in SAR analysis. This can 
proceed onto rational drug design using combinatorial chemistry as most 
antimicrobials in use today have undergone some semi-rational optimization 
[198]. The lead optimization of weak ligands using SAR can greatly increase the 
potency and can also be modified with respect to specificity [105]. This again, 
cannot be done when the target is unknown.  
 
 
5.1.2 Differential susceptibility assays 
 
The goal of any HTS is to identify a molecule that will influence the overall 
fitness of the microbe. This requires the bioactive molecule to inhibit the 
expression of a target gene(s). This in turn will affect the activity of the protein 
encoded by the gene and thus have an effect on the whole organism. Such 
discoveries are greatly accelerated using chemogenomics which combines the 
effect of compounds on biological targets together with modern genomics 
technologies. This includes knockdown experiments where there is a reduced 
level of target protein in the cell which is further reduced upon exposure to 
specific inhibiting molecules [267]. Such modular assays using bacterial genetics 
offer a number of advantages. Firstly, these assays make targets hypersensitive 
and screening more effective as the hits isolated from these screens would 
otherwise be missed. Secondly, once a modulation technique is optimized, the 
same procedure can be used on many different targets providing a technically 
simple, inexpensive and permanent tool as the engineered strains can be used in 
multiple screens. And lastly, such assays offer a means to identify inhibitors of 
uncharacterized targets which do not have a biochemical assay. It also aids in 
MOA studies of the compound as modulation of the target should relate to 
variations on the minimum inhibitory concentration and may produce phenotypic 
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changes that may assist in its functional elucidation [67]. Thus cellular responses 
upon exposure to small molecules can validate a therapeutic target before the 
direct biochemical function of the target is fully clarified [268].  
 
One such modulation technique which has demonstrated its success in 
drug screening is the expression of antisense RNA (section 4.1.1.1). This 
procedure requires little genetic manipulation compared to mutants created via 
homologous recombination and provides an invaluable genetic tool [269]. 
Additionally, this controlled gene expression system can be transferred to test the 
activity of active compounds in vivo.  
 
Below are some examples of inhibitors that have been verified using antisense 
RNA expression system: 
 
 The MOA of the polypeptide deformylase (PDF) in Staphylococcus 
aureus was confirmed using a TetR-regulated system that displayed 
increased susceptibility to a PDF specific inhibitor upon partial inhibition 
of PDF expression [269].  
 Increased susceptibility of ileS and fabI to mupirocin and triclosan, their 
respective inhibitors, was demonstrated upon antisense RNA expression 
[270].  
 Platensimycin, inhibitor of the enzyme FabF protein involved in the fatty 
acid biosynthesis pathway and a novel broad-spectrum antibiotic, was 
discovered by differential sensitivity assay  [271] 
 
Keeping in mind the above discussed parameters of a HTS, a cell-based targeted 
approach was employed to screen for inhibitors against parA, the gene encoding a 
Walker type ATPase.  
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5.1.3 ATPases  
 
ATPases function in a broad variety of biochemical process. They catalyse the 
hydrolysis of adenosine triphosphate (ATP) molecules into adenosine diphosphate 
(ADP) molecules which releases an inorganic phosphate (Pi). The 
dephosphorylation of the high energy phosphate bond releases energy which is 
then used to drive other chemical reactions. The most common type of ATPases 
comprise of the conserved Walker motifs, the form seen in ParA according to 
sequence homology. The Walker motifs contain the characteristic phosphate 
binding loop (P-loop) [272]. The P-loop is the mononucleotide binding fold and is 
also conserved in GTPases [273, 274]. Since the P-loop is so highly conserved, 
the ATPase active site has not been a very attractive target for drug discovery. 
However, as their structures have been further elucidated, it has been found that 
there are different classes of enzymes that have the P-loop and they have diverse 
nucleotide binding sites [275]. This has made it appealing to the drug discovery 
industry to design inhibitors that will only target specific types of ATPases.  
 
 There can be two different modes of actions for ATPase inhibitors; it can 
either bind to the active site and prevent ATP from binding (competitive inhibitors 
and/or adenine mimics) or it can bind to some other site on the ATPase that 
changes the conformation of the active site thus preventing ATP from binding to 
it (non-competitive inhibitors) [276]. Competitive inhibitors have to be highly 
selective however; various ATPases inhibitors have been designed with 
specificity to the target ATPases, that is, DNA gyrases and protein kinases 
inhibitors [277-279]. Such work demonstrates that targeting ParA is a plausible 
strategy for identifying antimicrobials to combat disease.   
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5.2 Objectives of chapter five 
 
The main aim of this chapter was to find molecules that will target the cell 
division process in mycobacteria.  
 
As discussed in chapter 4, ParA indicated that it might be essential for cell 
division in M. smegmatis under all the culture conditions tested in this work 
making it a viable target for drug screening. I hypothesized that any molecule 
affecting ParA will result in hypersensitivity and may exhibit phenotypic changes 
that are consistent with inhibiting cell division genes, that is, filamentous cell 
morphology [215, 221]. 
 
In order to test this hypothesis and discover such molecules, M. 
smegmatis-pMind_parA_GFP strain was subjected under antisense inducing 
conditions to differential susceptibility assays in conjunction with compound 
libraries under various culture conditions. My main objectives were to:  
 
 Run HTS of M. smegmatis-pMind_parA_GFP with a reference strain, both 
under antisense inducing conditions in various culture conditions 
 Isolate compounds that exhibited hypersensitivity in the M. smegmatis-
pMind_parA_GFP strain only  
 Perform microscopy to identify if the compounds exhibiting 
hypersensitivity also displayed filamentous cell morphology in the M. 
smegmatis-pMind_parA_GFP strain compared to the reference strain.  
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5.3 Results  
 
All HTS were performed in triplicate with a control strain M. smegmatis-
pMind2357. M. smegmatis-pMind2357 contains the MSMEG_2357 gene in the 
antisense orientation under the tetracycline promoter of pMind. MSMEG_2357 is 
a cysteine desulfurase, homologue of which is an essential gene in M. tuberculosis 
(Rv3025c; Supplementary Table S1- Appendix 9.2.2). This strain was closest in 
profile to M. smegmatis-pMind_parA_GFP in growth assays with respect to OD 
and CFU (data not shown) and MSMEG_2357 is not involved in cell division thus 
serving as an ideal reference strain in the HTS.  
 
All assays were set-up as described in section 2.13.1.1 under antisense 
inducing condition with 20 ng/mL Tc in LBT, carbon starvation (C
-
) and nitrogen 
starvation (N
-
) conditions. For the purpose of this thesis, only hits from the M. 
smegmatis-pMind_parA_GFP were analysed. Hits were also compared to wild 
type strains of M. smegmatis [124] to eliminate molecules that were not picked up 
in the reference strain. All wells that exhibited a 40% or more inhibition in at least 
two of the 3 screens were analyzed.  
 
This chapter presents all the hits obtained through the various HTS screens 
and discusses their potential as inhibitors of ParA. A total of 69 hits were 
identified from screening the M. smegmatis-pMind_parA_GFP strain against the 
compound libraries under three different culture conditions.  
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5.3.1 LOPAC Screen 
 
LOPAC (Library of Pharmacological Active Compounds) has 1280 compounds 
representing all major target classes. There were a total of 37 hits against M. 
smegmatis-pMind_parA_GFP from screening LOPAC; nine in LBT (Table 5.1), 
four in C
- 
(Table 5.2) and twenty-four in N
-
 (Table 5.3) conditions. 
 
 
5.3.1.1  LBT (LOPAC) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1: Graphical representation of LOPAC screens in LBT 
This graph shows the average percentage inhibition of M. smegmatis-pMind2357 and M. 
smegmatis-pMind_parA_GFP strains in LBT against LOPAC. The green box indicates all 
compounds that exhibited over 40% inhibition. The orange box indicates the positive 
control ethambutol; the blue boxes shows inhibition in both strains and the red boxes 
shows some molecules that exhibited inhibition in the target strain. Error bars not shown 
for clarity.  
0
20
40
60
80
100
200 400 600 800 1000 1200 1400
%
 I
n
h
ib
it
io
n
LOPAC Compound Index
pMind2357
pMind6939GFP
Key 
Chapter Five: Targeted Screening 
_______________________________________________________________ 
 
136 
Table 5.1: Hits from LOPAC in LBT 
Nine HTS hits against ParA from LOPAC in rich culture conditions.  
Cpd
No. 
Cpd 
name 
Compound 
structure 
MW 
(g/mol) 
Description/ 
Action 
1 Pyrazinecarboxamide 
 
123.12 
 
Antibiotic; tuberculostatic 
 
2 Tyrphostin AG 698 
 
308.34 
 
EGFR protein tyrosine 
kinase inhibitor 
 
3 SCH-202676 
hydrobromide 
 
348.27 
 
Allosteric agonist and 
antagonist of G protein 
coupled receptors (GPCRs) 
 
4 Diethylenetriaminepe
ntaacetic acid 
 
393.35 
 
Zinc-dependent proteases 
carboxypeptidase A and 
aminopeptidase N inhibitor; 
chelating agent 
 
5 Ketorolac tris salt 
 
376.41 COX (enzyme) inhibitor. 
Non-steroidal anti-
inflammatory (NSAID) drug 
 
6 Procainamide 
hydrochloride 
 
271.79 
 
Na+ channel blocker and 
Class I anti-arrhythmic 
 
7 Tetradecylthioacetic 
acid 
 
288.50 
 
Transcription agonist- 
Peroxisome proliferator-
activated receptor (PPAR)-
alpha agonist 
 
8 Prochlorperazine 
dimaleate 
 
606.10 
 
Dopamine antagonist- 
Antipsychotic agent; used in 
the treatment of spastic 
gastrointestinal disorders 
 
9 B-HT 933 
dihydrochloride 
 
254.16 
 
Selective alpha2 
adrenoceptor agonist 
 
All compounds in Table 5.1 exhibited more toxicity against the ParA antisense expressing 
strain compared to the reference strain. Cells from the wells containing these compounds 
were analysed under a fluorescence microscope for any discernable morphological 
changes. This analysis revealed that albeit showing a difference in the optical density 
between the two strains, there were no significant differences in the cellular morphology.  
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5.3.1.2  C- (LOPAC) 
 
 
 
Figure 5.2: Graphical representation of LOPAC screens in C- media 
This graph shows the average percentage inhibition of M. smegmatis-pMind2357 and M. 
smegmatis-pMind_parA_GFP strains in C
- 
media against LOPAC. The green box 
indicates all compounds that exhibited over 40% inhibition. The orange box indicates the 
positive control (ethambutol) and the red box shows inhibition in the target strain. Error 
bars not shown for clarity.  
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Table 5.2: Hits from LOPAC in C
-
 media 
 
Four HTS hits against ParA from LOPAC under carbon starvation conditions.  
Cpd
No. 
Compound 
name 
Compound 
structure 
MW 
(g/mol) 
Description/ 
Action 
10 CGS-15943 
 
285.69 
 
Highly potent, non-selective 
A1 adenosine receptor 
antagonist 
 
11 Myricetin 
 
 
318.24 
 
Casein Kinase II inhibitor 
 
12 4-
Hydroxybenzhydrazi
de 
 
152.15 
 
Phenylalanine ammonia-
lyase inhibitor; used to 
measure reducing sugar 
levels 
13 Fenofibrate 
 
360.84 
 
Transcription agonist- 
PPAR-alpha receptor 
agonist; lipid regulating drug 
 
 
ParA antisense expressing strains containing the compounds shown in Table 5.2 showing 
greater sensitivity in carbon starvation were analysed under the fluorescence microscope 
and were found to have no phenotypic effects compared to the control cells containing the 
same compounds.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter Five: Targeted Screening 
_______________________________________________________________ 
 
139 
5.3.1.3 N- (LOPAC) 
 
 
 
 
Figure 5.3: Graphical representation of LOPAC screens in N- media 
This graph shows the average percentage inhibition of M. smegmatis-pMind2357 and M. 
smegmatis-pMind_parA_GFP strains in N
-
 media against LOPAC. The green box 
indicates all compounds that exhibited over 40% inhibition. The orange box indicates the 
positive control ethambutol, the blue boxes shows inhibition in both strains and the red 
boxes shows inhibition in the target strain. Error bars not shown for clarity.  
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Table 5.3: Hits from LOPAC in N
-
 media 
Twenty-four HTS hits against ParA from LOPAC under nitrogen starvation conditions.  
Cpd
No. 
Compound 
name 
Compound 
structure 
MW 
(g/mol) 
Description/ 
Action 
14 Xanthine amine 
congener 
 
428.50 
 
A1 Adenosine receptor 
antagonist 
15 N6-Phenyladenosine 
 
343.34 
 
Potent A1 adenosine 
receptor agonist 
 
16 Amsacrine 
hydrochloride 
 
429.93 
 
DNA topoisomerase II 
inhibitor 
 
17 Anthrapyrazolone; 
1,9-Pyrazoloanthrone 
 
220.23 
 
Selective c-Jun N-terminal 
kinase (c-JNK) inhibitor. 
 
18 ODQ 
 
187.16 
 
Potent and selective NO-
sensitive guanylyl cyclase 
inhibitor 
19 Palmitoyl-DL-
Carnitine chloride 
 
436.08 
 
Long-chain acylcarnitine; 
modulator of PKC 
activation; intermediate in 
mitochondrial fatty acid 
oxidation 
20 Diphenhydramine 
hydrochloride 
 
291.82 
 
H1 Histamine receptor 
antagonist 
 
21 Sulindac sulfone 
 
372.42 Enzyme inhibitor- Non-
steroidal anti-inflammatory 
compound (NSAID); 
metabolite of sulindac 
 
22 AA-861 
 
 
326.44 
 
5-lipoxygenase inhibitor 
 
23 AL-8810 
 
402.51 
 
Prostaglandin F2alpha 
analog with selective 
antagonist effects at the 
prostaglandin F2alpha (FP) 
receptor  
24 Chloroquine 
diphosphate 
 
515.87 
 
Antimalarial; anti-amoebic; 
anti-inflammatory; binds 
strongly to double-stranded 
DNA 
 
25 (±)-Nipecotic acid 
 
129.16 
 
GABA uptake inhibitor 
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26 Atropine sulfate 
 
676.83 
 
Muscarinic acetylcholine 
receptor antagonist 
 
27 BW 245C 
 
368.48 Potent, selective DP 
prostanoid receptor agonist 
28 N-Acetyl-5-
hydroxytryptamine 
 
218.26 
 
Immediate precursor of 
melatonin 
 
29 BMY 7378 
dihydrochloride 
 
458.43 
 
Partial 5-HT1A serotonin 
receptor agonist; alpha1D 
adrenoceptor antagonist 
 
30 R-(-)-Fluoxetine 
hydrochloride 
 
345.80 
 
Selective serotonin reuptake 
inhibitor 
 
31 Apomorphine 
hydrochloride 
hemihydrate 
 
303.79 
 
Non-selective dopamine 
receptor agonist 
 
32 R(+)-SCH-23390 
hydrochloride 
 
324.25 
 
Selective D1 dopamine 
receptor antagonist 
 
33 R(+)-6-Bromo-APB 
hydrobromide 
 
455.19 
 
D1 Dopamine receptor 
agonist 
 
34 SKF 83565 
hydrobromide 
 
419.15 
 
Atypical D1 dopamine 
receptor agonist; displays 
antagonist activity in vitro 
and agonist activity in vivo 
 
35 Fenoldopam bromide 
 
386.68 
 
Peripheral D1 dopamine 
receptor agonist 
 
36 (±)-Octoclothepin 
maleate 
 
460.98 
 
D2 Dopamine receptor 
antagonist; serotonin 
receptor antagonist 
37 Methiothepin 
mesylate 
 
452.66 
 
5-HT1 Serotonin receptor 
antagonist; blocks serotonin 
autoreceptors 
 
The cells from the hit wells against ParA in N
-
 media (Table 5.3) were analyzed via a 
fluorescence microscope and compared to the control cells. Six out of the twenty-five 
compounds exhibited filamentous morphology. These were amsacrine hydrochloride, 
AA-861, R-(-)-fluoxetine hydrochloride, fenoldopam bromide, (±)-octoclothepin maleate 
and methiothepin mesylate (Appendix 9.4.1). 
 
B 
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5.3.2 Spectrum Collection 
 
The Spectrum Collection has 2000 compounds with a wide range of structures 
having various biological activities with 50% representing drugs, 30% 
representing natural products and 20% representing other non-drug bioactive 
compounds. There were a total of seven hits against M. smegmatis-
pMind_parA_GFP from screening the Spectrum Collection; five in LBT (Table 
5.4), one in C
- 
(Table 5.5) and one in N
-
 (Table 5.6) conditions. As can be seen 
from the graphs (Figure 5.6, 5.7 and 5.8), the lack of hits in this library owes to 
the fact that most of the hits came up in the reference strain as well.  
 
 
5.3.2.1  LBT (Spectrum Collection) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.4: Graphical representation of Spectrum Collection screens in LBT 
This graph shows the average percentage inhibition of M. smegmatis-pMind2357 and M. 
smegmatis-pMind_parA_GFP strains in LBT against Spectrum Collection. The green 
box indicates all compounds that exhibited over 40% inhibition. Error bars not shown for 
clarity.  
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Table 5.4: Hits from Spectrum Collection in LBT 
Five HTS hits against ParA from Spectrum Collection under rich culture conditions. UA 
= undetermined activity; E = experimental 
Cpd
No. 
Compound 
name 
Compound 
structure 
MW 
(g/mol) 
Description/ 
Action 
38 alpha-
Dihydrogedunol 
 
486.61 
 
Derivative, UA 
 
39 Benzocaine 
 
165.19 
 
anesthetic (topical) 
 
40 1,4-Naphthoquinone 
 
158.16 
 
coal tar product, E 
41 Haematommic Acid 
 
196.16 
 
UA 
42 Methyldopate 
Hydrochloride 
 
275.73 
 
Antihypertensive; 
Adrenergic alpha-Agonists 
 
 
All cells from the hit wells were analysed for morphological differences and compared to 
the control cells with the same compound. There were no differences in morphology 
between the two strains with any of the compounds shown in Table 5.4.  
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5.3.2.2  C- (Spectrum Collection) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.5: Graphical representation of Spectrum Collection screens in C
- 
media 
This graph shows the average percentage inhibition of M. smegmatis-pMind2357 and M. 
smegmatis-pMind_parA_GFP strains in C
-
 media against Spectrum Collection. The 
green box indicates all compounds that exhibited over 40% inhibition. Error bars not 
shown for clarity.  
 
 
Table 5.5: Hits from Spectrum Collection in C
-
 media 
One HTS hit against ParA from Spectrum Collection under carbon starvation conditions. 
UA = undetermined activity 
 Cpd
No. 
Compound 
name 
Compound 
structure 
MW 
(g/mol) 
Description/ 
Action 
43 3beta-
Acetoxydeoxyangole
nsic Acid, Methyl 
Ester 
 
514.62 
 
UA 
 
The hit from Spectrum Collection under carbon starvation condition against ParA did not 
display the morphological change that was expected upon perturbing cell division.  
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5.3.2.3  N- (Spectrum Collection) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.6: Graphical representation of Spectrum Collection screens in N- media 
This graph shows the average percentage inhibition of M. smegmatis-pMind2357 and M. 
smegmatis-pMind_parA_GFP strains in N- media against Spectrum Collection. The green 
box indicates all compounds that exhibited over 40% inhibition. Error bars not shown for 
clarity.  
 
 
Table 5.6: Hits from Spectrum Collection in N
-
 media 
One HTS hit against ParA from Spectrum Collection under nitrogen starvation 
conditions.  
Cpd
No. 
Compound 
Name 
Compound 
structure 
MW 
(g/mol) 
Description/ 
Action 
44 Phenoxybenzamine 
Hydrochloride  
 
 
340.287 Non-selective alpha-
adrenergic antagonist 
[280] 
 
The hit against ParA from the Spectrum Collection in N
-
 media displayed the filamentous 
morphology that is expected when cells are inhibited from proper cell division. This was 
not seen in the control strain (Appendix 9.4.2).  
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5.3.3  NIH Diversity Set 
 
The NIH Diversity Set consists of 2400 compounds with a broad range of 
structures derived from about 140, 000 compounds. There were a total of twenty-
five hits against M. smegmatis-pMind_parA_GFP from screening the NIH 
Diversity Set; twenty-one in LBT (Table 5.7), three in C
- 
(Table 5.8) and one in N
-
 
(Table 5.9) conditions.  
 
 
5.3.3.1  LBT (NIH Diversity Set) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.7: Graphical representation of the NIH Diversity Set screens in LBT 
This graph shows the average percentage inhibition of M. smegmatis-pMind2357 and M. 
smegmatis-pMind_parA_GFP strains in LBT against the NIH Diversity Set. The green 
box indicates all compounds that exhibited over 40% inhibition. Error bars not shown for 
clarity.  
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Table 5.7: Hits from NIH Diversity Set in LBT media 
Twenty-one HTS hits against ParA from the NIH Diversity Set under rich culture 
conditions. UA = undetermined activity 
Cpd
No. 
Compound 
Name/ ID 
Compound 
structure 
MW 
(g/mol) 
Description/ 
Action 
45 NSC57850 
 
239.23 Perturbs 3 pathways: 
cholesterol metabolism, 
proteasome and oxidative 
phosphorylation 
46 NSC131615 
 
295.16 Targets human cytochrome 
P450 
47 NSC117198 
 
273.28 Targets human cytochrome 
P450 
48 NSC195151 
 
315.2 Targets human cytochrome 
P450 
 
49 NSC116490 
 
388.52 Regulation of actin 
cytoskeleton, GTPase 
inhibitor activity, 
transcription regulation  
50 NSC65650 
 
166.22 UA 
51 3-Pyridazinealanine 
 
167.165 Targets voltage-gated K+ 
channel (human) 
52 NSC53069 
 
246.71 Nucleotide binding, affects 
ATP binding, GTPAse and 
serine/threonine kinase 
activity 
53 NSC138617 
 
332.22 Targets voltage-gated K+ 
channel (human) 
54 NSC83391 
 
308.78 Targets voltage-gated K+ 
channel (human) 
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55 NSC343040 
 
281.32 Targets ATP-binding protein 
yjeE, G-protein couple 
receptors 
56 NSC263791 
 
268.27 Targets human cytochrome 
P450 
57 NSC3589 
 
294.74 UA 
58 NSC245053 
 
266.42 UA 
59 NSC89419 
 
290.19 ATP binding, affecting 
cytoskeleton 
60 NSC70817 
 
 
228.29 Targets human cytochrome 
P450 
61 NSC187613 
 
287.18 UA 
62 Geraniol 
 
154.25 Targets lipoxygenase  
63 NSC110380 
 
351.02 Targets prostaglandin E 
receptor 2 
64 Guanazodine 
 
280.34 Causes hypertension 
65 Artemisinine 
 
282.33 Targets huntingtin, binds to 
heme and releases free 
radicals [281] 
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5.3.3.2   C- (NIH Diversity Set) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.8: Graphical representation of the NIH Diversity Set screens in C
-
 media 
This graph shows the average percentage inhibition of M. smegmatis-pMind2357 and M. 
smegmatis-pMind_parA_GFP strains in C
-
 media against the NIH Diversity Set. The 
green box indicates all compounds that exhibited over 40% inhibition. Error bars not 
shown for clarity.  
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Table 5.8: Hits from NIH Diversity Set in C
-
 media 
 
Three HTS hits against ParA from the NIH Diversity Set under carbon starvation 
conditions. UA = undetermined activity. 
Cpd
No. 
Compound 
Name/ ID 
Compound 
structure 
MW 
(g/mol) 
Description/ 
Action 
66 NSC22242 
 
224.24 UA 
67 NSC45382 
 
439.871 Targets human cytochrome 
P450, prostaglandin E 
receptor 2, Hiv-2 Reverse 
Transcriptase, RNase HI 
68 NSC368891 
 
375.918 UA 
 
Cellular morphology of all hits against ParA in C
-
 from the NIH Diversity Set (Table 5.8) 
were analysed under a fluorescence microscope. Of the three hits, only compound 66 
showed the expected phenotype (Appendix 9.4.3).  
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5.3.3.3 N- (NIH Diversity Set) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.9: Graphical representation of the NIH Diversity Set screens in N- media 
This graph shows the average percentage inhibition of M. smegmatis-pMind2357 and M. 
smegmatis-pMind_parA_GFP strains in N- media against the NIH Diversity Set. The 
green box indicates all compounds that exhibited over 40% inhibition. Error bars not 
shown for clarity.  
 
 
Table 5.9: Hits from NIH Diversity Set in N
-
 media 
One HTS hit against ParA from the NIH Diversity Set under nitrogen starvation 
conditions. UA = undetermined activity. 
Cpd
No. 
Compound 
Name/ ID 
Compound 
structure 
MW 
(g/mol) 
Description/ 
Action 
69 Mitomycin C 
 
378 antibiotic isolated from the 
broth of Streptomyces 
caespitosus, selectively 
inhibits DNA synthesis, 
cellular RNA and protein 
synthesis are also suppressed 
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5.4 Discussion 
 
The aim of this chapter was to identify small molecules as hits against ParA that 
may potentially be developed as ParA inhibitors.  This was performed using a 
whole-cell differential susceptibility assay. This assay is based on reverse 
chemical genetics approach with a gene driven analysis based on phenotypic 
changes and/or sensitivity created by the small molecules upon modulation of the 
target protein using antisense RNA.  
 
The first thing to take into consideration in this case is the justification for 
using ParA as a target. There are several arguments that support ParA as a 
plausible target. Firstly, as discussed in chapter 3, ParA cannot sustain transposon 
mutagenesis [126] and it appears to be required for growth under various culture 
conditions (chapter 4). Secondly, it is involved in an essential cellular pathway, 
that is, cell division [130, 234, 236, 238-240, 246, 247, 282-284] and thirdly, it is 
an enzyme [243, 282, 283, 285]. There are a number of advantages to using 
enzymes as targets. They have been widely used as targets for antibacterials and it 
is easy to develop functional assays for them [286]. Some even consider all 
bacterial enzymes to be potential drug targets [287]. Most eminently though, 
enzymes interact with small ligands and this increases the likelihood of them 
binding small molecule inhibitors [148]. Furthermore, ParA is an ATPase (section 
5.1.3). It is believed that inhibitors of some classes of enzymes are more 
effortlessly identified than others [46]. This makes ParA, an ATPase, an optimal 
target as ATPase inhibitors are well established [288-292]. As discussed in section 
4.4.1.3, ParA may bind to another protein ParB. This interaction can also be 
exploited for drug discovery as inhibiting protein-protein interaction has lead to 
successful drugs [293]. Lastly, ParA has not been previously targeted by any 
antibiotics thus exploitation of this unique target may reveal compounds with a 
novel mechanism of action. 
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5.4.1  Goals of targeted screening  
 
Current HTS employed by large pharmaceutical and biotechnology companies 
involves screening for hundreds of thousands and even millions of compounds 
[294, 295]. However, such screens are expensive and require the development of 
cost-effective ways of screening. With this in mind, this study implemented a so-
called ‘smart screening’ strategy [296]. This involved screening a relatively small 
but diverse set of compounds (between 2000 to 5000) in an attempt to learn what 
to screen next.  
 
The LOPAC library provided a diverse set of compounds as it contains 
active compounds from an assortment of biological arenas. It also contains some 
gold standards with well characterised mode of actions for assay validation. Since 
LOPAC is so extensively used, it was ideal to use in the case of ParA as this is a 
unique target increasing the chances of excluding the inhibitors of known targets 
and picking out novel hits as the success of exploiting drugs with known targets is 
extremely low [112]. The Spectrum Collection also fell in the category of 
structurally diverse compounds (section 5.3.2). Lastly, the NIH diversity Set 
included a range of structures which were derived from 3-point pharmacophores 
as a means to enhance the overall presentation of chemical diversity. The 
Spectrum Collection and the NIH Diversity Set also contain experimental 
bioactives and natural products increasing the potential of identifying novel 
structures against ParA. The resulting structures from the overall screening of the 
three libraries is not target biased, but are unique, providing useful starting 
structures for in silico screening of an uncharacterised target.  
 
 Finally, apart from the libraries used, the assays used for HTS are also 
coming under scrutiny for the generation of high quality hits and the removal of 
false positives from the hit lists. It is worth mentioning that no one screening 
strategy is void of artefacts, thus the successful development of any antibiotic 
requires more than one assay [112]. The method used for initial screening and hit 
identification in this study was a differential susceptibility assay (section 5.1.2). 
The reasons for using a screen as such are discussed in section 5.1.1. There is also 
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a caveat to this assay which can be used as an advantage. As attractive and 
common as it is to target a single protein, this concept can be very deceiving. It is 
a known fact that genes do not function in solitude. They form networks that 
interact with exquisite complexity [297] and it has been shown through 
transcription profiling that microbes undergo global alteration in transcription 
regulation upon sensing a change in its environment [298-302]. This sheds a 
different light on things, as a target may be essential but inhibiting the target with 
a molecule can change the transcription profile and perhaps even render the target 
non-essential under these conditions. Inhibiting the target can also lead to the 
upregulation of genes with similar functionality to overcome its handicap. Thus 
the changes in the network connectivity by molecules modulating the target gene 
can potentially uncover biological redundancy in the system [303] and it can also 
lead to the upregulation of other druggable targets. Thus this assay can validate a 
target with respect to functional connectivity with other genes. Identification of 
other genes in the same pathway that causes synthetic lethality can be used to 
exploit ParA further for drug targeting. Such experiments has been successfully 
conducted in M. tuberculosis with other genes [304]. Additionally, these targets 
can be subjected to combination drug therapy to exhibit more potent MIC as has 
been shown for meropenem with clavulonate [305].  
 
 
5.4.2  Biological aspects of the hits  
 
For the purpose of hit identification in this study, a cut-off of 40% inhibition was 
chosen. A 40% cut-off was decided upon from the data output of the HTS. All 
compounds exhibiting greater than 90% inhibition at 20 µM (screening 
concentration) were detected in the WT assay (scope of other work) so inhibition 
lower than 90% was screened for. An initial cut-off of 50% was used. Most 
compounds exhibited 50-60% inhibition in at least 2 of the 3 screens. However, 
often data from 1 of the 3 screens had a 45-49% inhibition, just falling below the 
50% cut-off. A greater variability than a standard assay was expected in these 
screen as the inhibition was dependent on two factors, the amount of antisense 
produced and the concentration of drug. While the concentration of drug would 
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have been nearly identical in all 3 screens (dispensed with liquid handler), the 
amount of antisense could be highly variable thus after looking at the data, the 
cut-off was dropped to 40% so potential hits or weak inhibitors would not be 
missed out. All hits were then compared to the reference strain to exclude 
molecules that were common to sensitive strains expressing antisense RNA of an 
essential gene and to distinguish hits that were specific to M. smegmatis-
pMind_parA_GFP. This cut-off is lower than what would normally be used 
however; the level of reduction of the target protein in the cell is unknown. It is 
also not known what level of protein is required for the cells to grow normally 
without displaying any discernable physiological characteristics. Thus using a low 
cut-off allowed us to pick out hits that may be weak inhibitors of the target and do 
not display a very high sensitivity due to some target protein still in the cell. It 
should also be kept in mind that growth inhibition assays are not as sensitive as in 
vitro biochemical assays [112] and many good leads only show a moderate effect 
upon initial screening and requires chemical modification before being considered 
as successful leads [295].  
 
 A major disadvantage of a whole-cell assay is that it does not only identify 
inhibitors that are specific to the target; there are often nonstoichiometric hits that 
lack any SAR relationship or seemingly affect unrelated proteins [306]. There are 
several different reasons why there are such promiscuous inhibitions. The most 
obvious of these is that some compounds have alkylating or acylating properties 
that covalently react with functional groups in the target protein [307]. 
Ambiguous false positives like these can be more rigorously analysed via 
pharmacological studies such as dose-response curves which can either confirm 
the false positives or identify them as potential leads. Compounds can also act on 
other proteins in the same pathway thus giving simialr phenotype for different 
cellular targets. Another reason that has been proposed for false positives is due to 
the formation of aggregates by self-association of small molecular weight 
compounds at micromolar concentration [306, 308, 309]. These aggregates has 
been shown to sequester and inhibit many different enzymes [308]. Consequently, 
like most screening hit lists, the list in this study is populated with such enzyme 
inhibitors. Some examples of these include kinase inhibitors (compound numbers 
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2, 11, 17, 18, 21 and 52) lipoxygenase inhibitors (compound numbers 22 and 62), 
COX inhibitor (compound number 5) and lyase inhibitor (compound number 12).  
 
 Another non-specific hit to ParA that was identified in this screen was 
amsacrine hydrochloride (compound number 16). This is a eukaryotic DNA 
topoisomerase II inhibitor that has shown antibacterial activity [310]. 
Topoisomerases acts by binding to DNA and amsacrine inhibits its activity by 
trapping the covalently bound enzyme-DNA complex. Such complexes can 
obstruct cellular processes like DNA replication and transcription, the 
predecessors of cell division. This, combined with expressing antisense RNA of 
ParA is bound to have some impact on the cell cycle which would explain why 
there was filamentous cell morphology observed with this drug (Appendix 9.4.1). 
Even though it has a different cellular target, it is involved in the same pathway as 
ParA and if the pathway is essential for the survival of the bacterial cell, inhibiting 
any steps in the pathway will display discernable phenotypic characteristics. An 
additional example of a non specific hit includes mytomycin C (compound 
number 69). It is a potent DNA crosslinker that has shown activity against M. 
bovis BCG [311]. It inhibits RNA and protein synthesis and may show a decrease 
in optical density when another process preventing the same pathway is perturbed. 
It is also toxic against mammalian cells.  
 
A surprising hit was pyrazinecarboxamide (compound number 1); also 
known as PZA, a first-line drug used for Tb therapy (section 1.5). It is a 
nicotinamide analog prodrug which is converted to its active form pyrazinoic acid 
(POA) by an enzyme called pyrazinamidase (PZase). There are various 
hypotheses as to what its mode of action might be [312, 313] however it may not 
have a single target. Its MIC varies from 8 µg/mL to 60 µg/mL in M. tuberculosis 
depending on the assay and culture conditions and it is believed to be active 
against semidormant bacilli but it has no activity against other mycobacterium 
species [312, 313]. M. smegmatis is highly resistant to PZA (MIC > 2 000 µg/mL) 
[314] due to the presence of a very efficient POA efflux mechanism [315]. In this 
assay, upon expression of ParA antisense, M. smegmatis exhibited approximately 
a 40% inhibition at 20 µM, that is, 2.463 µg/mL of PZA, much lower than the 
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normal 2 000 µg/mL. It is unlikely that ParA is the molecular target for PZA 
however down-regulating a gene involved in something as important as cell 
division may have caused a down-regulation of other cellular processes including 
the efflux mechanism of POA resulting in sensitivity at a low concentration. 
Another nicotinamide analog, 3-pyridazinealanine (compound 51), was also found 
to be a hit in this assay supporting the hypothesis that the POA efflux mechanism 
is down-regulated upon antisense expression of ParA. Interestingly both of these 
hits were picked up in rich media in different libraries but were not identified in 
screens conducted under nutrient limitation conditions.  
  
 There were some hits that could be potential competitive inhibitors of 
ParA. These include adenosine receptor antagonists (compound numbers 10, 14 
and 15), all of which mimicked the nitrogenous base of the ATP molecule, the 
substrate for ParA. Other hits that can also be considered competitive inhibitors 
were molecules that bind to nucleotide binding proteins (compound numbers 45, 
49 and 55). Most of these have non-selective activity thus it is improbable that 
they are exhibiting inhibition specifically against ParA. There were also some 
nucleotide binding molecules (compound numbers 52 and 59) that were picked up 
as hits. These molecules do not target ParA but bind to its substrate. Since the 
level of ParA may be reduced due to the expression of ParA antisense RNA, 
further reducing its substrate is likely to have detrimental effects on the cells.  
 
 Lastly there are hits that have obvious toxicity against mammalian cells 
and are not appropriate compounds to pursue. These includes molecules that 
target actin (compound number 49), molecules that target mammalian enzymes 
(compound numbers 16, 17, 46, 47, 48, 56, 60 and 67) and/or known toxins 
(compound numbers 39 and 40).  
 
 
5.4.3  Chemical aspects of the hits 
 
As discussed above, most HTS hits contain false positives. False positives related 
to biology are easily detected as they are not reproducible in subsequent screens. 
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False positive related to chemistry are harder to discern as the positive signal is 
related to the chemical structure being screened and are reproducible. Thus a hit 
list has to be closely examined by a medicinal chemist to identify potential leads 
from such false positives as it requires an understanding of the pharmacophore 
and its interaction with the target structure [306, 307]. This is important as the 
process of hit-to-lead go through chemical series that takes into account the 
biological properties and the quantitative structure-activity relationship (QSAR) 
of a compound.  
 
Of the 69 hits identified in these screens, there are certain compounds that 
are not very good medicinal chemistry targets or are difficult to perform SAR 
with. These include compound numbers 7, 10, 12, 19, 22, 38, 53, 63, 64 and 68. 
There are other compounds that have a complicated chemistry associated with 
them, another drawback from a medicinal chemistry point of view. These 
included compound numbers 24, 30, 31, 42, 43 and 55. Other compounds that 
looked plausible were compounds with similar structures, that is, compound 
numbers 32 & 33 and compound numbers 36 & 37. However compounds 32 &33 
have stereochemistry associated with them and compounds 36 & 37 are difficult 
to synthesize. Thus all hits were re-evaluated to determine their potential as new 
drug leads.  
 
 After the analysis of the biological activity and the chemical structure of 
the 69 hits that were identified in the screens, only ~ 20 compounds seemed to be 
likely leads. Some potential leads include compound numbers 4, 6, 9, 14, 15, 20, 
28, 35, 44, 45, 53, 54 and 66. Compound 35, fenoldopam bromide, also gave 
elongated cell morphology (Appendix 9.4.1) when exposed at 20 µM in nitrogen 
limitation media compared to the controls. Compound 44, phenoxybenzamine 
hydrochloride gave similar results with elongated cells (Appendix 9.4.2) in 
nitrogen starvation conditions. Compound 66, NSC22242 gave elongated cells in 
carbon starvation media (Appendix 9.4.3).  
 
 
 
Chapter Five: Targeted Screening 
_______________________________________________________________ 
 
159 
5.4.4 Summary 
 
In summary, this chapter has identified potential hits against ParA in a cell-based 
assay using HTS. This method preserved the interaction of the target protein with 
other macromolecules that are critical for cellular function and displayed 
compounds as ineffective in the presence of competitive parameters. From all the 
screens against the compound libraries, a total from 5680 compounds were 
screened in 3 different culture conditions. This collectively identified 69 hits that 
occurred repeatedly in the target strain but not in the WT or reference strains. 
After taking into consideration the biological functions and chemical structures of 
the 69 hits, approximately 20 compounds were identified as good hits to pursue. 
However, it is important to note that this was a preliminary screen and the hits 
identified in these screens have to be validated as compounds can display 
sensitivity due to an unpremeditated MOA in a cell-based assay. It would be ideal 
to have a secondary functional assay to distinguish that the sensitivity exhibited 
by the compounds is due to the inhibition of the specific target before it can be 
considered as a lead against ParA.  
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6.1 Introduction 
 
All hits identified as active in whole-cell assays have to be authenticated for 
specificity with respect to their targets to be considered as viable leads. The mode 
of inhibition provides confidence to inferring the SAR of the compound since this 
requires the physical binding of the molecule to the target. Such information can 
lead to rational drug design through combinatorial chemistry efforts to further 
embellish the inhibitory properties of the compound to generate novel antibiotics. 
The assays used for targeted screening in chapter 5 did not establish a direct 
relationship between the inhibitory molecules against ParA. This chapter validated 
some of the hits identified in chapter 5 as potential leads against ParA using a 
biochemical assay.  
 
 
6.1.1 Validation assays 
 
Specificity of bioactive compounds against particular targets from a cell-based 
assay is usually determined using cell-free in vitro assays (section 1.8). The 
follow-up of HTS with biophysical and enzymological studies are referred to as 
validation assays which isolates the quality hits from the false-positives [295].  
 
The development of a successful biochemical assay has to comply with 
multiple factors. Firstly, such an assay requires the expression and purification of 
the target protein in a soluble and active form. Acquisition of active protein is 
followed by the development and optimization of a functional assay to determine 
the best working conditions for the target [316]. However, this is not always 
plausible if the protein has no known function or conserved domains that can 
potentially be used to derive its hypothetical function.  In such cases, affinity-
based technologies are used to determine the specificity of compounds against the 
target. Affinity-based assays just require the binding of the compound to the target 
protein however it does not impart the target functionality [268]. Once SAR is 
observed, successful compounds are subsequently tested for cytotoxicity in 
mammalian cells before a compound is regarded as a good lead [46].  
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 Biochemical assays can also be utilized for kinetic studies. Such studies lead 
to an understanding of the basic principles of the enzyme catalysed reaction [317]. 
The fundamental concept of enzyme kinetics is conveyed by the Michaelis-
Menton equation which is derived from the assumption that a reaction forms an 
intermediate enzyme-substrate complex: [E] + [S] ↔ [ES] ↔ [E] + [P] where E, S 
and P represents enzyme, substrate and product respectively [318]. The Michaelis-
Menton equation can be used to measure the catalytic mechanism of an enzyme. 
The catalytic constants point towards the physiological concentrations of the 
reactants as enzymes generally work within or just above the Michaelis constants 
[317]. This can in turn be used to find out the mechanism via which a drug 
inhibits the enzyme activity. 
 
 
 
6.2 Objectives of chapter six 
 
This chapter focused on developing and optimizing a biochemical assay for ParA. 
This assay was subsequently used to validate the hits obtained in the HTS to 
distinguish between primary and off-target hits. 
 
 Given that the ParA protein contains the conserved Walker motif that is 
present in ATPases, I hypothesized that M. tuberculosis ParA may possess 
ATPase activity. I also hypothesized that ParA may require the ParB protein and 
parS DNA sites to stimulate its ATPase activity as has been found in other 
systems (section 4.4.1.3). 
 
 To investigate these hypotheses, the M. tuberculosis ParA and ParB 
proteins were cloned into expression vectors and soluble proteins were purified 
for the functional assay. The main aims of this chapter were to: 
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 Determine an optimal protocol for isolating soluble Par proteins and 
develop an in vitro biochemical assay for ParA 
 Test for the specificity of the inhibitors identified in chapter 5 in the in 
vitro assay and determine the types of inhibitions  
 Elucidate MIC values of ParA inhibitors in M. smegmatis, M. bovis BCG 
and M. tuberculosis  
 Perform in silico analyses of the interactions between the validated 
inhibitors and ParA. 
 
 
 
6.3 Results 
 
Both M. tuberculosis parA (Rv3918c) and parB (Rv3917c) genes were amplified 
from the M. tuberculosis H37Rv genomic DNA and cloned into expression 
vectors pBAD/HisB and pET-28a(+) (Table 2.2). These vectors were transformed 
into E.coli LMG194 and E. coli BL21 (DE3) respectively to express and purify 
recombinant proteins for the development of a biochemical assay.  
 
 
6.3.1 Protein over-expression  
 
A high yield of recombinant protein was required for the biochemical assay and 
subsequent hit validation thus various different expression protocols were used to 
determine the optimal conditions required for isolating a moderate amount of 
soluble protein (section 2.10.1).  
 
Expression with pBAD/HisB vector gave a low yield of soluble protein at 
37°C (Figure 6.1 and 6.2). The araBAD promoter also did not express at lower 
temperatures or significantly increase the level of expression upon osmotic stress 
or heat-shock (data not shown); both of which has shown to increase the 
expression of recombinant proteins with the T7 promoter in the pET system [128].  
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Consequently, both the parA and parB genes were subcloned from the 
pBAD/HisB vector into the pET-28a(+) vector and subjected to all the conditions 
stated in section 2.10.1.1. The ZYP-5052 auto-induction media [129] significantly 
increased the amount of soluble recombinant protein being expressed (Figure 6.1 
and 6.2) thus this protocol was used for the purification of recombinant ParA and 
ParB protein for all biochemical assays.  
 
 
 
 
 
Figure 6.1: Protein over-expression of ParA 
SDS-PAGE showing protein over expression of ParA at 37°C for 4 hours with E. coli 
LMG194-pBAD/HisB_ParA induced with L-arabinose and E. coli BL21-pET-
28a(+)_ParA induced with IPTG (section 2.10.1.1, protocol I). Gel lanes contain a) 
protein molecular weight marker, lane 1) uninduced cell lysate, lane 2) induced cell 
lysate, lane 3) soluble uninduced cell lysate, lane 4) soluble induced cell lysate. All lanes 
have the same amount of protein loaded. E. coli BL21-pET-28a(+)_ParA has more 
soluble protein present compared to E. coli LMG194-pBAD/HisB_ParA (lanes 4- red 
box) thus E. coli BL21-pET-28a(+) was used for the expression and purification of 
recombinant protein. The molecular weight of ParA without the His-Tag is 37.5 kDa.  
 
 
  E .coli LMG194-pBAD/HisB 
 
    a       1           2         3          4            
   E .coli BL21-pET-28a(+)  
 
1         2         3          4             
 
27.0 
34.6 
42.7 
Marker 
MW  
(kDa) 
 
 
Chapter Six: Hit Validation 
_______________________________________________________________ 
 
165 
 
 
 
 
Figure 6.2: Protein over-expression of ParB 
SDS-PAGE showing protein over expression of ParB at 37°C for 4 hours with E. coli 
LMG194-pBAD/HisB_ParB induced with L-arabinose and E. coli BL21-pET-
28a(+)_ParB induced with IPTG (section 2.10.1.1, protocol I). Gel lanes contain a) 
protein molecular weight marker, lane 1) uninduced cell lysate, lane 2) induced cell 
lysate, lane 3) soluble uninduced cell lysate, lane 4) soluble induced cell lysate. All lanes 
have the same amount of protein loaded. E. coli BL21-pET-28a(+)_ParB has more 
soluble protein present compared to E. coli LMG194-pBAD/HisB_ParB (lanes 4- red 
box) thus E. coli BL21-pET-28a(+) was used for the expression and purification of 
recombinant protein. The molecular weight of ParB without the His-Tag is 37.02 kDa. 
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Figure 6.3: Soluble fractions from different expression protocols  
SDS-PAGE showing: lane 1) protein molecular weight marker, lane 2) soluble fraction 
from E. coli LMG194-pBAD/HisB_ParA lysate after induction at 37°C, lane 3) soluble 
fraction from E. coli BL21-pET-28a(+)_ParA after induction at 37°C and lane 4) soluble 
fraction from E. coli BL21-pET-28a(+)_ParA in auto-induction media at 37°C. Lane 4 
contains half the amount of protein as in lanes 2 and 3. However, the amount of soluble 
ParA protein in lane 4 is still considerable higher compared to lanes 2 and 3 (red box).  
 
 
 
6.3.2  Protein purification 
 
Recombinant protein was purified as stated in section 2.10.2. All proteins purified 
for the biochemical assays were lysed via sonication as the Bug Buster
®
 Protein 
Extraction reagent promoted the formation of inclusion bodies that rendered most 
protein insoluble (data not shown). French pressing resulted in the loss of some 
lysate when transferring it into the chamber making sonication the optimal 
method for lysing the cells.  
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Figure 6.4: Purified protein 
SDS-PAGE showing: lane 1) protein molecular weight marker, lane 2) purified and 
desalted ParA protein and lane 3) purified and desalted ParB protein.  
 
 
6.3.3  Development of a ParA ATPase assay 
 
An initial biochemical assay was set-up to measure ATP hydrolysis with reagents 
as stated in section 2.11 except MgCl2 was used at a final concentration of 10 mM 
and the reaction contained 3 µg ParA protein, 3 µg ParB protein and 1 µg parS 
DNA (amplified from the M. tuberculosis genome). The reaction was started with 
the addition of ATP at saturating concentrations (1 mM) and incubated at 37°C 
for one hour. After 1 hour the amount of Pi released from the reactions was 
measured using the brilliant green assay (section 2.11.1) to determine if there was 
any ATP hydrolysed in the reactions. The results showed that there was ATP 
hydrolysis upon addition of ParA, no ATP hydrolysis upon addition of ParB and 
no further stimulation of ATPase activity upon the addition of ParB and parS to 
ParA compared to the activity exhibited by ParA alone (Figure 6.5). This assay 
showed that M. tuberculosis ParA possessed ATPase activity. It also demonstrated 
that the M. tuberculosis ParA ATPase did not require the presence of the ParB-
parS complex to catalyse and/or stimulate this reaction thus only ParA protein 
was used for the functional assay. 
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Figure 6.5: ParA ATPase activity 
This figure shows ATP hydrolysis in the presence of ParA and ParB protein. The first bar 
shows spontaneous ATP hydrolysis in the reaction buffer in the absence of any protein. 
The second bar demonstrates that there are no contaminating phosphates in the reaction 
reagents or protein preparations. The last three bars shows ATP hydrolysis in the presense 
of ParA, ParB and ParA:ParB:parS respectively. Results are representative of mean 
values of duplicates ± SE (n=2). * represent p values > 0.07 and ** represent p values < 
0.008.  
 
 
6.3.4  Optimization of the biochemical assay 
 
The influence of other parameters on the ATPase activity of ParA was 
investigated at saturating ATP concentration (1 mM) to find the ideal conditions 
for this enzyme. The reactions were set-up as indicated in Table 2.14 except for 
the variation of the parameter being tested. All assays contained 3 µg ParA protein 
and were incubated at 37°C for one hour unless otherwise stated. The ParA 
ATPase activity was tested at different temperatures (Figure 6.6A). This showed a 
reduced activity at lower temperature (25°C and 30°C) with optimal activity at 
higher temperatures (37°C and 42°C). Mg
2+
 was found to stimulate the ATPase 
  * 
  * 
  ** 
   ** 
Key: 
 
A – ParA 
B – ParB 
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activity of ParA the most compared to various other divalent cations (Figure 
6.6B). There was no ATPase activity in the absence of Mg
2+ 
with very little 
difference in the level of activity with Mg
2+
 concentration ranging from 0.25-50 
mM (Figure 6.6C).  
 
 
Figure 6.6: Effects of different parameters on ParA ATPase activity 
ATPase activity of ParA A) in different temperatures, B) with different divalent cations 
and C) with varying Mg
2+
 concentrations. All experiments were carried out in triplicate 
and the data is normalised against spontaneous ATP decay. Results are representative of 
mean values of triplicates ± SE. 
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6.3.5 Determination of the kinetic properties of the ParA ATPase 
 
Once the constituents and assay conditions of the functional assay were 
determined (Figure 6.5 and 6.6), the assay was optimized for hit validation to find 
the parameters required to give the maximum signal with the minimum amount of 
protein. A titration of protein from 0.25 µg to 3 µg was assayed to detect the 
lowest amount of protein required for detectable activity in one hour (Figure 
6.7A). From this assay it was established that 1 µg of ParA was required for 
detectable activity at 37°C in an hour. Approximately 1 µg of ParA was then 
assayed over different time points to find the time point that gave the maximum 
signal (Figure 6.7B). From these assays it was established that 1 µg of protein 
gave maximum signal after 4 hours at 37°C.  
 
 
 
 
Figure 6.7: Assay optimization for hit validation 
A) ATPase activity measured against varying concentrations of ParA at 37°C for 1 hour 
(n=3). This shows a linear correlation between the levels of activity to the concentration 
of protein from 0.5-3 µg. The minimum amount of protein required to exhibit activity 
after 1 hour at 37°C was 1 µg (grey bubble). B) ATPase activity with 1 µg of ParA at 
37°C measured at different time points showing a linear correlation between the levels of 
activity against time from 2-4 hours (n=2). Maximal signal was achieved at 4 hours (grey 
bubble). All experiments were carried out in duplicate and all data points are normalised 
against spontaneous ATP decay. Results are representative of mean values of duplicates ± 
SE. 
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The information from Figure 6.7 was used to set up assays to determine the 
kinetic parameters of ParA. The rate of the ATPase reaction was determined by 
measuring the amount of Pi released. The amount of Pi released in the reactions 
was calculated by constructing a standard curve with different concentrations of Pi 
against OD650. The standard curve was generated in the ATPase reaction buffer 
with different concentrations of pyrophosphate incubated with 3 U/mL inorganic 
pyrophosphatase at RT for 45 minutes (Invitrogen). After 45 minutes the 
concentration of Pi in the reaction was determined using the brilliant green assay 
(section 2.11.1) and the data was analysed with linear regression. 
 
The kinetic parameters of ParA were determined by incubating 1 µg of 
ParA with varying concentrations of substrate (ATP ranging from 0 - 1 mM) for 3 
hours at 37°C. Non-linear regression analysis of this data gave a Km of 0.2 ± 0.07 
mM and a Kcat of 22.57 ± 2.64/hr (means ± SE) (Figure 6.8). 
 
 
 
Figure 6.8: Kinetic parameters of M. tuberculosis ParA ATPase 
Saturation curve showing the relationship between the concentration of substrate (ATP) 
and the rate of reaction (n=10). The data have been fitted to the Michaelis-Menten 
equation. The insert graph shows the amount of Pi released versus OD650 (R
2
 = 0.998 and 
the line equation is y = 0.0263x. All experiments were carried out in duplicate. Results 
are representative of mean values of duplicates ± SE. 
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6.3.6 ATPase inhibitors 
 
The optimized ParA ATPase assay was used to test the specificity of the 
compounds identified as having an effect on the M. smegmatis-pMind_parA_GFP 
strain (chapter 5). All compounds tested in this study were made up in DMSO. 
Therefore the effect of DMSO in the biochemical assay was investigated. DMSO 
up to 20% had no significant effect on the ATPase activity (Figure 6.9). The effect 
of an ATPase inhibitor, sodium metavanadate (NaVO3- referred to as vanadate 
from this point forward) was also tested on the ParA ATPase activity. An assay 
with 1 µg ParA was set-up and incubated for 3 hours at 37°C with saturating ATP 
concentration (1 mM) and varying vanadate concentrations. This assay showed 
that vanadate inhibited the ATPase activity of ParA (Figure 6.9).  
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Figure 6.9: Effect of DMSO and vanadate on ATPase activity of ParA 
This graph (●) shows no significant inhibition of the ATPase activity with DMSO, p 
value > 0.7. The second graph (○) shows inhibition of ATPase activity upon the addition 
of 50 µM and 100 µM sodium metavanadate to ~ 70% and 40% respectively. All 
concentrations after 100 µM maintained ~ 40% activity (n=3). All data points are 
normalised against spontaneous ATP decay and all experiments were carried out in 
duplicate. Results are representative of mean values of duplicates ± SE. 
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6.3.7 Hit validation 
 
Initial hit validation assays were carried out with the compounds from the NIH 
Diversity Set as these were readily available in the laboratory. All 26 hits obtained 
from the cell-based assays in the three culture conditions (chapter 5- section 5.3.3) 
were tested at 100 µM to identify if these compounds specifically affected the 
ATPase activity of ParA (Figure 6.10). The assay was carried out with 1 µg ParA 
protein in the presence of 50 µM ATP and incubated at 37°C for 3 hours. ParA 
without any compound was used as a positive control (100% activity) and ParA 
with 100 µM sodium metavanadate was used as a negative control.  
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Figure 6.10: Effect of NIH hits on the ParA ATPase activity  
This graph exhibits the ATPase activity of ParA upon addition of 100 µM of the 26 
compounds obtained as hits from the NIH Diversity Set in the whole-cell assay. ‘+’ 
indicates positive control (uninhibited ParA) and ‘-' indicates negative control (ParA with 
100 µM NaVO3). Compound numbers 4 and 5 (indicated by red arrows) exhibited ~ 10% 
inhibition however; these were statistically not significant, p value > 0.1. All data is 
normalised against spontaneous ATP decay. Results are representative of mean values of 
duplicates ± SE. 
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Compound 4 in Figure 6.10 represent NSC57850, found to exhibit inhibition in 
the cell-based assay under nutrient rich conditions. It was also discussed as an 
optimal hit to pursue in section 5.4.3 after considering its biological roles and 
chemical structure. Compound 5 in Figure 6.10 represents NSC70817, also found 
to exhibit inhibition in the cell-based assay under nutrient rich conditions. This 
compound is cytotoxic as it targets human cytochrome P450 (PubChem).  
 
Even though the inhibition exhibited by these two compounds were 
insignificant, it was hypothesized that these drugs may show activity against ParA 
at higher concentrations as they showed some evidence of inhibition at 100 µM. 
Thus the assay was repeated with 500 µM of drugs. This illustrated that 
NSC57850 specifically inhibited the ATPase activity of ParA at 500 µM while 
NSC70817 had no effect (Figure 6.11). However, due to a limited supply of 
compound, NSC57850 could not be tested further in this work. 
 
Since NSC57850 could not be acquired, other hits that could be bought in 
were validated from the LOPAC and Spectrum Collection. However, these 
compounds had to be prioritized as they were not readily available in the 
laboratory. Two compounds, phenoxybenzamine hydrochloride 
(phenoxybenzamine) and fenoldopam bromide (fenoldopam), that were 
considered as good hits to pursue in chapter 5 (section 5.4.3) were procured to be 
tested in the biochemical assay. The results showed that increasing the 
concentration of phenoxybenzamine progressively inhibited the activity of the 
ParA ATPase (Figure 6.12A). Increasing concentrations of fenoldopam from 0 
µM to 100 µM inhibited the ATPase activity of ParA to ~ 60% but there was no 
further inhibition at 250 µM (Figure 6.12A). Greater than 250 µM of 
phenoxybenzamine and fenoldopam could not be tested as it precipitated in the 
reaction and interfered with the colour development of the brilliant green assay 
(data not shown).  
 
Another two compounds, methiothepin mesylate (methiothepin) and (±)-
octoclothepin maleate (octoclothepin), that had similar structures were also 
purchased to be tested. Addition of about 50 µM of methiothepin and 
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octoclothepin exhibited ~ 20% inhibition of the ParA ATPase activity but this did 
not show greater inhibition with increasing concentrations of drugs up to 250 µM 
and the activity was maintained at 80% (Figure 6.12B).  
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Figure 6.11: Effect on ATPase activity of ParA with varying concentrations 
NSC57850 and NSC70817 
This graph shows the effect of vanadate (■), NSC57850 ( ) and NSC70817 ( ) on the 
ATPase activity of ParA at 100 µM and 500 µM. Vanadate and NSC57850 showed that it 
inhibited the ParA activity at 500 µM. Due to a shortage in compounds, this experiment 
was carried out only with two different concentrations in duplicate. All data is normalised 
against spontaneous ATP decay. Results are representative of mean values of duplicates ± 
SE. * represent p values > 0.1 and ** represent p values < 0.03.  
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Figure 6.12: Effect on ATPase activity of ParA with phenoxybenzamine, 
fenoldopam, methiothepin and octoclothepin 
Effect on the ATPase activity of ParA with A) phenoxybenzamine (▼), fenoldopam (Δ), 
B) methiothepin (■) and octoclothepin (□). Both these graphs show that standard Tb 
drugs, ETH and streptomycin; have no significant effect on the ATPase activity of ParA. 
All data points are normalised against spontaneous ATP decay and all experiments were 
carried out in duplicate (n=2). Results are representative of mean values of duplicates ± 
SE.  
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6.3.8 Kinetic parameters of the inhibitors  
 
To determine the type of inhibition exerted by the inhibitors tested in Figure 6.12, 
the kinetic parameters of the ParA ATPase assay was investigated in the presence 
and absence of the inhibitors at various substrate concentrations. The assay was 
carried out with 1 µg ParA with ATP concentration ranging from 0.05 - 1 mM. 
These reactions were incubated for 3 hours at 37°C. Non-linear regression 
analysis of this data was used to determine the Michaelis constant (Km) and 
catalytic constant (Kcat) of the reactions in the presence of the inhibitors (Table 
6.1, means ± SE). These results showed that sodium metavandate, fenoldopam 
bromide, methiothepin mesylate and (±)-octoclothepin maleate exhibit 
competitive inhibition while phenoxybenzamine hydrochloride exhibit a mixed 
inhibition. 
 
 
Table 6.1: Kinetics parameters of ParA ATPase in the presence of inhibitors 
Compound Conc. (µM) Kcat /hr Km (mM) 
ParA (uninhibited) - 22.57 ± 2.64 0.2 ± 0.07 
Sodium metavanadate 500 29.76 ± 4.16 0.86 ± 0.21 
Phenoxybenzamine hydrochloride 250 6.38 ± 0.59 0.44 ± 0.09 
Fenoldopam bromide 250 29.19 ± 3.03 0.48 ± 0.1 
Methiothepin mesylate 250 25.25 ± 2.37 0.41 ± 0.09 
(±)-Octoclothepin maleate 250 21.01 ± 0.71 0.45 ± 0.02 
 
 
 
6.3.9 Anti-mycobacterial properties of ParA inhibitors 
 
Three of the compounds (phenoxybenzamine hydrochloride, fenoldopam bromide 
and (±)-octoclothepin maleate) were tested for their MIC values in M. smegmatis, 
M. bovis BCG and M. tuberculosis H37Ra to test their anti-mycobacterial activity.  
 
Dose-response assays (section 2.14) against M. smegmatis was conducted 
in three different culture conditions; nutrient rich (LBT), carbon starvation (C
-
) 
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and nitrogen starvation (N
-
). MIC values of these assays were determined on day 
4 for rich culture conditions and day 3 for nutrient starvation conditions (Table 
6.2). MIC values of M. bovis BCG and M. tuberculosis H37Ra were only 
determined in rich media on day 14.  
 
Of the three compounds tested, octoclothepin displayed the best MIC 
values in all three microbes with the lowest MIC in N
-
 conditions. 
Phenoxybenzamine displayed varying MIC values in M. smegmatis under 
different culture conditions with the highest MIC in rich culture conditions and 
lowest under N
-
 conditions. It also gave significantly high values in the slow 
growers. Fenoldopam had a high MIC under all culture conditions in M. 
smegmatis and in the slow-growers.  
 
These compounds were also tested for their stationary bactericidal activity 
(SBC- section 2.15) in M. smegmatis under nutrient rich, C
-
 and N
-
 conditions. 
Stationary bactericidal concentrations were determined after 4 days (Table 6.3). 
The SBC for fenoldopam could not be determined under any culture conditions as 
it was beyond the concentrations tested in these assays. Phenoxybenzamine 
exhibited a high but consistent SBC values under all culture conditions while 
octoclothepin displayed a lower SBC in nutrient rich compared to the nutrient 
starved conditions.  
 
Since fenoldopam bromide displayed very high MIC values in the slow-
growers and very high SBC values in M. smegmatis, it was excluded from further 
analysis in this study.  
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Table 6.2: MIC90 values of ParA inhibitors in mycobacterial cells  
 Fenoldopam 
(µM) 
Phenoxybenzamine 
(µM) 
Octoclothepin 
(µM) 
M. smegmatis: Rich media 
                        Carbon starvation 
                        Nitrogen starvation 
500 
≥ 1 000 
500 
≥ 1 000 
500.7 
132.2 
61.16 
78.92 
38.2 
M. bovis BCG: Rich media > 1 000 ≥ 1 000 37.88 
M. tuberculosis H37Ra: Rich media > 1 000 ≥ 1 000 56.88 
M. tuberculosis H37Rv: Rich media unknown > 1 000 34.7 
M. tuberculosis CDC1551: Rich media unknown > 1 000 17.4 
 
 
Table 6.3: SBC values in M. smegmatis under different culture conditions 
Condition Fenoldopam  
(µM) 
Phenoxybenzamine 
(µM) 
(±)-
Octoclothepin 
(µM) 
LBT  > 500 ≥ 500 
 
62.5 
C
-
 > 500 ≥ 500 
 
250 
N
-
 > 500 ≥ 500 
 
250 
 
 
6.3.10 Cytotoxicity of ParA inhibitors 
 
IC50 values of phenoxybenzamine and octoclothepin were also determined in HL-
60 cells (Table 6.4). These were compared to the 50% of the lethal dose (LD50) in 
mouse (published on ChemIDplus Advanced: 
http://chem.sis.nlm.nih.gov/chemidplus/chemidheavy.jsp).  
 
 
Table 6.4: Cytotoxicity in HL-60 cells and mouse 
 Streptomycin Phenoxybenzamine (±)-Octoclothepin  
HL-60 cells (IC50) > 250 µM 108.76 ± 3.88 µM 9.97 ± 7.72 µM 
 
Mouse (LD50- oral 
administration) 
 
500 mg/kg 
[319] 
 
1535 mg/kg 
[320] 
78 mg/kg 
[321] 
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6.3.11 In silico interaction between ParA and its inhibitors  
 
A homology model of M. tuberculosis ParA was generated based on the template 
structure of T. thermophilus SOJ [322]. This was used to dock in (R)- and (S)-
phenoxybenzamine, methiothepin and octoclothepin. Both isomers of 
phenoxybenzamine form a hydrogen bond between the oxygen atom and the OH 
of threonine 100 (Figure 6.13A). The benzylamine (C6H5CH2N-R2) binds to a 
relatively hydrophobic pocket lined by alanine130, proline308 and threonine99 
(data not shown). The remainder of the binding site is lined by threonine269, 
methionine270, isoleucine198, tyrosine327 and serine305. There is different 
conformation observed between crystal structures of SOJ with and without a 
ligand. The helix which includes threonine 100 is formed at an earlier position 
than the liganded form. This information tells that the phenoxybenzamine can fit 
into the ligand binding site of the models however; it does not provide any 
information its ability to inhibit this enzyme.  
 
Methiothepin and octoclothepin docked to the ligand binding site in an 
almost identical fashion with the chlorine and the methyl sulfane group binding to 
the hydrophobic pocket centred at alanine130 (Figure 6.13B). In all three 
molecules, an aromatic ring occupies a similar position to the adenine ring of 
ADP.  
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Figure 6.13: Molecular docking of ParA and its inhibitors  
A) Both (R) and (S) isomers of phenoxybenzamine docked into the binding site of the 
ParA homology model (colours: nitrogen - blue, oxygen – red, sulfur - green, chlorine - 
green, carbons - variable; ParA - Green ribbon, (R) and (S) isomers white and yellow 
carbons respectively). B) Methiothepin and octoclothepin (cyan and brown carbons 
respectively) docked into the ligand binding site. All figures were generated using Pymol.  
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6.4 Discussion 
 
The goal of this chapter was to validate the inhibitors identified in the cell-based 
assay (chapter 5) against ParA. This was achieved by designing a secondary 
functional assay for the ParA protein. The M. tuberculosis proteins were used for 
the development of the biochemical assay even though the initial cell-based 
assays were performed with M. smegmatis. M. smegmatis has been proven to be a 
suitable surrogate as a primary screen to shortlist compounds for testing against 
M. tuberculosis [33]. However, using M. tuberculosis proteins for the functional 
assay would not only validate the hits from the cell-based assay as being specific 
to the ParA protein, it would deem them relevant as potential leads for anti-
tubercular treatment as it is specifically against the protein of the disease causing 
microbe. 
 
The first obstacle in developing the functional assay was obtaining a 
moderate amount of soluble protein. Bacterial proteins are commonly over-
expressed in E. coli expression strains. Typically only 30–40% of M. tuberculosis 
proteins are obtained in soluble form when expressed in E. coli; that is after the 
exclusion of membrane proteins [323, 324]. E. coli LMG194 with pBAD/HisB 
vector and E. coli BL21 (DE3) with pET-28a(+) vector was used for the over-
expression of recombinant protein in various conditions as stated in section 
2.10.1. From these experiments it was concluded that the E. coli LMG194 strain 
with pBAD/HisB vector did not give high levels of recombinant M. tuberculosis 
Par proteins (0.05 mg/mL from a 500 mL culture) compared to the E. coli BL21 
strain with the pET-28a(+) vector (0.5 mg/mL from a 500 mL culture) (Figure 6.1 
and 6.2). The best condition to obtain the soluble fractions of the Par proteins was 
in the E. coli BL21 (DE3) strain in auto-induction media, ZYP-5052 (Appendix 
9.5.2) (Figure 6.3). Thus all proteins used for the biochemical assay in this work 
were expressed in E. coli BL21 with the pET-28a(+) vector in the ZYP-5052 
media.  
 
Once the optimal protocol was selected for the production of soluble 
recombinant protein, it was batch purified from 500 mL cultures. The ParB 
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protein was purified as stated in section section 2.10.2. The ParA protein 
immediately precipitated upon eluting it off the column when purified from the E. 
coli BL21 (DE3) strain. Some proteins are extremely sensitive to solution 
conditions and under non-optimal conditions, can alter their structure. Such a 
solution consists of molecules that are folded, misfolded or unfolded. In all 
instances, proteins can aggregate which is favored by crowding, for example, 
over-expression and this shows up as a precipitate. This was not seen when ParA 
was purified from the E. coli LMG194 strains as it had low concentrations of 
proteins. Some proteins are prone to aggregation at high concentrations [325]. The 
ParA plasmid partitioning protein has also been reported to be insoluble at high 
concentrations [247]. Approximately 10% glycerol was used as an osmolyte and 
was added to all buffers (from lysis buffer to elution buffer) in the purification of 
ParA which prevented its precipitation as glycerol has been shown to stabilize the 
native structure of proteins [326]. The desalted ParA protein was kept in 50% 
glycerol at -20° and used in the biochemical assay. The addition of glycerol did 
not affect the ATPase activity when added up to 15% (data not shown). 
 
 
6.4.1 ParA ATPase 
 
As discussed in section 4.4.1.3, the ParA plasmid partitioning protein possesses 
ATPase activity which is stimulated by the binding of the ParB-parS 
nucleoprotein complex [132, 239, 282]. In M. smegmatis, it has been shown that 
the ParB protein binds to oriC-proximal parS sequences and this is believed to be 
assisted by the ParA protein [165]. In this study, it was found that expressing the 
antisense RNA of parA and parB genes together could not be tolerated in M. 
smegmatis (section 4.3.2).  
 
Thus it was hypothesized that like the plasmid partitioning ParA, M. 
tuberculosis ParA may also possess ATPase activity. It was also hypothesized that 
this activity could potentially be stimulated with the ParB-parS nucleoprotein 
complex. To test these hypothesis, various concentrations of ParA and ParB 
protein with parS DNA was added to the in vitro ATPase assay (section 2.11) 
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similar to the work carried out by Jensen and Gerdes [132] and the activity was 
measured. Most enzyme reactions are measured by the formation of the product. 
As discussed in section 5.1.3, ATPases hydrolyse ATP to ADP and Pi. Thus the 
presence of ATPase activity in this work was determined by measuring the 
amount of Pi released using the brilliant green assay as stated in section 2.11.1.  
 
From this work, it was determined that the M. tuberculosis ParA protein 
possesses ATPase activity. It was also established that the M. tuberculosis ParA 
activity is not further activated either by the addition of the ParB protein or the 
parS DNA (Figure 6.5). This is similar to what was seen with the ParA ATPase 
activity in C. crescentus where the ATPase activity was not dependent on 
cooperative binding of ParB [243]. Thus for the functional assay, only the ParA 
protein was used. 
 
 The effects of some other factors on the ParA ATPase activity were also 
tested. The assay was incubated at varying temperatures (25°C-42°C). This 
demonstrated that lower temperatures did not give optimal activity. Not 
surprisingly, maximal activity was observed at 37°C and this level of activity was 
maintained up to 42°C (Figure 6.6A). The importance of several divalent cations 
was also tested on this assay. This revealed that Mg
2+
 was the best metal cofactor 
for ParA activity while Ca
2+
 and Mn
2+ 
stimulated the activity to a lower extent 
(Figure 6.6B). The optimal concentration of Mg
2+
 required for the assay was 
determined by measuring the ATPase activity in the presence of varying 
concentrations of MgCl2. In the absence of Mg
2+
, there was no ATPase activity 
with maximal activity at 1 mM. However, increasing the concentration of Mg
2+
 up 
to 50 mM did not significantly alter the level of ATPase activity.  
 
Once the biochemical assay for ParA was developed, it was optimised for 
inhibition assays, that is, optimal incubation times and enzyme concentrations 
within the linear range of the assay. This was established so a low concentration 
of potential inhibitor will be able to exert its effect as there will not be an 
abundance of protein in the assay. Assays were carried out with varying 
concentrations of protein and measurements at different time points were taken 
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(Figure 6.7). From these assays, it was determined that the optimal signal was 
achieved with 1 µg of ParA incubated at 37°C for 4 hours. It showed a linear 
increase in the ATPase activity with increasing enzyme concentration and time for 
at least 4 hours indicating that the enzyme was stable under these assay 
conditions. To determine the steady state conditions of this assay, the kinetic 
parameters of the enzyme were measured by incubating 1 µg of ParA protein for 3 
hours at 37°C with varying substrate concentrations. The graph of the rate of ATP 
hydrolysis against ATP concentration showed that M. tuberculosis ParA ATPase 
obeyed Michaelis-Menton kinetics (Figure 6.8). This showed that the reaction rate 
increased asymptotically as the substrate concentration increased. However, at 
high substrate concentration, the rate of the reaction was independent of the 
substrate concentration as all active sites became saturated and the reaction 
turnover rate became constant. Once the key kinetic parameters of the ParA 
ATPase were characterized, this assay was used to test for inhibitors against ParA. 
These inhibitors were compounds that were hits from the cell-based assays against 
the ParA antisense RNA expressing strain that were being validated for specificity 
and potency against ParA.  
 
 
6.4.2 Inhibition of the ParA ATPase activity 
 
Before the ParA functional assay was used for target validation, it was tested with 
a known ATPase inhibitor. There are no known inhibitors against ParA as it is a 
novel target however; sequence analysis shows that it possesses the conserved 
Walker A ATP binding domain (P-loop) with the signature GKT/S residues 
(Figure 6.1). This Walker motif possesses the critical phosphate-binding lysine 
(K) that binds to the β and γ phosphates of ATP [327]. Some such ATPases has 
been shown to be inhibited by vanadate [328, 329] where vanadate esters 
resemble the substrates and bind to the enzyme as substrate analogues [330]. This 
forms an enzyme-inhibitor (EI) complex and prevents substrate binding. This 
work tried to determine if the ParA ATPase activity was similarly affected by 
vanadate.  
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The ParA ATPase assayed with varying concentrations of sodium 
metavanadate exhibited a progressive inhibition of ATPase activity as the 
concentration of vanadate was increased (Figure 6.9). The maximum amount of 
inhibition achieved was 60%. This is similar to what has previously been seen 
with sodium orthovanadate with another ATPase, MutS, from P. aeruginosa 
[328]. MutS also contains the GKT/S signature region and exhibited a maximum 
of 60% inhibition.  
 
Since vanadate binds to the active site, its presence is likely to decrease the 
affinity of substrate binding which is typical of a competitive inhibitor. This 
would decrease the rate of the reaction thus increasing the Km. However, increase 
in substrate concentration in such a reaction would inevitably out-compete the 
inhibitor binding to the enzyme thus the kcat should remain unchanged. These 
kinetic parameters were investigated in the ParA ATPase assay with vanadate. 
Vanadate showed competitive inhibition with respect to ParA against ATP. There 
was an increase in Km of uninhibited ParA to ParA inhibited with 500 µM sodium 
metavanadate while the Kcat remained approximately the same.  
 
 
 
 
Figure 6.14: Walker A region of the ParA protein between different bacterial species 
Sequence alignment of the ATP binding motif of the Walker A region present in the ParA 
proteins between different bacterial species. Identical residues present in all sequences are 
marked with an asterisk (*) with universally conserved GKT/S signature region marked 
in the red rectangle. The GenBank accession numbers for the proteins analysed are: M. 
tuberculosis, CAA16230.2; M. bovis BCG, YP_980053.1; M. smegmatis, ABK74964.1; 
S. coelicolor, AAF16005.1; C. crescentus, AAB51267.1; P. aeruginosa, YP_794041 and 
P. putida, YP_534787.1.  
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6.4.3 Hit validation 
 
Given that a biochemical assay was successfully developed for the ParA protein 
and its activity effectively inhibited by a P-loop inhibitor, vanadate (Figure 6.9), 
the assay was subsequently used for the validation of the hits isolated from the 
cell-based assays. All hits from the NIH Diversity set were tested in the ATPase 
assay at 100 µM as all these compounds were readily available. Some of these 
have been disregarded as good compounds to pursue due to them being cytotoxic 
or not having ideal chemical structures for medicinal chemistry. However, these 
were still tested in order to discover if any of the chemical structures proved to be 
a potent inhibitor of the ParA protein as this is a novel target with no drugs known 
to specifically inhibit its activity. It was hypothesized that while these suboptimal 
drugs may not serve as effective therapeutics, they could potentially be used to 
identify the chemical structures that the ParA protein can bind to. These structures 
can than be used to build a model with data from high- to low-activity compound 
and be used to screen analogues in silico.  
 
Sodium vanadate was used as a positive control in the inhibition assays as 
it is a general Walker A ATPase inhibitor shown to exhibit activity against ParA 
(Figure 6.9). It was hypothesized that other compounds that may be weak 
inhibitors of ParA would not display as high an inhibition as vanadate. From the 
26 compounds tested, none of the compounds potently inhibited the ParA ATPase 
activity at 100 µM. However, two compounds (NSC57850 and NSC70817) 
showed approximately a 10% inhibition of the ParA ATPase activity at 100 µM 
(Figure 6.10). Both compounds were retested in the ATPase assay at 500 µM. It 
was hypothesized that if either of these compounds were inhibiting ParA, this 
would result in a further inhibition of the ATPase activity in a dose-dependent 
manner. This assay showed that 500 µM of NSC57850 decreased the ParA 
ATPase activity to approximately 70% while NSC70817 had no effect. 
NSC57850 is known to bind to nucleotide binding proteins and perturbs 
cholesterol metabolism, pathways involving ATPases and proteasome oxidative 
phosphorylation involving ATP synthase (BioInfoBank Institute). NSC57850 has 
a similar structure to the adenine moiety of ATP (Figure 6.15) thus it was 
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hypothesized that it may inhibit the ATPase activity of ParA by competing for the 
active site. However, due to a lack of this compound, this could not be tested. 
From these results, it can be concluded that except for NSC57850, the phenotypic 
changes observed from the rest of the 25 compounds from the NIH Diversity sets 
that were hits in the cell-based assay, that is, decreased in OD and/or elongated 
cell morphology under antisense inducing conditions, were due to another MOA.  
 
 
 
       
 
Figure 6.15: Structure of ATP and NSC57850  
A) Molecular structure of ATP, the substrate for ParA. The adenine base is shaded in 
grey. B) Molecular structure of the compound NSC57850. This compound has a similar 
structure to the adenine base of the ATP molecule (shaded in grey) and showed activity 
against ParA (Figure 6.11).  
 
 
The hits from the LOPAC and Spectrum Collection had to be prioritized and 
purchased as these compounds were not readily available in the laboratory. The 
hits that were discussed as being suboptimal in chapter 5 were excluded from 
further analysis. Four compounds were purchased from the LOPAC and Spectrum 
Collection: fenoldopam bromide, phenoxybenzamine hydrochloride, methiothepin 
mesylate and (±)-octoclothepin maleate. These compounds showed a decrease in 
OD and elongated cell morphology under nitrogen starvation conditions 
specifically in the ParA antisense RNA expressing strain. 
ATP NSC57850 
A B 
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All four compounds were tested at varying concentrations along with 50 
µM ATP and 1 µg of ParA. These assays were incubated at 37°C for 3 hours and 
the formation of Pi was measured to determine if there was any inhibition in the 
activity upon addition of the compounds. These assays were performed together 
with two standard Tb drugs, ethambutol and streptomycin, as controls (Figure 
6.12). The results showed that the ATPase activity of ParA was not affected by 
other drugs, that is, ETH and streptomycin.  
 
Fenoldopam bromide showed an initial decrease in the ParA ATPase 
activity to 70% at 50 µM and 60% at 100 µM. However, further increasing the 
fenoldopam bromide concentration did not increase this inhibition (Figure 6.12A). 
Fenoldopam is a selective dopamine D1 receptor agonist that is used as a 
vasodilator for treating emergency hypertension [331]. It has also been found to 
inhibit the B. subtilis Sfp phosphopantetheinyl transferase, the proliferation of 
several strains of Plasmodium falciparum and the HSP90 protein in humans 
(PubChem Bioassays). Inhibition of the HSP90 protein by fenoldopam is 
interesting as like ParA, the HSP90 protein also possesses a nucleotide binding 
pocket [332] and may act with a similar mechanism of action. However, the mode 
of HSP90 inhibition by fenoldopam has not yet been elucidated. It was 
hypothesized that if fenoldopam was binding to the active site, it would show a 
competitive type inhibition. Kinetic analysis with this compound showed a 
competitive mode of inhibition with respect to ParA (Table 6.1). It showed that 
the substrate binding affinity of ParA decreased in the presence of the drug 
(increase in Km) which was overcome by high concentrations of substrate (Kcat 
approximately the same). Thus the inhibitory effect of fenoldopam bromide was 
investigated on mycobacterial cells. This showed that fenoldopam bromide 
exhibited very high IC50 and MIC90 values in M. smegmatis, M.bovis BCG and M. 
tuberculosis H37Rva (Table 6.2). It also showed no stationary bactericidal activity 
thus it was disregarded as a good inhibitor to pursue and was not analysed any 
further. However, its structure can be used to find similar compounds that may 
inhibit ParA and have better anti-mycobacterial properties.  
 
Chapter Six: Hit Validation 
_______________________________________________________________ 
 
190 
Phenoxybenzamine hydrochloride was tested in a similar assay to 
fenoldopam. It inhibited the ATPase activity of ParA up to 50% at 250 µM in a 
dose-dependent manner (Figure 6.12A). Phenoxybenzamine (trade name 
diabenzyline) is an alpha adrenergic receptors antagonists [333] that is used as an 
anti-hypertensive. It is also used for the treatment of benign prostatic hyperplasia 
[334] and hypoplastic left heart syndrome [333]. From the molecular structure of 
phenoxybenzamine hydrochloride (Figure 6.16), it appears that it may not bind to 
ParA active site. This would classify phenoxybenzamine hydrochloride as a non-
competitive inhibitor. This is of significant interest as it presents a number of 
advantages over a competitive inhibitor that binds to the active site. Firstly, it will 
provide a novel MOA for drugs. Secondly, it will provide high selectivity as these 
drugs will not bind to the conserved region. Thirdly, a non-competitive inhibitor 
will not be affected by the concentration of substrate; that is, an increase in 
substrate concentration will not necessitate an increase in inhibitor concentration 
to have an effect [335]. Thus a low concentration of a potent inhibitor can still 
exhibit its effect at high substrate concentration. The type of inhibition mediated 
by phenoxybenzamine was elucidated using kinetics analysis which showed a 
mixed inhibition, that is decrease in the Km and Kcat (Table 6.1). This suggests that 
phenoxybenzamine binds to the enzyme and enzyme-substrate complex thus 
making it a non-competitive inhibitor. In silico docking of phenoxybenzamine 
hydrochloride with a ParA model supports this data showing that it can bind to the 
substrate binding pocket. This may affect substrate binding via steric hinderance. 
While phenoxybenzamine hydrochloride exhibited high IC50 and MIC90 values in 
the three mycobacterial species, it was not very cytotoxic in mammalian cells thus 
was considered a reasonable hit to pursue as further medicinal chemistry may led 
to a more potent analogue with a novel mode of inhibition of ParA. 
 
The last two compounds that were tested in this work were methiothepin 
mesylate and (±)-octoclothepin maleate. Both compounds had a very similar 
pattern of inhibition which was not very surprising as their molecular structures 
are very similar (Figure 6.16). Both compounds inhibited the ParA ATPase 
activity up to ~ 75-80% upon addition of 50 µM of drug but this inhibition was 
not increased upon increasing the concentration of the drugs (Figure 6.12B), 
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similar to the pattern of inhibition seen with vanadate (Figure 6.9), however, not 
as potent.  
 
 
 
Figure 6.16: Structure of compounds tested in the ParA ATPase assays 
A) Fenoldopam, a haloalkylamine, is a benzazepine derivative; B) phenoxybenzamine 
consists of two well spaced aromatic rings separated by a 3-carbon spacer; C) 
methiothepin and D) (±)-octoclothepin with very similar structures.  
 
 
Methiothepin is a non-selective 5-HT receptor antagonist [336, 337] that is used 
as an antipsychotic [338]. Other targets of methiothepin in humans include 
glucocerebrosidase, tumor protein p53, cytochrome P450 polypeptides, mitogen-
activated protein kinase and potassium channels. Methiothepin also inhibits 
proliferation of several strains P. falciparum and yeast (PubChem Bioassays). It 
has been found to be inhibitory against M. tuberculosis H37Rv in a high-
throughput screening by the Southern Research Institute however; its molecular 
target in M. tuberculosis is unknown (PubChem Bioassays). (±)-Octoclothepin is 
a neuroleptic, also used as an antipsychotic and has potent antidopaminergic and 
antiserotonin actions [339]. Similar to methiothepin, other targets of (±)-
octoclothepin in humans include tumor protein p53, cytochrome P450 
polypeptides and it also inhibits P. falciparum proliferation. Kinetics analysis of 
both these drugs showed a competitive mode of inhibition where the substrate 
binding affinity of ParA decreased in the presence of the drugs but this was 
overcome by high concentrations of substrate. This was confirmed with the in 
silico analysis where both methiothepin and octoclothepin docked to the ligand 
A B C D 
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binding site (Figure 6.13B). (±)-Octoclothepin maleate displayed the most potent 
anti-mycobacterial effects.  
 
 From these results phenoxybenzamine, methiothepin and octoclothepin 
may be good drugs to pursue where these compounds can be further modified to 
increase their potency against mycobacteria. The lowest MIC was exhibited by 
(±)-octoclothepin maleate in all mycobacterial species tested. Phenoxybenzamine 
only exhibited a low MIC under nutrient limited conditins in M. smegmatis. 
Nutrient limitation conditions could not be tested against the slow growers as the 
conditions are not yet optimized however, it is worth noting that all three species: 
M. smegmatis, M. bovis BCG and M. tuberculosis H37Ra, exhibited the same 
MIC under rich culture conditions (Table 6.2). Thus it is hypothesized that the 
slow-growers may show a similar MIC values under nutrient starvation 
conditions.  
 
 
6.5 Summary 
 
The work presented in this chapter demonstrates that M. tuberculosis ParA 
possesses ATPase activity. It also demonstrates that this activity is not stimulated 
by the ParB-parS nucleoprotein complex. The hydrolysis of ATP by ParA 
followed the Michaelis–Menten kinetics, yielding a Km and Kcat of 0.2 ± 0.07 mM 
and 22.57 ± 2.64/hr respectively. The recombinant enzyme also showed 
decreasing activity upon addition of a P-loop inhibitor, vanadate. To date there are 
no inhibitors of this enzyme described, creating the potential to exploit this as a 
novel anti-tubercular target to disrupt cell division.  
  
 The ATPase assays was used to verify inhibitors of ParA. Kinetics analysis 
shows that ParA has novel competitive (methiothepin and octoclothepin) and non-
competitive (phenoxybenzamine) inhibitors. This data is further supported by in 
silico analysis. These inhibitors represent a promising starting point for lead 
optimization. This study illustrates that the mycobacterial ParA warrant further 
drug discovery efforts.  
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7.1 General Discussion  
 
The emergence of drug resistance in disease causing pathogens has led to a search 
for novel drug targets and their cognate inhibitors to identify structurally diverse 
antibiotics to combat disease. To overcome resistance, existing antibiotics have 
been extensively modified; however, efficacious modifications are reaching their 
limit thus steadily escalating the need for new classes of antibiotics [114].  
 
Most drugs in current clinical use have been designed without the 
knowledge of their targets due to a lack of high-throughput technologies for target 
identification [140]. Nowadays, with the availability of whole genome sequences 
and high-throughput screening technologies, novel targets and their inhibitors can 
be more easily identified. The discovery of novel therapeutics requires the 
integration of various tools, information and approaches making it a resource-
intensive process [340]. This calls for a multidisciplinary approach requiring 
biological, chemical and technological interventions that is organised in numerous 
phases; from the proposal of a target to the launch of the treatment [295].  
 
This dissertation took a comprehensive approach towards mycobacterial 
drug discovery. It went from identifying potential drug targets, validating them as 
being required for growth under various culture conditions and identifying 
potential lead chemical structures against one of the validated targets.  
 
7.1.1 Summary of experiments and their findings 
 
The primary step in this research project was to find an ideal drug target in M. 
tuberculosis (section 3.1.1). To fulfil the criteria of such a target, the first thing 
that was considered was gene essentiality, a crucial factor in any drug discovery 
program [67, 137, 189, 341]. A study by Sassetti et. al. identified 614 genes in M. 
tuberculosis H37Rv that were unable to be recovered with transposon knockouts 
(Appendix 9.2.1) [126]. This served as a hypothesis that these genes may be 
essential, however, reputable proof of essentiality is only demonstrated by genetic 
manipulation of individual genes as whole genome analysis may have other 
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factors mitigating the failure to recover a mutant (section 4.1.1) [342]. Another 
factor that was considered in this study was gene conservation. There were two 
reasons for looking at gene conservation. Firstly, genes conserved across several 
bacterial species may indicate that they are essential for their viability and 
secondly highly conserved genes resist mutations thus targeting such genes may 
prevent the rise of resistance (section 1.7.2). Thus, with these two factors in mind, 
this study identified a total of 261 potential broad-spectrum targets in M. 
tuberculosis (Table 3.2). These targets belonged to various functional groups. The 
functional group that was undertaken for further analysis in this study was cell 
division. Cell division is an underexploited essential cellular process. It is an 
attractive pathway for drug targeting as it is required for the multiplication and 
viability of the organism and thus, is vital for infection [343]. Most bacterial cell 
division proteins do not have their catalytic activity determined [343]. There were 
nine putative essential cell division genes identified in this thesis. Three of these 
genes, Rv2440c (obg), Rv3917c (parB) and Rv3918c (parA), were chosen to be 
validated for their essentiality and potential as drug targets in the surrogate M. 
smegmatis (section 1.3.1).  
 
Essentiality testing in this study was conducted using the expression of 
antisense RNA in an inducible system. This system determines gene essentiality 
via the potential decrease in target protein concentration due to the expression of 
antisense RNA of the gene encoding the protein (section 4.1.1.1). There are 
several reasons for using this method. Apart from providing a means to judge 
gene essentiality, it also provided a cost-effective assay for HTS and it can be 
easily transferred into an in vivo study. Homologues of the three M. tuberculosis 
genes: obg, parA and parB respectively, were expressed in M. smegmatis in the 
antisense orientation under different culture conditions (section 4.3.5). Testing the 
viability of the cells under various culture conditions was used to discriminate 
between essential and conditionally essential genes (section 1.7.2). This was to 
reveal an ideal target that was required under all conditions.  
 
These experiments demonstrated that obg may be a conditionally essential 
gene as it only exhibited a low number of viable cells under rich culture 
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conditions upon antisense induction (Figure 4.10). All other culture conditions 
had the same number of viable cells as the control strain (Figure 4.12 and 4.14). 
parB has previously been demonstrated to be a non-essential gene in M. 
smegmatis [165]. This study supported the data showing no difference in the 
number of viable cells upon antisense expression of parB compared to the control 
strain under all culture conditions tested (Figure 4.10, 4.12 and 4.14). parA 
demonstrated that it may be required for cell viability under nutrient rich, carbon 
limitation and nitrogen limitation conditions. Antisense expression of parA 
exhibited a lower number of viable cells at late exponential phase in all three 
media compared to the control strain (Figure 4.10, 4.12 and 4.14 respectively).  
 
Apart from being required for cell viability under different cultures 
conditions, the results from these experiments indicated that ParA was not as 
highly required under nutrient starvation conditions as under rich culture 
conditions. This is not surprising as ParA is a cell division protein and therefore is 
likely to be required under optimal respiration conditions. Nutrient limitation 
leads to a global shift in gene expression and a gradual shutdown of respiration to 
a basal level [249]. This was demonstrated in another study by Betts et. al. in M. 
tuberculosis where Rv3918c expression was down-regulated upon nutrient 
starvation. From these data, it was theorized that ParA may be required for 
exponential growth in mycobacteria. This theory is supported in a study by Casart 
et. al. [234]. Their study demonstrated that the levels of parA mRNA decreased 
between the exponential phase to stationary phase in M. smegmatis and M. bovis 
BCG. 
 
Despite the transcriptional down-regulation of parA under nutrient 
starvation conditions, it was still required for the viability of the cells. Thus, ParA 
was chosen as a possible candidate for targeted drug screening. Nutrient limitation 
conditions are reflective of the environment in granulomas [344] thus inhibitory 
molecules against such a target would also be of significance for treating Tb 
bacilli under nutrient limitation conditions.  
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 Target-driven approaches are directed at an individual gene/protein; 
however, the ultimate target is the whole organism. Thus targeted drug screening 
in this study was performed using a differential susceptibility assay (section 5.1.2) 
employing antisense RNA expression. This assay captured the target in a broader 
biological context. This screen also evaluated the druggability of the target in the 
whole cell, that is, the ability of the target to be modulated with small molecules 
[345]. A total of 5680 compounds were screened in three different culture 
conditions (section 5.3) as culture conditions affect the activity profile of 
compounds [124]. From the HTS, a total of 69 hits were identified; however, only 
approximately 0.35% of these were deemed as suitable hits to pursue. The 
purpose of this primary screening was to identify a number of hit compounds to 
be tested in a secondary assay to determine whether any lead compounds could be 
identified. 
 
A secondary biochemical assay was developed to demonstrate the 
specificity of the identified bioactives. This functional assay was developed using 
the M. tuberculosis ParA protein encoded by Rv3918c. This assay was developed 
with the hypothesis that ParA may possess ATPase activity due to the conserved 
Walker A motif (Figure 6.14). It was also hypothesized that ParA may require 
another protein, ParB (encoded by Rv3917c), for its activity as in the plasmid 
partitioning system (section 4.4.1.3). The results from this study illustrated that 
the M. tuberculosis ParA possesses ATPase activity. It also demonstrated that 
ParA did not require other factors to stimulate its activity. Kinetic analysis of the 
enzyme established that the ATPase activity of ParA follows Michaelis-Menten 
kinetics. 
 
This biochemical assay was tested against a known ATPase inhibitor, 
sodium metavanadate. This revealed that the M. tuberculosis ParA ATPase 
activity was capable of being inhibited by vanadate in a competitive manner. The 
assay was consequently used to screen the hits obtained in the cell-based assays. 
This revealed five potential inhibitors of ParA: NSC57850, fenoldopam, 
phenoxybenzamine, methiothepin and octoclothepin. From the chemical structure 
of NSC57850 (Figure 6.15B), it appeared that it might be a competitive inhibitor 
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of ParA; however, due to limited supply of this compound it could not be tested 
with further experimentation. The modes of inhibition of the other compounds 
were determined by kinetic analyses. The results indicate that fenoldopam, 
methiothepin and octoclothepin exhibit competitive inhibition while 
phenoxybenzamine exhibit a mixed inhibition of the ParA ATPase. These results 
were supported with in silico docking with a ParA model. Thus this study 
identified various compounds that affected the ATP binding ability of ParA while 
phenoxybenzamine was the only compound that was identified as affecting the 
ATPase activity per se.  
 
Phenoxybenzamine, fenoldopam, and octoclothepin were further evaluated 
for their MIC values in growth assays with M. smegmatis, M. bovis BCG and 
various strains of M. tuberculosis (Table 6.2) and SBC values in M. smegmatis 
(Table 6.3). From these experiments, it was deduced that phenoxybenzamine and 
octoclothepin may be useful compounds to pursue.  
 
Phenoxybenzamine had the highest inhibition in the in vitro ATPase assay 
(Figure 6.12A) and was found to be active under nitrogen starvation conditions in 
the HTS. This was reflected in the cell-based assays with M. smegmatis where the 
MIC value was high in nutrient rich media and low in nutrient starvation medias 
(C
-
 and N
-
) with the lowest MIC value under N
-
 conditions. However, 
phenoxybenzamine displayed high SBC values in all culture conditions. 
Octoclothepin displayed a significantly lower MIC than all other compounds 
tested. Similar to phenoxybenzamine, it was picked up as a hit under N
-
 
conditions which was again reproduced in growth assay with M. smegmatis, 
giving a high MIC value with nutrient rich and C
-
 media but a low MIC value in 
N
-
 media. Interestingly, octoclothepin gave the lowest SBC in rich media. These 
results indicate that M. smegmatis is more resistant to octoclothepin in starvation 
conditions at stationary phase but susceptible in starvation conditions in the 
exponential phase. Such a compound may not be capable of treating persistent 
bacilli as it is believed that nutrient starvation is reflective in the persistent state of 
M. tuberculosis [249]. However, the MIC and SBC values for octoclothepin in the 
starvation conditions were still lower than that of phenoxybenzamine.  
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Apart from having good anti-mycobacterial activity, it is critical to 
demonstrate that these leads have no overt toxicity associated with them. Thus 
phenoxybenzamine and octoclothepin were tested for the cytotoxicity in HL-60 
cells and compared against already published mouse LD50 values (Table 6.4). This 
demonstrated that while octoclothepin was potent against mycobacteria, it was 
also very toxic against the mammalian cells. However, it is important to note that 
despite its toxicity, octoclothepin is already in clinical use for other purposes so it 
can still be tolerated in humans, making it a tractable lead compound. On the other 
hand, while phenoxybenzamine had a high MIC and SBC, it also has a relatively 
high mouse LD50 value, especially when compared to streptomycin, a current anti-
tubercular drug used for therapy, making it a good lead. These leads can now be 
used in another round of screening of related structures and SAR studies to 
develop new anti-tubercular drugs to target cell division.  
 
 
7.1.2  Other findings  
 
One subject that has so far not been discussed in this thesis is the phenotype seen 
with the M. smegmatis-pMind_parA+parB_GFP strain (Figure 4.6). Upon 
creation of this strain, it was found that the basal level of antisense expression of 
parA and parB simultaneously (from incomplete repression of the promoter) had a 
severe effect on the growth of the cells. It was hypothesized that ParB maybe 
required for ParA ATPase activity. Since ParA was found to be essential, it was 
deduced that down-regulating a protein that may be required for its activity, as 
well as the ParA protein, could not be tolerated by the cells. However, subsequent 
experiments demonstrated that ParB was not required for ParA ATPase activity.  
 
Another possible explanation for the requirement of ParA and ParB 
together is that they may represent a regulatory pair in vivo. The ADP bound ParA 
has been discussed as a repressor for the parAB operon in other systems [244, 
247]. In the P1 plasmid, the ParA repressor activity is stimulated by ParB; 
however, ParB has no effect on par gene expression on its own [247]. In C. 
crescentus, ParB regulates the activity of ParA by modulating its nucleotide-
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bound state and acts as a nucleotide exchange factor [243]. This study illustrated 
that the ParAB proteins in M. smegmatis are required together. I hypothesize that 
the ParB protein may have a similar role as discussed above in regulating the 
repressor effect of ParA. A careful analysis of ParA-ParB interactions has to be 
executed to determine the exact role of these proteins in mycobacteria.  
 
 
7.2 Critical Evaluation  
 
7.2.1 Target validation technique 
 
The target validation experiments in this study were carried out using an inducible 
antisense RNA expression system. Sophisticated as it is to use a regulatable 
system for gene expression, such a system never leads to zero gene product [286]. 
Of the three genes tested in this study, only antisense expression of parA showed 
a significant effect in all culture conditions tested thus was regarded as being 
essential for growth under these conditions. parB has previously been 
demonstrated to be non-essential which was validated in this study, however, obg 
could be an essential gene but the methods used in this study may have been 
inadequate to distinguish this. For example, if this protein is not required at very 
high concentrations in the cell, decreasing the amount of protein by antisense 
expression may not have reduced the amount of protein to a level that was 
sufficiently low to exhibit significant differences in cell viability. This is of 
significance in the persistent state, where metabolites are required at a much lower 
concentrations as a result of slow growth [115]. Therefore, before a gene is 
regarded as non-essential, it is imperative that a knock-out mutant is created and 
failure to grow the mutant in the absence of the gene be used as an absolute 
measure of its essentiality; something that was not performed in this study.  
 
 Another limitation to using genetics to validate drug targets is gene 
redundancy. In such situations, multiple genes may be individually dispensed 
although they can be inhibited by the same drug. An example of this are the 
rRNAs which are encoded by multiple genes that can be individually inactivated 
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without a substantial effect on cell growth [346]. However, aminoglycosides 
demonstrate that rRNA are valid targets [347].  
 
 
7.2.2  High-throughput assays 
 
The assay used for targeted HTS in this thesis while theoretically sound, in 
retrospect, may not have been optimal. This was deduced from the functional 
assay with the isolated protein. This in vitro assay demonstrated that vanadate, an 
ATPase inhibitor, only exhibited a 30% inhibition of the ParA ATPase activity at 
50 µM (Figure 6.9). The concentration of compounds used for screening in the 
HTS with the cell-based assay was 20 µM and the inhibition cut-off used to 
discern hits was 40%. While this method lead to identification of some inhibitors 
of ParA, weak inhibitors of ParA would not have been picked out in these screens.  
 
 
7.2.3  In vitro assay 
 
The HTS in this thesis was carried out using M. smegmatis but the validation 
assay was performed with the M. tuberculosis protein. This is a logical 
progression as M. tuberculosis is eventually the target organism; however, this 
study did not investigate if the ParA of M. smegmatis and M. tuberculosis were 
functionally equivalent. If they are not a 100% equivalent, some of the hits from 
the HTS would be specific to M. smegmatis and would have no effect on the M. 
tuberculosis protein which may be one of the reasons why there were a high 
number of false positives (Figure 6.10).  
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7.3 Future Research Directions 
 
As with any short-term research project, this work has generated a number of 
future goals and improvements that can be implemented in the search for ParA 
inhibitors. 
 
7.3.1 Future goals 
 
The compounds isolated from this study have to undergo further development in 
order to be regarded as viable anti-tubercular drugs. Some of the aims required to 
achieve this include:  
 
 Firstly, the crystallization of the ParA protein as it is the shape of a target that 
determines the activity of a compound with respect to the molecular 
interaction between the target and the inhibitor. The 3-dimensional structure 
of the protein can be conclusively used to confirm the inhibitors identified in 
this study [348] and their mode of inhibition.  
 
 Secondly, using the crystal structure of the enzyme-inhibitor complexes to 
understand the forces required for its formation [349]. This information can in 
turn be used for SAR [350] where the structure of the target and the bound 
ligands can be used to design analogues compounds [157]. This can allow 
rapid design of molecules with increased activity [105, 157] as the inhibitors 
identified in this study are required at very high concentrations and does not 
lead to 100% inhibition of ParA. Creation and screening an analog library can 
be quickly analysed using various computational methods which will greatly 
reduce the cost associated with drug development [351].  
 
 Thirdly, testing all potent analogues in an in vivo system to determine their 
toxicity and efficacy to predict if these compounds have any clinical 
applications.  
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7.3.2 Improvements  
 
There are also some improvements that can be applied to the HTS of ParA 
inhibitors.  
 
 In order to minimize the number of false positives isolated against ParA from 
the cell-based assays, a secondary screen should be developed in a 1536 well 
plate format with the in vitro assay. Such an assay would decrease the 
reaction volume thereby increasing the drug concentration per reaction. This 
will either confirm the hits from the cell-based assays as potent inhibitors of 
ParA or as non-specific hits before further work is invested in the hits isolated 
from the primary screen.  
 
 The use of the 3-D structure of the protein for high-throughput docking or in 
silico screens using different global optimization algorithms that can 
minimize the ligand–protein intermolecular and ligand intramolecular 
interaction energies to prioritize compounds to be tested in vitro [352]. This 
can allow a large number of drugs to be screened without huge costs 
associated with it.  
 
 Finally, the results from all the screens can be used to create a hypothesis as 
to the chemotypes ParA binds to. This information can be used to screen the 
natural extract libraries to identify novel classes of compounds that inhibit 
ParA.  
 
 
 
 
 
 
 
 
Chapter Seven: General Discussion 
_______________________________________________________________ 
 
204 
7.4 Concluding Remarks 
 
The use of genomic data, molecular techniques and high-throughput screening, as 
discussed throughout this thesis, has presented a number of conclusions regarding 
the mycobacterial chromosome partitioning protein ParA.   
 
A. The ParA protein is essential for cell viability in M. smegmatis under 
nutrient rich, carbon starvation and nitrogen starvation conditions (chapter 
4). It is inferred that ParA may also be essential for viability in M. 
tuberculosis as this protein is highly conserved, arranged in a similar 
operon in both species and is unable to sustain transposon insertions.  
B. The M. tuberculosis ParA protein possesses ATPase activity. This activity 
is not enhanced by the addition of other factors (ParB protein and parS 
DNA- chapter 6). 
C. M. tuberculosis ParA ATPase activity can be inhibited by a P-loop 
inhibitor, sodium metavanadate.  
D. Kinetic studies indicate that the M. tuberculosis ParA ATPase activity is 
capable of being inhibited by competitive and non-competitive inhibitor 
binding in vitro (chapter 6).  
E. Preliminary results indicate that M. smegmatis can be used as a model to 
identify specific inhibitors of the M. tuberculosis ParA protein (chapter 5 
and 6).  
 
In summary, this thesis demonstrates that ParA can be used as an effective target 
to find therapeutics to contribute towards an active and robust pipeline of anti-
tubercular drugs. The compounds identified in this study now require considerable 
effort to be expended in detailed quantitative structure-activity relationships to 
define the minimal structures required for their activity. Ultimately, a combination 
of functional, structural and biophysical analyses will allows us to achieve this. 
This may lead to the development of novel ParA inhibitors.  
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9.1 Maps of plasmids used in this study 
 
 
                                       
 
 
 
         
                           
   
 
 
Figure 9.1: Vectors used in this study 
 A) pCR
®
2.1 TA cloning vector used for direct ligation of PCR fragments, B) 
pBAD/HisB expression vector used for over-expressing proteins in E. coli LMG194, C) 
pET28a(+) expression vector used for over-expressing proteins in E. coli BL21 (DE3) 
and D) tetracycline inducible vector used for conditional gene expression in M. 
smegmatis. 
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9.2  Essential Genes 
 
9.2.1 List of Essential Genes published by Sassetti et. al.  
 
Table 9.1: List of Essential Genes published by Sassetti et. al.  
List of 614 genes identified as essential for the growth and viability of M. tuberculosis 
H37Rv via high density transposon mutagenesis under optimal conditions by Sassetti et 
al., 2003 [126].  
Rv 
designation 
Rv 
designation 
Rv 
designation 
Rv 
designation 
Rv 
designation 
Rv 
designation 
Rv 
designation 
Rv 
designation 
Rv 
designation 
Rv0001 Rv0527 Rv0900 Rv1310 Rv1630 Rv2196 Rv2539c Rv2992c Rv3458c 
Rv0005 Rv0528 Rv0946c Rv1311 Rv1631 Rv2200c Rv2540c Rv2995c Rv3459c 
Rv0014c Rv0529 Rv0949 Rv1315 Rv1641 Rv2201 Rv2552c Rv2996c Rv3462c 
Rv0015c Rv0540 Rv0951 Rv1326c Rv1649 Rv2210c Rv2554c Rv2999 Rv3464 
Rv0041 Rv0541c Rv0952 Rv1327c Rv1650 Rv2211c Rv2555c Rv3001c Rv3465 
Rv0058 Rv0542c Rv0955 Rv1339 Rv1652 Rv2215 Rv2580c Rv3002c Rv3490 
Rv0060 Rv0553 Rv0957 Rv1342c Rv1653 Rv2217 Rv2582 Rv3003c Rv3538 
Rv0085 Rv0555 Rv0973c Rv1347c Rv1654 Rv2218 Rv2611c Rv3009c Rv3559c 
Rv0086 Rv0556 Rv0982 Rv1348 Rv1655 Rv2219 Rv2612c Rv3011c Rv3564 
Rv0102 Rv0557 Rv0993 Rv1349 Rv1656 Rv2220 Rv2613c Rv3014c Rv3579c 
Rv0112 Rv0558 Rv1002c Rv1350 Rv1658 Rv2221c Rv2614c Rv3018c Rv3580c 
Rv0118c Rv0562 Rv1005c Rv1380 Rv1659 Rv2225 Rv2623 Rv3025c Rv3581c 
Rv0127 Rv0588 Rv1007c Rv1381 Rv1661 Rv2229c Rv2673 Rv3029c Rv3582c 
Rv0189c Rv0607 Rv1011 Rv1382 Rv1662 Rv2231c Rv2682c Rv3030 Rv3593 
Rv0205 Rv0627 Rv1014c Rv1383 Rv1663 Rv2235 Rv2697c Rv3031 Rv3596c 
Rv0208c Rv0628c Rv1017c Rv1388 Rv1683 Rv2242 Rv2698 Rv3032 Rv3597c 
Rv0224c Rv0635 Rv1018c Rv1389 Rv1689 Rv2244 Rv2700 Rv3042c Rv3598c 
Rv0226c Rv0636 Rv1023 Rv1390 Rv1695 Rv2245 Rv2702 Rv3043c Rv3602c 
Rv0227c Rv0638 Rv1024 Rv1391 Rv1697 Rv2246 Rv2703 Rv3048c Rv3604c 
Rv0228 Rv0640 Rv1025 Rv1392 Rv1699 Rv2247 Rv2710 Rv3051c Rv3607c 
Rv0236c Rv0651 Rv1026 Rv1406 Rv1701 Rv2251 Rv2726c Rv3101c Rv3608c 
Rv0282 Rv0652 Rv1027c Rv1409 Rv1708 Rv2260 Rv2727c Rv3105c Rv3609c 
Rv0283 Rv0666 Rv1092c Rv1415 Rv1711 Rv2268c Rv2739c Rv3109 Rv3610c 
Rv0284 Rv0667 Rv1094 Rv1416 Rv1712 Rv2283 Rv2746c Rv3111 Rv3611 
Rv0285 Rv0668 Rv1098c Rv1420 Rv1713 Rv2319c Rv2747 Rv3112 Rv3625c 
Rv0286 Rv0674 Rv1122 Rv1436 Rv1714 Rv2325c Rv2748c Rv3113 Rv3627c 
Rv0289 Rv0675 Rv1126c Rv1437 Rv1715 Rv2338c Rv2753c Rv3131 Rv3634c 
Rv0290 Rv0682 Rv1128c Rv1438 Rv1730c Rv2343c Rv2754c Rv3132c Rv3635 
Rv0291 Rv0683 Rv1133c Rv1446c Rv1738 Rv2357c Rv2786c Rv3135 Rv3646c 
Rv0292 Rv0684 Rv1166 Rv1448c Rv1753c Rv2361c Rv2812 Rv3137 Rv3648c 
Rv0311 Rv0685 Rv1169c Rv1449c Rv1828 Rv2364c Rv2813 Rv3139 Rv3658c 
Rv0312 Rv0697 Rv1177 Rv1456c Rv1832 Rv2365c Rv2817c Rv3140 Rv3660c 
Rv0334 Rv0700 Rv1182 Rv1457c Rv1850 Rv2373c Rv2827c Rv3177 Rv3666c 
Rv0335c Rv0701 Rv1186c Rv1459c Rv1963c Rv2378c Rv2828c Rv3198c Rv3669 
Rv0337c Rv0702 Rv1187 Rv1461 Rv2013 Rv2382c Rv2830c Rv3201c Rv3679 
Rv0338c Rv0703 Rv1188 Rv1462 Rv2026c Rv2386c Rv2832c Rv3240c Rv3708c 
Rv0347 Rv0704 Rv1193 Rv1463 Rv2041c Rv2391 Rv2833c Rv3243c Rv3709c 
Rv0350 Rv0705 Rv1194c Rv1464 Rv2050 Rv2392 Rv2837c Rv3244c Rv3710 
Rv0351 Rv0706 Rv1201c Rv1465 Rv2093c Rv2397c Rv2839c Rv3245c Rv3712 
Rv0352 Rv0707 Rv1202 Rv1466 Rv2109c Rv2398c Rv2841c Rv3248c Rv3713 
Rv0357c Rv0708 Rv1208 Rv1475c Rv2110c Rv2399c Rv2845c Rv3255c Rv3721c 
Rv0372c Rv0709 Rv1215c Rv1476 Rv2111c Rv2400c Rv2846c Rv3257c Rv3722c 
Rv0383c Rv0710 Rv1223 Rv1477 Rv2121c Rv2412 Rv2855 Rv3264c Rv3752c 
Rv0384c Rv0714 Rv1229c Rv1479 Rv2122c Rv2418c Rv2856 Rv3265c Rv3778c 
Rv0399c Rv0715 Rv1232c Rv1480 Rv2130c Rv2421c Rv2869c Rv3267 Rv3781 
Rv0400c Rv0716 Rv1248c Rv1485 Rv2138 Rv2437 Rv2881c Rv3271c Rv3782 
Rv0404 Rv0718 Rv1254 Rv1490 Rv2145c Rv2438c Rv2882c Rv3275c Rv3790 
Rv0410c Rv0719 Rv1274 Rv1539 Rv2150c Rv2439c Rv2883c Rv3281 Rv3791 
Rv0411c Rv0720 Rv1278 Rv1547 Rv2151c Rv2440c Rv2889c Rv3285 Rv3792 
Rv0412c Rv0721 Rv1284 Rv1594 Rv2152c Rv2441c Rv2890c Rv3332 Rv3793 
Rv0415 Rv0722 Rv1285 Rv1595 Rv2153c Rv2442c Rv2897c Rv3336c Rv3795 
Rv0416 Rv0732 Rv1286 Rv1599 Rv2154c Rv2444c Rv2903c Rv3341 Rv3799c 
Rv0417 Rv0736 Rv1292 Rv1600 Rv2155c Rv2447c Rv2904c Rv3343c Rv3800c 
Rv0422c Rv0744c Rv1293 Rv1601 Rv2156c Rv2448c Rv2906c Rv3356c Rv3801c 
Rv0423c Rv0755c Rv1294 Rv1602 Rv2157c Rv2457c Rv2907c Rv3372 Rv3802c 
Rv0425c Rv0772 Rv1295 Rv1603 Rv2163c Rv2460c Rv2908c Rv3396c Rv3805c 
Rv0429c Rv0780 Rv1296 Rv1605 Rv2164c Rv2477c Rv2916c Rv3398c Rv3806c 
Rv0430 Rv0781 Rv1297 Rv1606 Rv2165c Rv2500c Rv2925c Rv3411c   Rv3808c 
Rv0440 Rv0788 Rv1298    Rv1609 Rv2166c Rv2507 Rv2926c Rv3417c   Rv3834c 
Rv0450c Rv0798c Rv1299 Rv1610 Rv2174 Rv2510c Rv2927c Rv3418c Rv3858c 
Rv0462 Rv0803 Rv1300 Rv1611 Rv2178c Rv2511 Rv2967c Rv3422c    Rv3859c 
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Rv0479c Rv0808 Rv1301 Rv1612 Rv2179c Rv2515c Rv2968c Rv3423c Rv3907c 
Rv0500 Rv0811c Rv1303 Rv1613 Rv2182c Rv2516c Rv2969c Rv3427c Rv3913 
Rv0509 Rv0817c Rv1305 Rv1614 Rv2188c Rv2524c Rv2971 Rv3436c Rv3915 
Rv0510 Rv0824c Rv1306 Rv1617 Rv2192c Rv2533c Rv2977c Rv3441c Rv3917c 
Rv0511 Rv0875c Rv1307 Rv1622c Rv2193 Rv2534c Rv2981c Rv3443c Rv3918c 
   Rv0524 Rv0883c Rv1308 Rv1626 Rv2194 Rv2537c Rv2986c Rv3455c Rv3921c 
Rv0525 Rv0884c Rv1309 Rv1629 Rv2195 Rv2538c Rv2987c Rv3457c Rv3923c 
Rv0526 Rv0894        
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9.2.2 Conserved Essential Genes 
Supplementary Table S1 
 
Rv 
annotation 
MSMEG 
annotation Species conserved in 
%ID; MTB vs 
MSMEG Mycobacterium tuberculosis functional annotation 
Rv0001 MSMEG_6947 Bacillus subtilis 77 chromosomal replication initiation protein (dnaA) 
Rv0005 MSMEG_0005  Bacillus subtilis 80 DNA topoisomerase IV subunit B (gyrB) 
Rv0014c MSMEG_0028 Streptococcus pneumoniae 65 Transmembrane serine/threonine-protein kinase B (pknB) 
Rv0015c MSMEG_0030  Streptococcus pneumoniae 87 Transmembrane serine/threonine-protein kinase A (pknA) 
Rv0041 MSMEG_6917 Bacillus subtilis 76 leucyl-tRNA synthetase (leuS) 
Rv0058 MSMEG_6892  Bacillus subtilis 66 replicative DNA helicase (dnaB) 
Rv0284 MSMEG_0617  Escherichia coli 72 Possible conserved membrane protein (FtsK) 
Rv0352 MSMEG_0711 Staphylococcus aureus 71 Probable chaperone protein (dnaJ1)  
Rv0422c MSMEG_0825  Haemophilus influenzae 60 phosphomethylpyrimidine kinase (thiD) 
Rv0440 MSMEG_0880  Bacillus subtilis 84 chaperonin (groEL)  
Rv0462 MSMEG_0903  Staphylococcus aureus 81 dihydrolipoamide dehydrogenase (lpd) 
Rv0500 MSMEG_0943 Escherichia coli 65 pyrroline-5-carboxylate reductase (proC) 
Rv0510 MSMEG_0953  Escherichia coli 77 porphobilinogen deaminase (hemC) 
Rv0524 MSMEG_0969  Escherichia coli 71 glutamate-1-semialdehyde aminotransferase (hemL) 
Rv0526 MSMEG_0971  Bacillus subtilis 70 Possible thioredoxin protein 
Rv0527 MSMEG_0972  Helicobacter pylori 61 Possible cytochrome C-type biogenesis protein (ccdA) 
Rv0529 MSMEG_0974  Bacillus subtilis 66 Possible cytochrome C-type biogenesis protein (ccsA) 
Rv0542c MSMEG_1062 Bacillus subtilis 60 O-succinylbenzoic acid--CoA ligase (menE) 
Rv0555 MSMEG_1109  Bacillus subtilis 75 2-oxoglutarate decarboxylase (menD) 
Rv0558 MSMEG_1115 Escherichia coli 82 ubiquinone/menaquinone biosynthesis methyltransferase (menH) 
Rv0562 MSMEG_1133  Bacillus subtilis 67 Probable polyprenyl-diphosphate synthase GRCC1 (grcC1) 
Rv0640 MSMEG_1346  Staphylococcus aureus 85 50S ribosomal protein L11 (rplK) 
Rv0651 MSMEG_1364 Staphylococcus aureus 76 50S ribosomal protein L10 (rplJ) 
Rv0667 MSMEG_1367  Bacillus subtilis 89 DNA-directed RNA polymerase beta subunit (rpoB) 
Rv0675 MSMEG_1390 Staphylococcus aureus 75 enoyl-CoA hydratase (echA5) 
Rv0682 MSMEG_1398 Helicobacter pylori 99 30S ribosomal protein S12 (rpsL) 
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Rv0683 MSMEG_1399 Bacillus subtilis 96 30S ribosomal protein S7 (rpsG) 
Rv0684 MSMEG_6535  Staphylococcus aureus 37 elongation factor EF-2 (fusA1) 
Rv0685 MSMEG_1401  Escherichia coli 83 elongation factor Tu (tuf) 
Rv0700 MSMEG_1435 Bacillus subtilis 98 30S ribosomal protein S10 (rpsJ) 
Rv0701 MSMEG_1436 Escherichia coli 88 50S ribosomal protein L3 (rplC) 
Rv0702 MSMEG_1437  Staphylococcus aureus 82 50S ribosomal protein L4 (rplD) 
Rv0704 MSMEG_1439  Staphylococcus aureus 92 50S ribosomal protein L2 (rplB) 
Rv0705 MSMEG_1440  Staphylococcus aureus 97 30S ribosomal protein S19 (rpsS) 
Rv0707 MSMEG_1442  Haemophilus influenzae 97 30S ribosomal protein S3 (rpsC) 
Rv0708 MSMEG_1443  Bacillus subtilis 93 50S ribosomal protein L16 (rplP) 
Rv0710 MSMEG_1445 Bacillus subtilis 93 30S ribosomal protein S17 (rpsQ) 
Rv0714 MSMEG_1465 Staphylococcus aureus 80 50S ribosomal protein L14 (rplN) 
Rv0715 MSMEG_1466 Bacillus subtilis 87 50S ribosomal protein L24 (rplX) 
Rv0716 MSMEG_1467 Bacillus subtilis 83 50S ribosomal protein L5 (rplE) 
Rv0718 MSMEG_1469 Bacillus subtilis 96 30S ribosomal protein S8 (rpsH) 
Rv0719 MSMEG_1470 Staphylococcus aureus 87 50S ribosomal protein L6 (rplF) 
Rv0720 MSMEG_1471 Bacillus subtilis 88 50S ribosomal protein L18 (rplR) 
Rv0721 MSMEG_1472  Salmonella typhimurium 76 30S ribosomal protein S5 (rpsE) 
Rv0732 MSMEG_1483  Escherichia coli 82 preprotein translocase (secY)  
Rv0772 MSMEG_5852  Haemophilus influenzae 73 phosphoribosylamine--glycine ligase (purD) 
Rv0780 MSMEG_5841  Haemophilus influenzae 77 phosphoribosylaminoimidazole-succinocarboxamide synthase (hemH) 
Rv0808 MSMEG_5800  Streptococcus pneumoniae 84 amidophosphoribosyltransferase (purF) 
Rv0973c MSMEG_5493 Bacillus subtilis 64 Probable acetyl-/propionyl-coenzyme A carboxylase alpha chain (accA2) 
Rv0993 MSMEG_5471  Escherichia coli 75 Probable UTP-glucose-1-phosphate uridylyltransferase (galU) 
Rv1007c MSMEG_5441  Bacillus subtilis 70 methionine--tRNA ligase (metG) 
Rv1014c MSMEG_5432  Haemophilus influenzae 77 peptidyl-tRNA hydrolase (pth) 
Rv1017c MSMEG_5427  Bacillus subtilis 87 ribose-phosphate pyrophosphokinase (prsA) 
Rv1018c MSMEG_5426  Streptococcus pneumoniae 68 Probable UDP-N-acetylglucosamine pyrophosphorylase (glmU)  
Rv1023 MSMEG_5415 Bacillus subtilis 82 phosphopyruvate hydratase (eno) 
Rv1092c MSMEG_5252 Escherichia coli 83 pantothenate kinase (coaA) 
Rv1098c MSMEG_5240  Haemophilus influenzae 82 fumarate hydratase (fumC) 
Rv1193 MSMEG_5114 Bacillus subtilis 63 acyl-CoA synthase (fadD36) 
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Rv1223 MSMEG_5070  Helicobacter pylori 71 Probable serine protease (htrA) 
Rv1229c MSMEG_5068 Salmonella typhimurium 73 Probable mrp-related protein (mrp)  
Rv1292 MSMEG_4959  Bacillus subtilis 81 arginyl-tRNA synthetase (argS) 
Rv1293 MSMEG_4958  Helicobacter pylori 80 Probable diaminopimelate decarboxylase (lysA)  
Rv1297 MSMEG_4954  Staphylococcus aureus 91 transcription termination factor Rho (rho) 
Rv1298 MSMEG_4951 Haemophilus influenzae 80 50S ribosomal protein L31 (rpmE) 
Rv1299 MSMEG_4950  Bacillus subtilis 76 peptide chain release factor 1 (prfA) 
Rv1308 MSMEG_4938  Streptococcus pneumoniae 78 ATP synthase subunit A (atpA) 
Rv1309 MSMEG_4937 Streptococcus pneumoniae 74 ATP synthase subunit C (atpG) 
Rv1310 MSMEG_4936  Streptococcus pneumoniae 94 ATP synthase subunit B (atpD) 
Rv1311 MSMEG_4935 Streptococcus pneumoniae 81 ATP synthase subunit epsilon (atpC) 
Rv1315 MSMEG_4932 Staphylococcus aureus 88 UDP-N-acetylglucosamine 1-carboxyvinyltransferase (murA) 
Rv1326c MSMEG_4918  Haemophilus influenzae 81 glycogen branching enzyme (glgB) 
Rv1349 MSMEG_6553  Salmonella typhimurium 67 Probable drugs-transprot transmembrane ATP-binding protein ABC transporter (MdlB) 
Rv1350 MSMEG_2206 Bacillus subtilis 77 3-ketoacyl-(acyl-carrier-protein) reductase (fabG) 
Rv1381 MSMEG_3044  Staphylococcus aureus 83 dihydroorotase (pyrC) 
Rv1389 MSMEG_3051 Helicobacter pylori 75 guanylate kinase (gmk) 
Rv1390 MSMEG_3053  Streptococcus pneumoniae 79 DNA-directed RNA polymerase omega subunit (rpoZ) 
Rv1392 MSMEG_3055  Bacillus subtilis 87 S-adenosylmethionine synthetase (metK) 
Rv1406 MSMEG_3064 Escherichia coli 67 methionyl-tRNA formyltransferase (fmt) 
Rv1409 MSMEG_3067  Escherichia coli 64 Probable bifunctional riboflavin biosynthesis protein (ribG) 
Rv1416 MSMEG_3073 Escherichia coli 74 riboflavin synthase subunit beta (ribH) 
Rv1436 MSMEG_3084  Escherichia coli 87 glyceraldehyde-3-phosphate dehydrogenase (gap) 
Rv1437 MSMEG_3085  Bacillus subtilis 71 phosphoglycerate kinase (pgk) 
Rv1438 MSMEG_3086 Streptococcus pneumoniae 80 triosephosphate isomerase (tpi) 
Rv1449c MSMEG_3103  Bacillus subtilis 77 transketolase (tkt) 
Rv1461 MSMEG_3122  Bacillus subtilis 94 hypothetical protein Rv1461 (component of SufBCD complex) 
Rv1462 MSMEG_3123  Bacillus subtilis 78 hypothetical protein Rv1462 (SufB) 
Rv1463 MSMEG_3124  Bacillus subtilis 85 Probable conserved ATP-binding protein ABC transporter (FeS assembly) 
Rv1464 MSMEG_3125  Staphylococcus aureus 83 Probable cysteine desulfurase (csd) 
Rv1465 MSMEG_3126  Bacillus subtilis 83 Possible nitrogen fixation related protein (IscU) 
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Rv1547 MSMEG_3178 Escherichia coli 84 DNA polymerase III subunit alpha (dnaE1) 
Rv1601 MSMEG_3207  Haemophilus influenzae 81 imidazoleglycerol-phosphate dehydratase (hisB) 
Rv1603 MSMEG_3209  Haemophilus influenzae 85 Probable phosphoribosyformimino-5-aminoimidazole carboxamide ribotide isomerase (hisA) 
Rv1609 MSMEG_3217  Salmonella typhimurium 80 anthranilate synthase component I (trpE) 
Rv1612 MSMEG_3220  Streptococcus pneumoniae 84 tryptophan synthase subunit beta (trpB) 
Rv1617 MSMEG_3227  Staphylococcus aureus 84 pyruvate kinase (pykA) 
Rv1622c MSMEG_3232  Escherichia coli 60 Probable integral membrane cytochrome D ubiquinol oxidase (subunit II) cydB 
Rv1629 MSMEG_3839  Staphylococcus aureus 77 DNA polymerase I (polA) 
Rv1630 MSMEG_3833  Haemophilus influenzae 84 30S ribosomal protein S1 (rpsA) 
Rv1631 MSMEG_2076 Bacillus subtilis 44 dephospho-CoA kinase/unknown domain fusion protein (coaE) 
Rv1641 MSMEG_3793  Bacillus subtilis 86 translation initiation factor IF-3 (infC) 
Rv1649 MSMEG_3778  Bacillus subtilis 80 phenylalanyl-tRNA synthetase alpha subunit (pheS) 
Rv1650 MSMEG_3777  Salmonella typhimurium 65 phenylalanyl-tRNA synthetase beta subunit (pheT) 
Rv1652 MSMEG_3776  Escherichia coli 71 N-acetyl-gamma-glutamyl-phosphate reductase (argC) 
Rv1655 MSMEG_3773  Staphylococcus aureus 69 acetylornithine aminotransferase (argD) 
Rv1659 MSMEG_3769  Haemophilus influenzae 71 argininosuccinate lyase (argH) 
Rv1661 MSMEG_0408  Bacillus subtilis 37 Probable polyketide synthase (pks7) 
Rv1662 MSMEG_0408  Bacillus subtilis 43 Probable polyketide synthase (pks8) 
Rv1689 MSMEG_3758 Escherichia coli 70 tyrosyl-tRNA synthetase (tyrS) 
Rv1695 MSMEG_3750  Escherichia coli 83 inorganic polyphosphate/ATP-NAD kinase (ppnK) 
Rv1699 MSMEG_3746 Bacillus subtilis 90 CTP synthetase (pyrG) 
Rv1701 MSMEG_3744  Escherichia coli 78 tyrosine recombinase (xerD) 
Rv1711 MSMEG_3740  Escherichia coli 75 hypothetical protein Rv1711 (RsuA) 
Rv1712 MSMEG_3739 Bacillus subtilis 61 cytidylate kinase (cmk) 
Rv1713 MSMEG_3738  Staphylococcus aureus 72 GTP-binding protein (engA) 
Rv1714 MSMEG_3607  Staphylococcus aureus 28 Probable oxidoreductase (fabG) 
Rv1850 MSMEG_3625  Staphylococcus aureus 76 Urease alpha subunit (ureC) 
Rv2093c MSMEG_3886  Helicobacter pylori 66 Probable Sec-independent protein translocase transmembrane protein (tatC)  
Rv2121c MSMEG_4180 Haemophilus influenzae 84 Probable ATP phosphoribosyltransferase (hisG) 
Rv2130c MSMEG_4215  Escherichia coli 51 hypothetical protein Rv2030c  
Rv2150c MSMEG_4222  Bacillus subtilis 78 cell division protein (ftsZ) 
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Rv2152c MSMEG_4226  Haemophilus influenzae 70 UDP-N-acetylmuramate--L-alanine ligase (murC) 
Rv2153c MSMEG_4227  Salmonella typhimurium 63 N-acetylglucosaminyl transferase (murG) 
Rv2154c MSMEG_4228 Salmonella typhimurium 54 FtsW-like protein (ftsW)  
Rv2155c MSMEG_4229  Bacillus subtilis 60 UDP-N-acetylmuramoyl-L-alanyl-D-glutamate synthetase (murD) 
Rv2156c MSMEG_4230  Bacillus subtilis 74 phospho-N-acetylmuramoyl-pentapeptide-transferase (murX) 
Rv2157c MSMEG_4231 Streptococcus pneumoniae 59 
Probable UDP-N-acetylmuramoylalanyl-D-glutamyl-2,6-diaminopimelate- D-alanyl-D-alanyl ligase 
(murF)  
Rv2163c MSMEG_4233 Salmonella typhimurium 75 Probable penicillin-binding membrane protein (pbpB) 
Rv2165c MSMEG_4235 Streptococcus pneumoniae 63 S-adenosyl-methyltransferase (mraW) 
Rv2166c MSMEG_4236  Mycoplasma genitalium 89 hypothetical protein Rv2166c  
Rv2182c MSMEG_4248 Bacillus subtilis 73 1-acylglycerol-3-phosphate O-acyltransferase (plsC) 
Rv2188c MSMEG_4253 Haemophilus influenzae 67 hypothetical protein Rv2188c (rfaG) 
Rv2192c MSMEG_4258  Haemophilus influenzae 65 anthranilate phosphoribosyltransferase (trpD) 
Rv2215 MSMEG_4283 Escherichia coli 72 dihydrolipoamide acyltransferase (sucB) 
Rv2217 MSMEG_4285  Haemophilus influenzae 76 lipoyltransferase (lipB) 
Rv2218 MSMEG_4286  Staphylococcus aureus 84 lipoyl synthase (lipA) 
Rv2220 MSMEG_4290  Salmonella typhimurium 84 Glutamine synthetase (glnA1) 
Rv2225 MSMEG_4298  Helicobacter pylori 71 3-methyl-2-oxobutanoate hydroxymethyltransferase (panB) 
Rv2231c MSMEG_3206  Haemophilus influenzae 27 hypothetical protein Rv2231c (cobC) 
Rv2245 MSMEG_4327 Streptococcus pneumoniae 83 3-oxoacyl-(acyl carrier protein) synthase (kasA) 
Rv2246 MSMEG_4328  Streptococcus pneumoniae 79 3-oxoacyl-(acyl carrier protein) synthase (kasB) 
Rv2343c MSMEG_4482  Bacillus subtilis 76 DNA primase (dnaG) 
Rv2357c MSMEG_4485  Mycoplasma genitalium 80 glycyl-tRNA synthetase (glyS) 
Rv2361c MSMEG_4490  Escherichia coli 76 Long (C50) chain Z-isoprenyl diphosphate synthase 
Rv2364c MSMEG_4493 Bacillus subtilis 79 GTP-binding protein (era)  
Rv2373c MSMEG_4504  Staphylococcus aureus 71 PROBABLE CHAPERONE PROTEIN (dnaJ2)  
Rv2397c MSMEG_4530 Staphylococcus aureus 79 Probabe sulfate-transport ATP-binding protein ABC transporter (cysA1)  
Rv2398c MSMEG_4531 Escherichia coli MG1655 73 Probable sulfate-transport integral membrane protein ABC transporter (cysW)  
Rv2399c MSMEG_4532  Haemophilus influenzae 73 Probable sulfate-transport integral membrane protein ABC transporter (cysT)  
Rv2421c MSMEG_4581  Bacillus subtilis 76 nicotinic acid mononucleotide adenyltransferase (nadD) 
Rv2440c MSMEG_4623 Staphylococcus aureus 66 Probable GTP1/OBG-family GTP-binding protein (obg) 
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Rv2441c MSMEG_4624  Helicobacter pylori 91 50S ribosomal protein L27 (rpmA) 
Rv2442c MSMEG_4625  Bacillus subtilis 88 50S ribosomal protein L21 (rplU) 
Rv2444c MSMEG_4626 Haemophilus influenzae 69 Possible ribonuclease E (rne)  
Rv2447c MSMEG_4232 Streptococcus pneumoniae 29 Probable folylpolyglutamate synthase protein (folC) 
Rv2448c MSMEG_4630  Bacillus subtilis 78 valyl-tRNA synthetase (valS) 
Rv2457c MSMEG_4671 Salmonella typhimurium 95 ATP-dependent protease ATP-binding subunit (clpX) 
Rv2460c MSMEG_4672  Haemophilus influenzae 88 ATP-dependent Clp protease proteolytic subunit (clpP2) 
Rv2477c MSMEG_4700  Haemophilus influenzae 84 Probable macrolide-transport ATP-binding protein ABC transporter  
Rv2500c MSMEG_4715 Salmonella typhimurium 73 Possible acyl-CoA dehyrogenase (fadE19) 
Rv2511 MSMEG_4724  Haemophilus influenzae 79 oligoribonuclease (orn) 
Rv2534c MSMEG_3035  Staphylococcus aureus 80 elongation factor P (efp) 
Rv2537c MSMEG_1922  Helicobacter pylori 44 3-dehydroquinate dehydratase (aroD) 
Rv2538c MSMEG_3033  Haemophilus influenzae 77 3-dehydroquinate synthase (aroB) 
Rv2539c MSMEG_3031  Haemophilus influenzae 77 shikimate kinase (aroK) 
Rv2540c MSMEG_3030  Haemophilus influenzae 77 chorismate synthase (aroF) 
Rv2555c MSMEG_3025  Salmonella typhimurium 78 alanyl-tRNA synthetase (alaS) 
Rv2580c MSMEG_2976 Staphylococcus aureus 75 histidyl-tRNA synthetase (hisS) 
Rv2614c MSMEG_2931 Streptococcus pneumoniae 79 threonyl-tRNA synthetase (thrS) 
Rv2682c MSMEG_2776  Salmonella typhimurium 77 1-deoxy-D-xylulose-5-phosphate synthase (dxs1) 
Rv2703 MSMEG_2758  Bacillus subtilis 87 RNA polymerase sigma factor (sigA) 
Rv2710 MSMEG_2752  Staphylococcus aureus 93 RNA polymerase sigma factor (sigB) 
Rv2727c MSMEG_2734  Escherichia coli 58 tRNA delta(2)-isopentenylpyrophosphate transferase (miaA) 
Rv2746c MSMEG_2692  Streptococcus pneumoniae 61 Probable PGP synthase (pgsA3) 
Rv2753c MSMEG_2684  Bacillus subtilis 75 dihydrodipicolinate synthase (dapA) 
Rv2786c MSMEG_2653  Escherichia coli 76 hypothetical protein Rv2786c (ribF) 
Rv2832c MSMEG_0508  Staphylococcus aureus 54 Probable Sn-glycerol-3-phospahte transport ATP-binding protein (ugpC) 
Rv2839c MSMEG_2628  Bacillus subtilis 90 translation initiation factor IF-2 (infB) 
Rv2841c MSMEG_2625  Bacillus subtilis 83 transcription elongation factor (nusA) 
Rv2845c MSMEG_2621 Haemophilus influenzae 73 prolyl-tRNA synthetase (proS) 
Rv2846c MSMEG_2619 Haemophilus influenzae 71 Possible integral membrane efflux protein (efpA)  
Rv2869c MSMEG_2579  Escherichia coli 61 Probable conserved transmembrane protein 
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Rv2881c MSMEG_2543  Salmonella typhimurium 59 Probable integral membrane phosphatidate cytidylyltransferase (cdsA) 
Rv2882c MSMEG_2541  Bacillus subtilis 80 ribosome releasing factor (frr) 
Rv2883c MSMEG_2540  Streptococcus pneumoniae 83 uridylate kinase (pyrH) 
Rv2889c MSMEG_2520  Bacillus subtilis 70 elongation factor Ts (tsf) 
Rv2890c MSMEG_2519 Staphylococcus aureus 93 30S ribosomal protein S2 (rpsB) 
Rv2897c MSMEG_2509  Haemophilus influenzae 66 hypothetical protein Rv2897c  
Rv2904c MSMEG_2440 Bacillus subtilis 80 50S ribosomal protein L19 (rplS) 
Rv2906c MSMEG_2438  Streptococcus pneumoniae 82 tRNA (guanine-N(1)-)-methyltransferase (trmD) 
Rv2916c MSMEG_2430 Bacillus subtilis 81 Probable signal recognition particle protein (ffh) 
Rv2925c MSMEG_2418  Bacillus subtilis 78 ribonuclease III (rncS) 
Rv2977c MSMEG_2398 Escherichia coli 59 thiamine monophosphate kinase (thiL) 
Rv2981c MSMEG_2395  Bacillus subtilis 76 D-alanylalanine synthetase (ddlA) 
Rv2986c MSMEG_2389 Bacillus subtilis 85 Probable DNA-binding protein HU homolog (hupB) 
Rv2987c MSMEG_2388 Haemophilus influenzae 86 isopropylmalate isomerase small subunit (leuD) 
Rv2992c MSMEG_2383 Bacillus subtilis 72 glutamyl-tRNA synthetase (gltS) 
Rv2995c MSMEG_2379 Haemophilus influenzae 77 3-isopropylmalate dehydrogenase (leuB) 
Rv2996c MSMEG_2378  Staphylococcus aureus 76 Probable D-3-phosphoglycerate dehydrogenase (serA1)  
Rv3009c MSMEG_2367  Staphylococcus aureus 81 aspartyl/glutamyl-tRNA amidotransferase subunit B (gatB) 
Rv3011c MSMEG_2365  Staphylococcus aureus 77 glutamyl-tRNA amidotransferase subunit A (gatA) 
Rv3014c MSMEG_2362 Salmonella typhimurium 79 DNA ligase (ligA) 
Rv3025c MSMEG_2357  Escherichia coli  74 Probable cysteine desulfurase (iscS)  
Rv3032 MSMEG_0933 Saccharomyces cerevisiae 27 Possible transferase 
Rv3043c MSMEG_4437 Staphylococcus aureus 82 Probable cytochrome C oxidase polypeptide I (ctaD) 
Rv3048c MSMEG_1033  Mycoplasma genitalium 93 ribonucleotide-diphosphate reductase beta subunit (nrdF2) 
Rv3051c MSMEG_1019  Mycoplasma genitalium 92 ribonucleotide-diphosphate reductase alpha subunit (nrdE) 
Rv3105c MSMEG_2086  Bacillus subtilis 75 peptide chain release factor 2 (prfB) 
Rv3140 MSMEG_2080  Escherichia coli  81 Probable acyl-coA dehydrogenase (fadE23) 
Rv3177 MSMEG_6831 Haemophilus influenzae 37 Possible peroxidase 
Rv3240c MSMEG_1881  Bacillus subtilis 78 Probable preprotein translocase (secA1) 
Rv3246c MSMEG_1874  Bacillus subtilis 84 Two component sensory transduction transcriptional regulatory  protein (mtrA) 
Rv3255c MSMEG_1836  Saccharomyces cerevisiae 74 Probable mannose-6-phosphate isomerase (manA) 
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Rv3257c MSMEG_1834 Bacillus subtilis 80 Probable phosphomannomutase (pmmA) 
Rv3285 MSMEG_1807 Bacillus subtilis 81 Probable bifunctional protein acetyl-/propionyl-coenzyme A carboxylase (accA3) 
Rv3332 MSMEG_2119  Haemophilus influenzae 47 Probable n-acetylglucosamine-6-phosphate deacetylase (nagA) 
Rv3336c MSMEG_1657  Escherichia coli 79 tryptophanyl-tRNA synthetase (trpS) 
Rv3356c MSMEG_1647 Bacillus subtilis 82 Probable bifunctional protein (folD) 
Rv3396c MSMEG_1610 Staphylococcus aureus 83 bifunctional GMP synthase/glutamine amidotransferase protein (guaA) 
Rv3398c MSMEG_4240  Haemophilus influenzae 31 Probable multifunctional geranylgeranyl pyrophospahte synthetase (idsA1) 
Rv3411c MSMEG_1602  Bacillus subtilis 77 inositol-5-monophosphate dehydrogenase (guaB2) 
Rv3418c MSMEG_1582 Bacillus subtilis 99 co-chaperonin (groES) 
Rv3422c MSMEG_1577 Bacillus subtilis 63 hypothetical protein Rv3422c  
Rv3423c MSMEG_1575  Bacillus subtilis 61 alanine racemase (alr) 
Rv3436c MSMEG_1568  Escherichia coli 85 D-fructose-6-phosphate amidotransferase (glmS) 
Rv3441c MSMEG_1559  Bacillus subtilis 67 Probable phospho-sugar mutase/ mrsA protein homolog (mrsA) 
Rv3443c MSMEG_1556  Escherichia coli 80 50S ribosomal protein L13 (rplM) 
Rv3457c MSMEG_1524  Bacillus subtilis 90 DNA-directed RNA polymerase alpha subunit (rpoA) 
Rv3458c MSMEG_1523 Haemophilus influenzae 83 30S ribosomal protein S4 (rpsD) 
Rv3459c MSMEG_1522  Bacillus subtilis 92 30S ribosomal protein S11 (rpsK) 
Rv3462c MSMEG_1519 Bacillus subtilis 98 translation initiation factor IF-1 (infA) 
Rv3464 MSMEG_1512 Haemophilus influenzae 83 dTDP-glucose 4,6-dehydratase (rmlB) 
Rv3559c MSMEG_6011 Bacillus subtilis 78 short chain dehydrogenase  
Rv3579c MSMEG_6073  Mycoplasma genitalium 61 Possible tRNA/rRNA methyltransferase 
Rv3580c MSMEG_6074  Escherichia coli 78 cysteinyl-tRNA synthetase (cysS1) 
Rv3581c MSMEG_6075  Haemophilus influenzae 64 2-C-methyl-D-erythritol 2,4-cyclodiphosphate synthase (ispF) 
Rv3582c MSMEG_6076  Haemophilus influenzae 58 2-C-methyl-D-erythritol 4-phosphate cytidylyltransferase (ispD) 
Rv3596c MSMEG_6091  Staphylococcus aureus 88 Probable ATP-dependent protease ATP-binding subunit (clpC1)  
Rv3598c MSMEG_6094  Bacillus subtilis 74 lysyl-tRNA synthetase (lysS) 
Rv3602c MSMEG_6097 Helicobacter pylori 60 pantoate--beta-alanine ligase (panC) 
Rv3608c MSMEG_6103  Streptococcus pneumoniae 63 Dihydropteroate synthase 1 (folP1)  
Rv3609c MSMEG_6104  Streptococcus pneumoniae 86 GTP cyclohydrolase I (folE) 
Rv3610c MSMEG_6105 Staphylococcus aureus 76 Membrane-bound protease- cell division protein (ftsH) 
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Rv3627c MSMEG_6113 Haemophilus influenzae 56 hypothetical protein Rv3627c  
Rv3634c MSMEG_6142  Haemophilus influenzae 63 UDP-glucose 4-epimerase (galE1) 
Rv3646c MSMEG_6157  Haemophilus influenzae 81 DNA topoisomerase I (topA) 
Rv3708c MSMEG_6256  Bacillus subtilis 78 aspartate-semialdehyde dehydrogenase (asd) 
Rv3709c MSMEG_6257 Helicobacter pylori 84 aspartate kinase (ask) 
Rv3712 MSMEG_6276 Streptococcus pneumoniae 64 Possible ligase 
Rv3713 MSMEG_6277 Streptococcus pneumoniae 83 Possible cobyric acid synthase (cobQ2)  
Rv3721c MSMEG_6285  Staphylococcus aureus 72 DNA polymerase III subunits gamma and tau (dnaZX) 
Rv3752c MSMEG_6327  Escherichia coli 80 Possible cytidine/deoxycytidylate deaminase 
Rv3778c MSMEG_6363  Bacillus subtilis 70 Possible aminotransferase  
Rv3781 MSMEG_6366  Bacillus subtilis 88 Probable O-antigen/lipopolysaccharide transporter (rfbE) 
Rv3799c MSMEG_6391 Haemophilus influenzae 81 Probable propionyl-CoA carboxylase beta chain 4 (accD4)  
Rv3800c MSMEG_6392  Streptococcus pneumoniae 70 Polyketide synthase (pks13)  
Rv3834c MSMEG_6413  Bacillus subtilis 71 seryl-tRNA synthetase (serS) 
Rv3907c MSMEG_6926 Streptococcus pneumoniae 80 Probable poly(A) polymerase (pcnA) 
Rv3913 MSMEG_6933  Streptococcus pneumoniae 67 Probable thioredoxin reductase (trxB2) 
Rv3917c MSMEG_6938 Staphylococcus aureus 76 Probable chromosome partiontioning protein (parB) 
Rv3918c MSMEG_6939 Helicobacter pylori 79 Probable chromosome partitioning protein (parA)  
Rv3921c MSMEG_6942 Haemophilus influenzae 72 putative inner membrane protein translocase component YidC  
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9.3 Cellular morphology of M. smegmatis strains under different 
culture conditions 
 
9.3.1 Cell morphology of cultures in LBT 
 
 
       
 
     
Figure 9.2: Cell morphology of cultures in LBT 
The above pictures show the cell morphology of all the strains cultured in LBT with 20 
ng/mL Tc stained with DAPI at 144 hours. A) M. smegmatis-pMindGFP B) M. 
smegmatis-pMind_parB_GFP C) M. smegmatis-pMind_obg and D) M. smegmatis-
pMind_parA_GFP. There was no detectable difference in the cell morphology between 
the different strains. All cells were approximately 2-6 µm long.  
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9.3.2 Cell morphology of cultures in C- media 
 
 
     
 
      
 
 
 
Figure 9.3: Cell morphology of cultures in C
-
 media 
The above pictures show the cell morphology of all the strains cultured in C
-
 media with 
20 ng/mL Tc stained with DAPI at 72 hours. A) M. smegmatis-pMindGFP B) M. 
smegmatis-pMind_parB_GFP C) M. smegmatis-pMind_obg and D) M. smegmatis-
pMind_parA_GFP. All strains had cells ~ 4-7 µm long except M. smegmatis-
pMind_parA_GFP which formed slightly smaller rods ~ 2-4 µm long.  
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9.3.3 Cell morphology of cultures in N- media 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                     
 
                                                                                                                                                           
 
Figure 9.4: Cell morphology of cultures in N
-
 media 
The above pictures show the cell morphology of strains cultured in N
-
 media with 20 
ng/mL Tc stained with DAPI at 72 hours of A) M. smegmatis-pMindGFP, B) M. 
smegmatis-pMind_parB_GFP, C) M. smegmatis-pMind_obg and D) M. smegmatis-
pMind_parA_GFP. The cells were slightly elongated in nitrogen starvation media, ~ 6-11 
µm in length. M. smegmatis-pMind_obg and M. smegmatis-pMind_parA_GFP cultures 
had irregularly located foci along the length of the cells.  
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9.4 Cellular Morphology of M. smegmatis strains in HTS 
 
9.4.1 Cell morphology in N- media with LOPAC hits 
             
 
 
 
                  
 
 
 
            
 
 
 
            
 
Figure 9.5: Cell morphology of cultures in N
-
 media with hits from LOPAC 
A 
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B 
E 
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F 
Chapter Nine: Appendices 
_______________________________________________________________ 
243 
All pictures were taken after 72 hours incubation in N
-
 media with 20 ng/mL Tc when 
screening for compounds in LOPAC. A) M. smegmatis_pMind2357 and B) M. 
smegmatis_pMind_parA_GFP cells without any compounds and stained with DAPI. Both 
these strains show cells ~ 6-10 µM in length. GFP picture of M. 
smegmatis_pMind_parA_GFP cells in the presence of 20 µM C) amsacrine hydrochloride 
showing cells ~ 15-20 µM in length, D) AA-861 showing cells ~ 7-17 µM in length, E) 
R-(-)-fluoxetine hydrochloride showing cells ~ 20-25 µM in length, F) fenoldopam 
bromide showing cells ~ 10-16 µM in length, G) (±)-octoclothepin maleate showing cells 
~ 15-20 µM in length and H) methiothepin mesylate showing cells ~ 15-20 µM in length. 
Cells of M. smegmatis_pMind2357 with the above mentioned compounds showed no 
difference compared to the cells shown in A) (data not shown).  
 
 
 
9.4.2 Cell morphology in N- media with Spectrum Collection hits 
 
    
 
Figure 9.6: Cell morphology of cultures in N
-
 media with hits from Spectrum 
Collection 
Pictures were taken after 72 hours incubation in N
-
 media with 20 ng/mL Tc when 
screening for compounds in the Spectrum Collection. Both pictures show cells in 20 µM 
phenoxybenzamine hydrochloride with A) M. smegmatis_pMind2357 cells stained with 
DAPI (2 µM – 5 µM) and B) M. smegmatis_pMind_parA_GFP cells (5 µM – 15 µM). 
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9.4.3 Cell morphology in C- media with NIH Diversity Set hit 
 
   
 
Figure 9.7: Cell morphology of cultures in C
-
 media with hits from NIH Diversity 
Set 
Pictures were taken after 72 hours incubation in C
-
 media with 20 ng/mL Tc when 
screening for compounds in NIH Diversity Set. Both pictures show cells in 20 µM of 
compound NSC22242 with A) M. smegmatis_pMind2357 stained with DAPI, cells ~ 2-5 
µM in length and B) GFP image of M. smegmatis_pMind_parA_GFP, cells ~ 10-17 µM 
in length.  
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9.5 Media and Solutions 
 
9.5.1  Hartmans-de Bont minimal media [125] 
 
100x Metal Salts Solution      
o CaCl2.2H2O   0.1 g    
o CoCl2.2H2O   0.04 g    
o CuSO4.5H2O   0.02 g 
o EDTA    1 g 
o FeSO4.7H2O   0.5 g     
o MgCl2.6H2O   10 g      
o MnCl2.2H2O   0.1 g 
o NaMoO4.2H2O  0.02 g 
o ZnSO4.7H2O   0.2 g 
 
100x Phosphates 
o K2HPO4   155 g  
o NaH2PO4    85 g  
 
100x Nitrogen 
o (NH4)2SO4   200 g     
 
The above solutions were made to 1 L with deionized water in Schott bottles, 
sterilized by autoclaving for 30 minutes at 121°C on a liquid cycle and stored at 
4°C and used for up to 12 months.  
 
 
 
HdeB Base        
o H2O    945 mL     
o 100x Metal salts  10 mL      
o 10% Tween 80  5 mL      
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Oxygen Starvation (O2
-
) Media 
o HdeB base   960 mL   
o 100x Nitrogen  10 mL 
o 100x Phosphate  10 mL 
o 10% Glycerol   20 mL 
   
Carbon Starvation (C
-
) Media 
o HdeB base   960 mL   
o 100x Nitrogen  10 mL 
o 100x Phosphate  10 mL 
o 10% Glycerol   8 mL 
o H2O    12 mL 
 
Nitrogen Starvation (N
-
) Media 
o HdeB base   960 mL   
o 100x Nitrogen  0.1 mL 
o 100x Phosphate  10 mL 
o 10% Glycerol   20 mL 
o H2O    9.9 mL 
 
All solutions were sterilized by autoclaving for 30 minutes at 121°C on a liquid 
cycle and stored at RT and used within a week.  
 
 
9.5.2 ZYP-5052 
 
ZY 
o N-Z amine AS or tryptone  10 g  
o Yeast extract    5 g 
 
ZY was made up to 919 mL with deionized water in Schott bottles, sterilized by 
autoclaving for 30 minutes at 121°C on a liquid cycle and stored at 4°C.  
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20x NPS (pH ~ 6.75) 
(NPS = 100 mM PO4, 25 mM SO4, 50 mM NH4, 100 mM Na, 50 mM K) 
o (NH4)2SO4   66  
o KH2PO4   136 g 
o 1 M Na2HPO4   142 g 
 
50x 5052 
o Glycerol   250 g (w/v) 
o Glucose   25 g 
o α-lactose   100 g 
 
The above two solutions were made up to 1 L with deionized water in Schott 
bottles, sterilized by autoclaving for 30 minutes at 121°C on a liquid cycle and 
stored at 4°C.  
 
ZYP-5052 
o ZY    919 mL 
o 1 M MgSO4   1 mL 
o 100x metal salts*  10 mL 
o 50x 5052   20 mL 
o 20x NPS   50 mL  
 
* Metal salts was prepared as in HdeB minimal media (section 8.5.1). All the 
solutions were added in the order given to avoid precipitation. MgSO4 was filter 
sterilized.  
 
 
9.5.3 Solutions 
 
Proteinase K – 1 mg lyophilized powder was dissolved in 1 mM Tris (pH 8.0) and 
1.5 mM calcium acetate and stored at -20°C. 
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Alkaline Lysis Solution I 
o 1 M Glucose   5 mL 
o 1 M Tris-Cl (pH 8.0)  2.5 mL 
o 0.5 M EDTA (pH 8.0) 2 mL 
 
Alkaline Lysis Solution I was made up to 100 mL with deionized water, 
autoclaved for 30 minutes at 121°C on a liquid cycle and stored at 4°C. 
 
Alkaline Lysis Solution II 
o 0.2 M NaOH        
o 1% SDS (w/v)  
 
Alkaline Lysis Solution II was always freshly prepared before use. 
 
Alkaline Lysis Solution III 
o 5 M Potassium acetate 60.0 mL  
o Glacial Acetic Acid  11.5 mL 
o H2O    28.5 mL 
 
Alkaline Lysis Solution III comprised 3 M potassium and 5 M acetate. This was 
prepared via autoclaved for 30 minutes at 121°C on a liquid cycle and stored at 
4°C. 
 
Destain 
o Methanol   400 mL 
o Acetic acid   100 mL 
 
Destain was made up to 1 L with with deionized and stored at RT. 
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Coomassie Stain 
o Coomassie Brilliant Blue 1.25 g 
o Methanol    223 mL 
o Acetic acid   45 mL 
 
Coomassie stain was made up to 400 mL with deionized and stored at RT. 
Brilliant blue was dissolved in methanol before the addition of acetic acid and 
water.  
 
 
9.5.4 Buffers 
 
All buffers were kept at RT 
 
1 M Tris-HCl 
o Tris base    121.1 g  
 
Tris base was dissolved in 800 mL deionized water, the pH was adjusted by 
adding concentrated HCl and the volume made up to 1 L. 
 
0.5 M EDTA (pH 8.0) 
o EDTA    186. 2 g  
 
EDTA was dissolved in 800 mL deionized water, the pH was adjusted with 10 M 
NaOH with vigorous stirring with a magnetic stirrer and the volume made up to 1 
L.  
 
10x Tris EDTA (TE) buffer 
o 100 mM Tris-Cl (pH 7.4) 
o 10 mM EDTA (pH 8.0) 
 
This was sterilized by autoclaving for 30 minutes at 121°C on a liquid cycle.  
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10x Phosphate-buffered Saline (PBS) 
o NaCl    80 g 
o KCl    2 g 
o Na2HPO4   14.4 g 
o KH2PO4   2.4 g 
 
This was dissolved in 800 mL water, the pH was adjusted to 7.4 by adding 
concentrated HCl and the volume made up to 1 L. The solution was sterilized by 
autoclaving for 30 minutes at 121°C on a liquid cycle. The 10x stocks of PBS was 
diluted to 1x PBS with ddH20 before use.  
 
10x PBST 
o 10x PBS (as described above)   
o 1% Tween 80   
 
10x stocks of PBST was diluted to 1x PBST with ddH20 before use.  
 
50x TAE buffer 
o Tris base   242 g 
o Glacial acetic acid  57.1 mL 
o 0.5 M EDTA (pH 8.0) 100 mL 
 
This was made up to 1 L with ddH20, stored at RT and diluted down to 1x with 
ddH20 before use.  
 
10x Transfer Buffer 
o Tris base   60.4 g      
o Glycine   288 g    
 
This was made up to 2 L with ddH20, stored at RT and diluted down to 1x with 
ddH20 and 10% methanol (v/v) before use.  
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  10x SDS Running buffer 
o Tris base   0.2 g 
o Glycine    44g 
o SDS    1 g 
 
This was made up to 1 L with ddH20, stored at RT and diluted down to 1x with 
ddH20 before use.  
 
2X Sample Buffer  
o 0.5 M Tris-HCl pH 6.8   2.5 mL 
o Glycerol    2 mL 
o 10% SDS (w/v)   4 mL 
o 2-mercaptoethanol   1 mL 
o 1.5% Bromophenol Blue  1 mL 
 
This was made up to 20 mL with ddH20. The solution was mixed with a stir bar 
and stored at -20°C as 1 mL aliquots in 1.5 mL microfuge tubes.  
 
 
9.5.5 SDS gels 
 
12% separating gel (makes 50 mL) 
o 40% acrylamide     14.6 mL 
o 2% bis-acrylamide   8 mL 
o 1.5 M Tris-HCl pH 8.8  12.5mL 
o 10% SDS (w/v)   0.5 mL 
o ddH20     14.15 mL 
 
for 5 mL: 
o 10% APS    0.05 mL 
o TEMED    0.006 mL 
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4% stacking gel (makes 25 mL) 
o 40% acrylamide     2.4 mL 
o 2% bis-acrylamide   1.3 mL 
o 1 M Tris-HCl pH 6.8   3.15 mL 
o 10% SDS (w/v)   2.5 mL 
o ddH20     15.4 mL 
 
for 2.5 mL 
o 10% APS    0.025 mL 
o TEMED    0.0042 mL 
 
Both gels were made with all reagents mixed together except APS and TEMED 
and kept at 4°C. APS and TEMED were added (as indicated above) just before the 
gels were poured. 
 
 
 
 
 
 
 
 
  
 
